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IV. Abstract 
 
Modern neuroscience relies heavily on sophisticated tools that allow us to visualize and 
manipulate cells with precise spatial and temporal control. Transgenic mouse models, for 
example, can be used to manipulate cellular activity in order to draw conclusions about the 
molecular events responsible for the development, maintenance and refinement of healthy 
and/or diseased neuronal circuits. Although it is fairly well established that circuits respond 
to activity-dependent competition between neurons, we have yet to understand either the 
mechanisms underlying these events or the higher-order plasticity that synchronizes entire 
circuits. In this thesis we aimed to develop and characterize transgenic mouse models that 
can be used to directly address these outstanding biological questions in different ways. 
 
We present SLICK-H, a Cre-expressing mouse line that can achieve drug-inducible, 
widespread, neuron-specific manipulations in vivo. This model is a clear improvement over 
existing models because of its particularly strong, widespread, and even distribution pattern 
that can be tightly controlled in the absence of drug induction. We also present SLICK-
V::Ptox, a mouse line that, through expression of the tetanus toxin light chain, allows long-
term inhibition of neurotransmission in a small subset (<1%) of fluorescently labeled 
pyramidal cells. This model, which can be used to study how a silenced cell performs in a 
wildtype environment, greatly facilitates the in vivo study of activity-dependent competition 
in the mammalian brain. As an initial application we used this model to show that tetanus 
toxin-expressing CA1 neurons experience a 15% - 19% decrease in apical dendritic spine 
density. Finally, we also describe the attempt to create additional Cre-driven mouse lines 
that would allow conditional alteration of neuronal activity either by hyperpolarization or 
inhibition of neurotransmission. Overall, the models characterized in this thesis expand upon 
the wealth of tools available that aim to dissect neuronal circuitry by genetically 
manipulating neurons in vivo. 
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Chapter 1 Introduction 
 
1.1 Activity-Dependent Refinement of Neuronal Networks  
 
The human brain is composed of ~80 billion neurons interconnected by a vast network of 
synapses and another ~80 billion supporting glial cells (Azevedo et al., 2009). Neurons 
extend axonal projections and dendritic arbors to form complex but specific patterns. This 
connective specificity is guided by molecular cues and further refined as synapses are 
eliminated, added, stabilized, strengthened or weakened. This synaptic plasticity enables 
cells to undergo short- and long-term modifications in response to synaptic activity and 
experience. At the core of several forms of plasticity, like long-term potentiation (LTP), long-
term-depression (LTD), and homeostasis, are the postsynaptic dendritic spines. These small 
protrusions that extend from dendritic branches receive most of the excitatory 
neurotransmission in the brain. Their unique structural and functional properties make them 
an ideal potential substrate for higher cognitive functions like memory and learning. This 
introduction will focus on the wiring of the brain and on the activity-dependent refinement 
of these synapses. Particular attention is given to the involvement of the postsynaptic 
terminal in synaptic plasticity. Finally, the role of synaptic failure or deficiency in disease is 
highlighted. 
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1.1.1 Neuronal circuit development  
The vast and intricate networks of the brain require precise connectivity in order to function 
properly. Throughout the human lifespan, neurons form and refine synaptic connections in 
the following general pattern: (1) during fetal development, axonal and dendritic 
arborization is established with the aid of environmental guidance cues, (2) synaptic 
innervation increases during infancy, peaking at 1-2 years to as much as 50% above the adult 
mean, (3) throughout adolescence this number decreases sharply as axonal and dendritic 
arbors are pruned in response to synaptic activity, (4) the adult brain retains relatively stable 
synaptic connections but can also undergo a substantial amount of activity-dependent 
plasticity (Huttenlocher, 1979, Zuo et al., 2005, Pan and Gan, 2008). 
 Axonal arbor formation and refinement 1.1.1.1
1.1.1.1.1 Growth cone function 
 
 
 
Figure 1.1 – The structure of the growth cone 
 The leading tip of the axon consists of dynamic, finger-like filopodia separated by sheets 
of membrane called lamellipodia. The dynamics of these cytoskeletal components 
determine its shape and movement. From Lowery and Van Vactor (2009) 
 
The growth cone is a dynamic structure located at the tip of migrating axons that responds 
to environmental cues and is critical to axonal pathfinding (Tojima, 2012). Its task is to steer 
axons towards their final target locations, sometimes farther than a thousand times the 
diameter of their cell body (Tessier-Lavigne and Goodman, 1996). The growth cone contains 
a mobile cytoskeleton composed of filopodia (thin extensions of bundled F-actin) and 
lamellipodia (flat web-like extensions of meshed F-actin) whose mobility in response to 
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environmental cues is responsible for directing axonal growth (Fig 1.1) (Dent and Gertler, 
2003). Axon progression occurs in three steps called protrusion, engorgement, and 
consolidation (Goldberg and Burmeister, 1986). During consolidation microtubules facilitate 
axonal advance by transiently entering the growth cone and forming a new axonal segment 
(Dent and Gertler, 2003). The process of axonal pathfinding occurs in several contexts, 
including topographic map formation in the developing nervous system (Udin and Fawcett, 
1988) and repair and regeneration in the mature brain (Giger et al., 2010). 
1.1.1.1.2 Guidance molecules 
There are many different types of environmental guidance molecules that can act as 
repulsive or attractive signals for the growth cone (Maskery and Shinbrot, 2005). Adhesive 
cues like cell adhesion molecules (CAMs) and extracellular matrix molecules pave a physical 
path through which axons can navigate (Maness and Schachner, 2007, Evans et al., 2007), 
membrane-bound proteins such as slits and ephrins, prevent the axons from deviating from 
their path (Chilton, 2006) and a wide range of diffusible chemotropic signals, including 
semaphorins, netrins, morphogens, growth factors, transcription factors, neurotrophic 
factors and neurotransmitters provide further specificity to individual axons (Zou and 
Lyuksyutova, 2007, Butler and Tear, 2007, Sanford et al., 2008, Mattson et al., 1988). When 
axons reach their target locations, axonal arborization is initiated by instructive neurotrophic 
signals like nerve growth factor (Lentz et al., 1999, Patel et al., 2000). Many of these 
molecules can impose either repellant or attractive cues depending on the spatiotemporal 
specificity of expression (Lowery and Van Vactor, 2009). These guidance cues are responsible 
for activating or modulating signaling pathways within the growth cone that affect its 
motility; these include kinases, phosphatases, Ca2+, and Rho-family GTPases, as well as 
endo/exocytotic machinery (Tojima, 2012).  
1.1.1.1.3 Activity-dependent axonal refinement 
Upon initial axonal arbor formation, which is regulated by guidance cues and axonal growth 
cones, an overabundance of connections is formed that is further refined in response to 
synaptic activity (Spitzer, 2006). The morphology of arborization, described in terms of 
branch number, length and order, can be modified by pruning or by branch additions 
(Gibson and Ma, 2011). In the visual system, for example, axons originating from the retina 
of both eyes converge onto the lateral geniculate nucleus (LGN) and then segregate into 
eye-specific layers (Wong, 1999, Huberman et al., 2008). Similarly, axons originating from 
the LGN form ocular dominance columns in the primary visual cortex according to eye 
preference. Both of these patterns arise from a refinement process by which inappropriately 
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placed branches are eliminated in response to spontaneous wave activity in the retina, LGN, 
and visual cortex (Huberman et al., 2008). A vast amount of studies have built on this 
knowledge. During synaptogenesis, for example, activity leads to the preferential formation 
of new branches (Meyer and Smith, 2006, Ruthazer et al., 2006). A time-lapse study in the 
Xenopus retina showed that neuronal activity promotes axon branch elimination during 
topographic map formation in an NMDAR-dependent manner (Ruthazer et al., 2003).  
Another time-lapse study performed in thalamocortical slice cultures showed that global 
pharmacological suppression reduces axonal arbor size by preventing branch addition 
(Uesaka et al., 2007). These studies, among many others, demonstrate that axonal branching 
and development are subject to activity-dependent processes. 
 
Finally, activity-dependent axonal modulation has been widely proven to be a competitive 
process. A classic example of how activity-dependent competition shapes connectivity is the 
neuromuscular junction, where several axons initially innervate an immature muscle fiber 
and then compete with each other until ultimately a single axon innervates a mature fiber 
(Sanes and Lichtman, 1999). Several key studies that make observations of cells under 
manipulation show that these processes take place in the central nervous system as well 
(Buffelli et al., 2003, Yu et al., 2004, Hua et al., 2005, Gosse et al., 2008, Ben Fredj et al., 
2010, Yasuda et al., 2011, Plazas et al., 2013). Ample evidence, for example shows that 
suppressing the excitability or synaptic release of single neurons places them at a 
competitive disadvantage to wildtype cells, and that the phenotype produced is not 
observed under global suppression (Fig 1.2) (Yu et al., 2004, Hua et al., 2005, Yasuda et al., 
2011, Plazas et al., 2013).  
 
Most studies of this nature have found that when a neuron is selectively silenced in a 
competitive environment, axonal arbors are reduced in size and complexity (Fig 1.2) and that 
this can lead to eventual cell death, although axonal targeting is generally unaffected (Yu et 
al., 2004, Hua et al., 2005, Yasuda et al., 2011). In some studies, global suppression by 
tetrodotoxin eliminates the competitive disadvantage and restores normal arborization (Hua 
et al., 2005, Yasuda et al., 2011). Along these lines, chimeric zebrafish in one study were 
engineered to contain only one retinal ganglion cell (RGC) in each eye in order to eliminate 
the effects of normal competition. Complementing previous studies, these single RCG axons 
innervated properly but did not undergo pruning, suggesting that competition plays a role in 
branch elimination (Gosse et al., 2008).  
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Figure 1.2 – Competition in the brain. Competition between neighboring axons plays a part in the 
growth and branching of axon arbors. Retinal ganglion cells convey information from the retina to the 
optic tectum in the zebrafish brain. a: Individual retinal ganglion cells silenced by transfection with the 
potassium channel Kir2.1. develop reduced axonal arbors compared to  adjacent wildtype cells. b: 
Silencing of all retinal ganglion cells by injecting the neurotoxin tetrodotoxin into the eye restores the 
ability of the Kir2.1-expressing cell to grow a normal-sized axonal arbor. (S – silenced cell, A – active 
cell). From Ottersen (2005) 
 
On the other hand, some studies have found that arbors are increased in size and complexity 
when silenced (Ruthazer et al., 2003, Ben Fredj et al., 2010, Dong and Aizenman, 2012). 
These inconsistencies may arise from differences in the experimental setup or in the area of 
the brain examined, but in any case they suggest a complex role for the mechanisms by 
which competition shapes axonal branching. Although specific mechanisms are not yet clear, 
some potential players are brain-derived neurotrophic factor (BDNF) with its receptor p75 
(Singh et al., 2008, Grimbert and Cang, 2012, Je et al., 2012), the semaphorins SEMA3A with 
its receptors (Yaron et al., 2005, Plazas et al., 2013), and netrin and its receptor UNC-40 
(Alexander et al., 2010, Hao et al., 2010). These molecular mechanisms governing activity-
dependent competition are currently under intense investigation. 
 
 Dendritic arbor formation and refinement 1.1.1.2
 
On the postsynaptic end of a neuron, dendritic arbor development is similarly a dynamic 
“trial and error” process where filopodia expand and contract in response to their 
environment (Dailey and Smith, 1996). Dendrite arborization patterns are cell-type specific, 
so for example, pyramidal neurons in the cortex and hippocampus are characterized by a 
prominent apical dendrite from which higher order branches extend (Parrish et al., 2007). 
These type-specific dendritic arbor patterns partly arise from the different types, 
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combinations and amounts of intrinsic transcription factors for each cell-type (Parrish et al., 
2006, Jan and Jan, 2010). Similarly to axons, dendrites also respond to extrinsic factors, 
including CAMs, slits, ephrins, semaphorins, netrins, trophic factors and neurotransmitters 
that either attract or repel growing dendrites in order to further shape the dendritic tree 
(Jan and Jan, 2010, Kulkarni and Firestein, 2012). The precise mechanisms by which these 
molecules promote arborization are not well understood but include signaling pathways like 
kinases, phosphatases, and small GTPases (Jan and Jan, 2010). Interestingly, the 
chemotropic signals involved in neurite guidance can elicit different responses between 
dendrites and axons, between dendrites from different cell-types and even between 
dendrites of the same neuron (Parrish et al., 2007).  
1.1.1.2.1 Dendritic fields 
An important factor in dendritic arbor formation is the organization of dendritic fields. 
Dendrites of the same neuron tend to avoid each other (self-avoidance), as do dendrites of 
same-type neurons (tiling), while dendrites from different neuronal types can inhabit the 
same regions (coexistence) (Jan and Jan, 2010, Grueber and Sagasti, 2010). An example of 
these dendritic properties can be seen in the mammalian retina where each of the 50+ 
neuronal types covers the retinal surface completely but without overlapping with same-
type branches (Masland, 2001). The ability to selectively avoid same-type dendrites without 
repelling other neuronal types is partly attributed to Down syndrome cell adhesion molecule 
(DSCAM)-mediated homotypic binding, although the specificity of this mechanism is not fully 
understood in mammalian systems (Fuerst et al., 2008, 2009). This is in contrast to dendritic 
development in Drosophila where the large abundance of DSCAM splice variants allows each 
cell type to possess a unique “bar code” involved in homotypic repulsion (Wojtowicz et al., 
2004). Other adhesion molecules like N-cahderin and Flamingo (fmi) are also speculated to 
play a part in mammalian dendritic tiling (Zhu and Luo, 2004, Kimura et al., 2006). Arbor size 
is another factor in dendritic development. In some neurons, like cerebellar Purkinje cells, 
dendritic arbor complexity increases in proportion to the organism’s growth (Wen et al., 
2009). Several signaling cascades, including secretory, endocytic, and cytoskeletal pathways 
are beginning to emerge as regulators of this dendritic scaling (Jan and Jan, 2010). 
1.1.1.2.2 Activity-dependent dendritic refinement 
Similarly to axonal branching, dendritic arborization is shaped, refined and maintained by 
synaptic activity (Katz and Shatz, 1996, Sanes and Lichtman, 1999, Lichtman and Colman, 
2000, Hashimoto and Kano, 2005). The growth and branching of dendritic arbors is steered 
by synaptic activity in a repetitive general pattern: (a) newly extended filopodia form a new 
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synapse, (b) most of these are eliminated but (c) a fraction of them are maintained, (d) these 
filopodia become stabilized, and finally (e) mature into new dendritic branches (Cline, 2001, 
Niell et al., 2004). Activity deprivation results in reduced stability of dendritic branches and 
consequently leads to reduced arborization (Haas et al., 2006, Tyler et al., 2007, Cline and 
Haas, 2008). Although less intensely studied than axonal competition, activity-dependent 
competition also shapes dendritic arbors. In hippocampal cultures, activity suppression in a 
small subset of cells (by potassium channel overexpression) leads to reduced synaptic inputs 
as measured by dendritic spine density and excitatory postsynaptic current (EPSC) 
amplitude; this effect is not observed following global suppression by tetrodotoxin (Burrone 
et al., 2002). Moreover, a homeostatic increase in synaptic input is observed when 
suppression is induced after synaptic connectivity has been established (Burrone et al., 
2002).  
 
More recent studies investigating the effects of activity-dependent competition on synaptic 
inputs find slightly different results. In rat cortical layers 2/3, an siRNA-based knockdown of 
Na+ channels in a small subset of pyramidal neurons reveals an increase in spine density 
attributed to the cells’ inability to prune immature filopodia (Komai et al., 2006). In the 
Xenopus visual system, potassium channel overexpression in a small population of cells does 
not affect dendritic arborization, although axonal arbors were found to be significantly larger 
than usual (Dong and Aizenman, 2012). These results vary considerably but are based in 
different organisms, areas of the brain and developmental timepoints, and also employ 
different methods of activity suppression. This may indicate that dendritic activity-
dependent competition is not universally regulated among regions in the CNS or throughout 
different developmental stages.  
 
 Synapse formation and refinement 1.1.1.3
 
As mentioned before, synaptogenesis occurs at a high rate during human fetal development 
and childhood, as neurons attempt to innervate the immature brain (Huttenlocher, 1979). 
The period of adolescence, however, is dominated by synapse elimination/pruning; although 
new synapses continue to be formed, there is a large net loss of synaptic connections 
(Lichtman and Colman, 2000). Throughout adulthood, the balance between synaptogenesis 
and synapse elimination results in a slow but steady net loss of synaptic connectivity (Pan 
and Gan, 2008). Studies performed in mice  show that throughout an animal’s lifespan, a 
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large portion of dendritic spines are stabilized and maintained (Zuo et al., 2005), presumably 
forming the cellular basis for memory (Kasai et al., 2010). Moreover, the highly dynamic 
nature of synapses during childhood could provide the molecular basis for early learning 
(Pan and Gan, 2008). 
1.1.1.3.1 Synapse recognition and assembly 
As described previously, filopodia of developing neurites (axons and dendrites) constantly 
probe the environment in search of suitable synaptic connections. Synaptic recognition 
between potential partners is mediated by several factors including homophilic binding of 
synaptic adhesion molecules, repulsion signals from non-synaptic partners, transient 
synaptic partners that provide cues for target field selection, glial cells that secrete guidance 
cues and also serve as intermediary targets, and morphogenic gradients that prevent 
neurites from innervating prematurely (Shen and Scheiffele, 2010). Once appropriate pre- 
and postsynaptic partners come together, an array of signaling pathways is responsible for 
the process of synaptic differentiation, which can occur in a bidirectional, anterograde, or 
retrograde manner (Shen and Scheiffele, 2010). Finally, activity-dependent competition 
drives the elimination of redundant synapses to ensure connective specificity in the brain 
(Shen and Scheiffele, 2010). 
 
Adhesion complexes, which physically hold the synapse together also play an important role 
in assembling the functional components of both pre- and postsynaptic machinery. Neurexin 
and neuroligin, for example, contain PDZ-binding motifs at their C-terminals (Gerrow and El-
Husseini, 2006) that allow them to interact with key proteins at both the presynaptic 
terminal, where they trigger the accumulation of synaptic vesicles and active zone 
components (Dean et al., 2003), and at the postsynaptic terminal, where they promote 
dendritic spine formation and recruit key scaffolding proteins involved in post synaptic 
density (PSD) assembly (Gerrow et al., 2006).  
 
In addition to adhesive molecules, anterograde (presynaptic-derived) and retrograde 
(postsynaptic-derived) signals facilitate postsynaptic and presynaptic differentiation, 
respectively (Shen and Scheiffele, 2010). Axonally secreted pentraxins, for example, recruit 
postsynaptic glutamate receptors by interacting with the extracellular N-terminal domain of 
AMPA receptor subunits (Passafaro et al., 2003, Sia et al., 2007). Presynaptic ephrin ligands 
cluster postsynaptic ephrin receptors, which in turn bind to and cluster NMDA receptor 
subunits (Kayser et al., 2008, Dalva et al., 2000). In the opposite direction, postsynaptic 
factors like Wnt7a and the fibroblast growth factor FGF22 are released upon synapse 
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formation and induce presynaptic modifications like synaptic vesicle accumulation (Hall et 
al., 2000, Umemori et al., 2004). 
1.1.1.3.2 Synapse elimination 
In the immature brain, more connections are established than are ultimately maintained 
(Katz and Shatz, 1996, Sanes and Lichtman, 1999, Hua and Smith, 2004). Many lines of 
evidence indicate that (a) synapse elimination is an integral and crucial feature of early 
circuit development and that (b) activity-dependent synaptic elimination continues to refine 
neuronal connections in the adult brain (Lichtman and Colman, 2000, Buffelli et al., 2003, 
Luo and O'Leary, 2005, Pan and Gan, 2008). In postmortem human tissue, for example, a 
high rate of synapse formation during childhood is followed by a massive reduction in 
synaptic connections throughout adolescence (Pan and Gan, 2008). In the developing mouse 
cortex, 13%-20% of excitatory synapses are eliminated during postnatal weeks 4-6 with only 
5%-8% formed during the same period; moreover a net loss of 25% occurs between 1 and 4 
months (Zuo et al., 2005). Importantly, sensory deprivation preferentially reduces the rate of 
spine elimination in these mice (Zuo et al., 2005).   
 
Although it is well established that synapse elimination is activity-dependent, there is a poor 
understanding of how synapses are tagged for elimination, the precise cellular mechanisms 
for synapse elimination, and how synapse elimination leads to branch pruning (Stephan et 
al., 2012). One potential tagging system for synapses undergoing elimination is the 
complement protein cascade, classically an immune system phagocytic process (Stevens et 
al., 2007). In line with this, glial cells have been shown to engulf presynaptic terminals in 
response to the compliment cascade in an activity-dependent manner (Schafer et al., 2012, 
Chung and Barres, 2012). Secreted semaphorins and their receptors have also been found to 
influence synapse elimination mechanisms (Liu et al., 2005). This is currently an area of 
intense research and its importance is underscored by the fact that several diseases, 
including Fragile X syndrome, are associated with deficiencies in synapse elimination and 
axonal or dendritic pruning (Kulkarni and Firestein, 2012). 
1.1.1.3.3 Synapse stability and turnover 
Aside from synapse elimination, two important aspects of neuronal circuit remodeling are 
the ability for synapses to strengthen and stabilize and the adaptive capacity for synaptic 
turnover (Grutzendler et al., 2002, Trachtenberg et al., 2002, Holtmaat et al., 2005, Xu et al., 
2009, Yang et al., 2009, Roberts et al., 2010, Lai et al., 2012). Both of these processes occur 
in response to neuronal activity. Long-term two-photon studies in mice reveal that up to 
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96% of excitatory synapses in the adult cortex remain stable over a one-month period 
(Grutzendler et al., 2002), and that over an 18-month period 70% of synapses can be stably 
maintained (Zuo et al., 2005). In the mouse barrel cortex 60%-70% of stable synapses are 
predicted to persist throughout an animal’s lifespan; this includes synapses that were 
established during development and survived elimination, as well as synapses that were 
established later in life (Yang et al., 2009). Some studies reveal lower rates of stably 
maintained synapses (Trachtenberg et al., 2002, Holtmaat et al., 2005), although these 
inconsistencies are attributed to the use of cranial window versus thinned-skull techniques 
(Xu et al., 2007). The smaller but significant population of synapses that undergoes constant 
turnover in the mature brain endows neuronal circuits with a substantial capacity for 
experience-dependent modification (Caroni et al., 2012). Importantly, sensory deprivation 
alters synapse dynamics in several of these studies showing the activity-dependent nature of 
synapse stability and turnover (Pan and Gan, 2008, Yang et al., 2009). Taken together, these 
data reiterate that synapses are plausible substrates for long-term information storage 
(Caroni et al., 2012).  
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1.1.2 The role of dendritic spines in postsynaptic plasticity  
 Dendritic spine morphology and biochemistry 1.1.2.1
1.1.2.1.1 General morphology 
Dendritic spines are the postsynaptic sites for most of the glutamatergic/excitatory 
connections in the brain. They are small membranous protrusions that generally extend 
from the dendritic shaft by a thin “neck” and terminate in a spine “head” (Lee et al., 2012). 
Spine structures (Fig 1.3) vary greatly but can be broadly classified as “mushroom-like” 
(defined neck and head), “stubby” (no neck, head protrudes directly from the shaft) or 
“thin” (long and thin, no clear neck/head distinction) (Peters and Kaiserman-Abramof, 1970). 
These morphological differences are thought to reflect functional changes in synaptic 
strength and maturity (Yuste and Bonhoeffer, 2001, Kasai et al., 2003, Hayashi and 
Majewska, 2005). The spine head membrane contains the post-synaptic density (PSD), an 
electron rich conglomeration of proteins and molecules responsible for most of the 
excitatory synaptic transmission in the brain (Gold, 2012). The spine possesses a dynamic 
actin cytoskeleton that is thought to underlie structural plasticity of the spine (Penzes and 
Rafalovich, 2012). It also contains several supporting organelles like mitochondria (Li et al., 
2004), endocytic vesicles (Kelly et al., 2011), spine apparatus (Vlachos, 2012) and smooth 
endoplasmic reticulum (Spacek and Harris, 1997). The thin neck of the spine is thought to 
provide biochemical and electrical compartmentalization; this isolation is thought to account 
for the relationship between spine morphology and synaptic function, and for synapse-
specific plasticity (Lee et al., 2012, Yuste, 2011).  
 
  
Figure 1.3 – Dendritic spine classifications 
Laser-scanning confocal micrograph shows distal primary apical dendrite from a Layer 5 cortical 
pyramidal neuron in an adult Fmr1-KO mouse. Filopodia-like (F), long-thin (L), mushroom (M) and 
stubby (S) spines are identified based on structural measures. From www.psychogenics.com. 
1µm 
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1.1.2.1.2 The post-synaptic density (PSD)  
 
 
 
Figure 1.4 - Molecular organization of the PSD of excitatory synapses 
Schematic diagram of the major proteins of the PSD, with protein interactions indicated by direct 
contacts or overlaps. The relative numbers of the proteins shown correlate roughly with their relative 
abundance in PSDs of forebrain. Copy numbers of most adhesion molecules and ion channels are 
unknown (dark gray lines). Each CaMKII shape represents a dodecamer. From Sheng and Kim (2011) 
 
The postsynaptic density (PSD; Fig 1.4) is a membrane specialization that generally occurs at 
the tip of dendritic spine heads, is directly apposed to the presynaptic active zone, and 
contains hundreds of proteins involved in excitatory synaptic transmission (Sheng and Kim, 
2011). The core functional proteins of the PSD are the glutamate receptors (Husi et al., 
2000): N-methyl-ᴅ-aspartate receptors (NMDAR), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropinoic acid receptors (AMPAR), and metabotropic glutamate receptors 
(Traynelis et al., 2010). Signaling proteins such as kinases (e.g. CaMKIIα), phosphatases (e.g. 
tyrosine phosphatases) and small GTPases (e.g. Ras, Rac, Rho) are responsible for regulating 
various biochemical pathways in response to synaptic activity (Kennedy et al., 2005, Sheng 
and Hoogenraad, 2007). This includes actin-cytoskeleton reorganization, local protein 
synthesis, neuronal apoptosis, regulation of glutamate receptors, and others (Kennedy et al., 
2005, Murakoshi and Yasuda, 2012). Small GTPases act as binary molecular switches that are 
turned “on” by guanine exchange factors (GEF; e.g. kalirin/ RhoGEF) and turned “off” by 
GTPase activating proteins (GAP; e.g. SynGAP/RasGAP) (Takai et al., 2001). Cell adhesion 
molecules like neuroligins and N-cadherin help to anchor the PSD into close proximity with 
the presynaptic active zone and are also important for synapse specificity (Missler et al., 
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2012). Finally, key scaffolding proteins like PSD-95, GKAP/SAPAP, Shank and Homer cluster 
proteins into a dynamic laminar structure (Valtschanoff and Weinberg, 2001) that allows 
glutamate receptor activity to be coupled to its downstream signaling pathways (Sheng and 
Kim, 2011). The activity of key PSD proteins is thought to underlie the cellular mechanisms 
for several forms of synaptic plasticity including long-term potentiation/depression 
(LTP/LTD) and homeostatic plasticity (Malenka and Bear, 2004, Matsuzaki, 2007, Turrigiano, 
2012).  
1.1.2.1.3 Organelles 
Dendritic spines contain several organelles that support its biochemical functions locally 
(Sheng and Hoogenraad, 2007). Smooth endoplasmic reticulum (SER), for example, is 
widespread in dendritic shafts and extends its network into a large subset of spines (Spacek 
and Harris, 1997). Their main function is most likely related to local calcium storage and 
release, as well as protein transport to the postsynaptic membrane (Horton and Ehlers, 
2004). Another organelle called the spine apparatus (SA) is composed of stacked SER and is 
present at mature dendritic spines (Gray, 1959, Segal et al., 2010). The SA is thought to be 
involved in local calcium storage and protein synthesis/recycling, although mechanistic 
evidence remains to be found (Sheng and Hoogenraad, 2007, Vlachos, 2012). Although 
postsynaptic proteins are generally created in the cell body and then transported to the 
spine (Horton and Ehlers, 2004), some mRNAs are known to be translated locally in 
dendrites (Schuman et al., 2006), including the mRNAs for AMPARs to some extent (Ju et al., 
2004). Consistent with this notion, polyribosomes are present in the dendrite shaft (Gardiol 
et al., 1999) and have been shown to translocate into the spine following LTP (Ostroff et al., 
2002). These translation-related organelles are thought to play an important role in synaptic 
plasticity (Sheng and Hoogenraad, 2007).  
 
Endocytic machinery components such as clathrin-coated vesicles, multi-vesicular bodies, 
and tubular compartments are also essential to synaptic function. (Racz et al., 2004, Park et 
al., 2004, Brown et al., 2005). The endocytic zone, located on the extrasynaptic membrane 
(lateral to the PSD) is a site where synaptic proteins are endocytosed, exocytosed, recycled 
or degraded (Blanpied et al., 2002, Racz et al., 2004). Recycling endosomes, for example, can 
provide a local supply of AMPA receptors; evidence shows that these endosomes are 
translocated into the spine following NMDAR activation to increase the number of 
membrane-bound AMPARs (Park et al., 2004, 2006). Endosomal recycling thus facilitates fast 
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NMDAR-mediated recruitment of AMPARs during LTP, as well as trafficking of other 
receptors at the postsynapse (Kelly et al., 2011). 
 
Finally, an increasing body of evidence shows that mitochondria, which are recruited to the 
spine in response to electrical stimulation, are essential to the morphological plasticity of 
dendritic spines (Li et al., 2004, Sheng and Hoogenraad, 2007). Although a precise 
mechanism of action has not yet been revealed, their ability to buffer intracellular calcium 
levels is likely to be relevant (Chan, 2006). Some recent studies look at postsynaptic 
mitochondrial dysfunction in the context of Alzheimer’s disease and find that it is correlated 
with spine reduction and dendritic branch loss (Rui et al., 2010, Baloyannis, 2011). A 
mitochondrial role in AMPA receptor trafficking to the postsynaptic membrane has also 
been suggested (Rui et al., 2010).  
 
 Postsynaptic plasticity in dendritic spines 1.1.2.2
 
A generally accepted model for LTP in dendritic spines is reviewed by Nicoll and Roche 
(2013) and goes as follows: (1) NMDA receptors are activated when presynaptic glutamate is 
coupled with postsynaptic depolarization. (2) NMDAR activation induces rapid Ca2+ influx, 
which (3) promotes activation of calcium/ calmodulin-dependent protein kinase II (CaMKII) 
and (4) leads to the rapid recruitment of additional AMPA receptors to the postsynaptic 
membrane, which in turn (5) results in a long-lasting increase in excitatory postsynaptic 
current (EPSC) amplitude. Strong evidence suggests that activation of CaMKII, which is highly 
abundant in the PSD (Cheng et al., 2006), is one of the most crucial steps in LTP (Lisman et 
al., 2012). The multiple roles that CaMKII plays at the synapse are reviewed by Lisman et al 
and include: (a) it binds to the NMDAR subunit NR2B, (b) it phosphorylates the AMPAR 
subunit GluR1 and its associated protein stargazin in order to enhance AMPAR trafficking to 
the postsynaptic membrane, and (c) bundles and stabilizes actin filaments, thus regulating 
actin cytoskeletal modifications. Importantly, NMDAR-CaMKII complex formation is 
necessary for LTP to occur, as is NMDA activation (Barria and Malinow, 2005). Although 
some forms of plasticity have been identified that are not NMDAR-dependent, notably at 
hippocampal mossy fibers (Nicoll and Malenka, 1995), the vast majority of studies focus on 
the CA1 where LTP is particularly robust (Nicoll and Roche, 2013). 
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1.1.2.2.1 Molecular basis of synaptic plasticity 
One of the most prominent features of biochemical plasticity in dendritic spines is the 
reorganization of several PSD proteins (Murakoshi and Yasuda, 2012). During LTP, for 
example, CaMKII and AMPAR levels increase immediately and in proportion with spine 
volume changes (Lee et al., 2009, Patterson et al., 2010) whereas the opposite occurs in LTD 
(Zhou et al., 2004). Several hours after LTP induction, the scaffolding proteins PSD-95 and 
Shank are enriched and the PSD enlarges in proportion to spine volume, which is thought to 
have a stabilizing effect (Knott et al., 2006). During LTD loss of PSD-95 occurs immediately 
and is coupled with a shrinking spine volume (Woods et al., 2011).  
 
These biochemical processes are regulated by signaling pathways that include kinases like 
CaMKII, ERK (extracellular signal-related kinase) and PAK (p-21 activated kinase), as well as 
small GTPases such as Ras and the Rho family GTPases RhoA, Cdc42 and Rac. CaMKII activity 
is upstream of many of these GTPase pathways (Murakoshi et al., 2011) and although the 
relationship between the two pathways is not yet clear, it has been suggested that CaMKII 
may regulate GEFs and/or GAPs (Stornetta and Zhu, 2011). CaMKII also facilitates AMPAR 
trafficking by directly phosphorylating its subunits (Kristensen et al., 2011). 
1.1.2.2.2 Structural plasticity 
In dendritic spines morphological changes are thought to reflect physiological changes in 
synaptic strength and maturity of the spine (Matsuzaki, 2007). In general, spines with larger 
heads are more stable and promote stronger synaptic connections while smaller spines are 
more dynamic and therefore undergo synaptic plasticity more readily (Kasai et al., 2003, 
Matsuzaki et al., 2004). In line with this, LTP and LTD are associated with respective 
enlargement or reduction of dendritic spine size (Okamoto et al., 2004, Zhou et al., 2004), 
PSD volume (Kasai et al., 2003), and amount of membrane-bound AMPARs (Malinow and 
Malenka, 2002, Kessels and Malinow, 2009). Although under certain conditions spines have 
the ability to deviate from form-function coupling, the strong correlation between structural 
and functional plasticity implies that they share a common molecular mechanisms (Lee et 
al., 2012). Finally, compartmentalization provided by the dendritic spine neck could be 
responsible for this form-function relationship (Lee et al., 2012). 
 
Rapid actin cytoskeleton remodeling is thought to underlie morphological plasticity in 
dendritic spines (Penzes and Rafalovich, 2012, Bosch and Hayashi, 2012).  LTP causes fast 
actin polymerization whereas LTD is accompanied by actin depolymerization (Okamoto et 
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al., 2004). Moreover, mutating actin filaments blocks LTP and suppresses spine enlargement 
(Matsuzaki et al., 2004). Actin treadmilling, whereby actin monomers are polymerized at one 
end and depolymerized at the other, is thought to drive these activity-dependent 
morphological changes (Star et al., 2002, Honkura et al., 2008, Frost et al., 2010). During LTP, 
endosomal exocytosis is believed to be crucial for adding membrane area to the spine (Park 
et al., 2006) while simultaneously delivering AMPARs to the synaptic membrane (Kessels and 
Malinow, 2009, Makino and Malinow, 2009).  
 
These changes are regulated by a complex signaling network that relays input  information 
from membrane receptors like NMDARs to the actin-binding proteins (ABPs) that directly 
polymerize/ depolymerize actin (Okamoto et al., 2004, Murakoshi and Yasuda, 2012). 
CaMKII bundles F-actin to regulate its stability (Okamoto et al., 2007) and also regulates the 
activity of small GTPases (Murakoshi et al., 2011) like Rho family GTPases, which in turn 
regulate APB activity (Penzes and Rafalovich, 2012). Rho activation for example, inhibits 
actin  polymerization and causes spine loss/shrinkage while activation of Cdc42 and Ras 
promotes actin polymerization and leads to increased spine number (Saneyoshi et al., 2010). 
Epigenetic mechanisms like methylation, acetylation, and micro-RNA regulation also play a 
role in activity-dependent spine remodeling (Penzes and Rafalovich, 2012). Finally, 
microtubules have also been found to contribute to dendritic spine plasticity (Jaworski et al., 
2009). 
1.1.2.2.3 Biochemical and electrical compartmentalization 
Rapid actin cytoskeletal reorganizations are thought to not only reflect biochemical changes 
in dendritic spines but also to actively facilitate functional plasticity. Morphological 
modifications to the spine neck, which isolates spines from their parent dendrites, could 
attenuate the way in which spines respond to synaptic activity.   
 
The idea of a biochemical compartment was first proposed when NMDAR-mediated calcium 
influx was shown to be tightly restricted to the spine under certain conditions (Muller and 
Connor, 1992). It was later established that calcium diffusion into the dendritic shaft is 
restricted in spines with thin necks but not in spines with wider neck diameters (Noguchi et 
al., 2005).  Similar to intracellular diffusion, the lateral mobility of membrane proteins is also 
restricted by spine neck morphology (Choquet, 2010). AMPA receptors, for instance, exhibit 
a twofold decrease in lateral diffusion out of the spine when a defined neck is present 
(Ashby et al., 2006).  
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Biochemical compartmentalization is not absolute, however, as spines need to retain the 
ability to communicate with the parent dendrite. Although precise regulation mechanisms 
remain to be elucidated, it is clear that spines can differentially regulate diffusion of several 
signaling molecules. For example, during LTP CamKII and Cdc42 are restricted to the spine 
head (Harvey et al., 2008, Lee et al., 2009) whereas Ras and RhoA diffuse into the parent 
dendrite and spread into neighboring synapses (Harvey et al., 2008, Murakoshi et al., 2011). 
Several studies also point out that GFP also experiences restricted diffusion and lateral 
motility through the spine neck, suggesting that the obstruction is caused by geometric 
parameters, and not by intrinsic trafficking properties of the proteins involved (Bloodgood 
and Sabatini, 2005, Ashby et al., 2006). These forms of biochemical isolation facilitate 
synapse-specific plasticity by providing autonomy to individual synapses. 
 
Until recently, the idea of an electrical compartment was mostly dismissed based on the 
prediction that the spine neck would provide only negligible ohmic resistance (Koch and 
Zador, 1993, Svoboda et al., 1996). A recent study, however, measures spine neck resistance 
to be up to ~500MΩ for subsets of dendritic spines (Harnett et al., 2012). This study shows 
that spine neck resistance amplifies synaptic depolarization locally (1.5-45 fold), which 
increases the activity of voltage-dependent (i.e. NMDAR-mediated) pathways within the 
spine (Harnett et al., 2012). If longer/thinner spine necks provide a higher ohmic resistance 
and therefore produce a more intense local depolarization (Harnett et al., 2012), this would 
be consistent with the fact that thinner spines are more prone to LTP (Matsuzaki et al., 
2004).  
 
Aside from facilitating synapse-specific plasticity, electrical isolation could also serve to 
linearize dendritic input integration; this would avoid “electrical shunting” and subsequent 
reduction to the cell’s overall excitability (Tsay and Yuste, 2004, Yuste, 2011). One study 
shows that input amplitudes received by the soma are inversely proportional to the neck 
length of individual synapses and independent from spine location or head size (Araya et al., 
2006). In addition, computational models predict that spine neck isolation can preserve local 
excitatory postsynaptic potentials (EPSPs), thereby protecting spines from the location-
dependent variability of dendritic impedance (Gulledge et al., 2012).   
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Taken together, these findings suggest that spines can in fact act as both biochemical and 
electrical compartments capable of locally filtering and processing synaptic inputs (Harnett 
et al., 2012, Yuste, 2011). Moreover, the ability of the cytoskeleton to rapidly modify neck 
shape/length endows dendritic spines with the capacity to control the geometric parameters 
that affect its response to synaptic activity (Lee et al., 2012).  
 Dendritic spine pathology 1.1.2.3
 
Dendritic spine anomalies (size, shape and density) are prominent in several 
neuropsychiatric diseases that involve information-processing deficits and impairments to 
neuronal plasticity and connectivity (Fig 1.5) (Penzes et al., 2011).  Among these are 
schizophrenia (SZ), Alzheimer’s disease (AD), autism spectrum disorders, addiction, Down’s 
syndrome, Fragile X syndrome, Rett’s syndrome, and non-syndromic intellectual disability 
(Russo et al., 2010, Kulkarni and Firestein, 2012); some of these are detailed below. These 
diseases are characterized by varying degrees of cognitive and behavioral impairment 
including distorted perception, memory loss, and socio-linguistic deficiencies; at the 
molecular level, they exhibit dendritic arbor anomalies and altered spine density/size, albeit 
expressed in different regions of the brain and at different developmental timepoints 
(Penzes et al., 2011). The similarities between these diseases, with spines as a common 
substrate, further strengthen the idea that dendritic spine function is at the core of certain 
cognitive processes (Kasai et al., 2010). 
 
 
 
 
Figure 1.5 - Schematic representation of dendritic spines and branching 
abnormalities in diseased brains. From Kulkarni and Firestein (2012) 
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1.1.2.3.1 Dendritic spine anomalies in schizophrenia 
Schizophrenia is a genetically heterogeneous disease that affects thought, perception, 
emotion and cognition and emerges in late adolescence or early adulthood (Silveira et al., 
2012). Despite its heterogeneity, a common pathology in SZ is substantial loss of gray matter 
in the prefrontal cortex (PFC) (Zipursky et al., 1992) that is caused by a decrease in dendritic 
arborization and spine density instead of neuronal death (Selemon and Goldman-Rakic, 
1999, Glausier and Lewis, 2012). In human postmortem tissue spine density is severely 
decreased, specifically in the PFC (Garey et al., 1998, Glantz and Lewis, 2000), auditory 
cortex (Sweet et al., 2009), striatum (Roberts et al., 1996) and CA3 (Kolomeets et al., 2005, 
2007). Cortical deficits occur only in layer 3 (Kolluri et al., 2005), which is noteworthy 
considering that layer 3 neurons undergo more pruning during adolescence than other 
layers (Bourgeois et al., 1994). Taken together, these findings may suggest that synapse 
elimination during adolescence is a prominent and common feature of the disease (Penzes 
et al., 2011).  
1.1.2.3.2 Dendritic spine anomalies in Alzheimer’s disease 
Alzheimer’s disease arises much later in life and is clinically indicated by severe memory loss 
and mood alterations (Yu and Lu, 2012). At the molecular level it is characterized by the 
presence of neurofibrillary tangles and amyloid beta oligomers, by neuronal death and by 
dendritic branch and spine anomalies in the hippocampus and cortex (Tackenberg et al., 
2009, Yu and Lu, 2012). Postmortem human tissue reveals spine density decrease in all 
cortical layers, in both pyramidal and non-pyramidal neurons (Davies et al., 1987, el Hachimi 
and Foncin, 1990), as well as in the hippocampus (Ferrer and Gullotta, 1990, Baloyannis et 
al., 2004, 2011). In transgenic mice, human-derived amyloid-beta oligomers can potently 
inhibit LTP, enhance LTD, and reduce spine density (Shankar et al., 2008). Particularly 
interesting are the findings that spine loss is more highly correlated to cognitive function 
than are neuronal death or number of tangles or oligomers (DeKosky and Scheff, 1990, Terry 
et al., 1991). This evidence has led to the idea that synaptic dysfunction occurs early in AD 
and may be a causative pathology rather than an outcome of disease (Selkoe, 2002, Arendt, 
2009, Penzes et al., 2011). 
1.1.2.3.3 Dendritic spine anomalies in intellectual disability and mental retardation 
Several neuropsychiatric diseases related to intellectual disability and mental retardation 
also have synaptic origins but vary in their exact pathologies (Levenga and Willemsen, 2012). 
For example, autism spectrum disorders and Fragile X syndrome experience an increase in 
spine density (Hutsler and Zhang, 2010, He and Portera-Cailliau, 2012) whereas Down’s and 
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Rett’s syndromes exhibit decreased  spine density (Kaufmann and Moser, 2000). Fragile X 
not only displays an increased spine density, but also an increased proportion of long/thin 
spines that are considered to represent immature synapses (Irwin et al., 2001). Down’s 
syndrome displays irregularly sized spines, both larger and smaller, in addition to decreased 
density (Marin-Padilla, 1972, 1976, Takashima et al., 1981, 1989). The similarity in synaptic 
pathologies across neuropsychiatric diseases supports the belief that spine function 
underlies higher cognitive processes like memory and learning (Kasai et al., 2010).  
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1.2 Molecular tools for the in vivo study of neuronal networks 
 
1.2.1 Visualizing the brain  
 
The ability to visualize neurons in precise detail is an important cornerstone of modern 
neuroscience. Classical neuroanatomical studies that traced neuronal connectivity relied 
heavily on silver stains like Golgi and “Nauta-Gygax” stains, Nissl staining, and others 
(Heimer, 2003, Switzer, 2000, Jones, 2007). Many of these staining methods are still relevant 
today and serve to compliment modern techniques. The Golgi stain is still used in the study 
of dendritic spines (Dagnino-Subiabre et al., 2012, Bianchi et al., 2012) and Nissl staining is 
still used to map cellular populations following immunocytochemical detection (Kadar et al., 
2009). These classical staining methods, however, are restricted by their toxicity and by the 
fact that they cannot selectively stain with brain area- or cell type-specificity. 
 
As an alternative, retrograde tracers became popular in the 1970’s, beginning with the use 
of horseradish peroxidase (Kristensson and Olsson, 1971). Fluorescent dyes followed, for 
example, lucifer yellow (Maranto, 1982), nuclear yellow, fast blue (Bentivoglio et al., 1980), 
and  lipophilic carbocyanine dyes like DiI, DiO and DiD (Honig and Hume, 1989). These dyes 
can be introduced by several methods including microinjection and ballistics (Lo et al., 1994). 
The particle-mediated ballistic delivery of carbocyanine dyes is termed “DiOlistic” labeling 
(Gan et al., 2000). Although these types of labeling are widely used even today (Jung et al., 
2013), their application is limited to slices and cell culture. In the last two decades, methods 
that deliver genetically encoded markers have allowed neuronal visualization in intact 
organisms as well. For example, genes for LacZ (Soriano, 1999, Kiernan, 2007) or alkaline 
phosphatase (Cordell et al., 1984) can be genetically introduced as cell markers for any 
specific cell-type. However, LacZ is only expressed in the cell body and alkaline phosphatase 
requires an enzymatic reaction. The discovery of green fluorescent protein (GFP), a non-
toxic, uniformly expressed protein whose fluorescence does not require exogenous factors, 
overcame many of the limitations of its predecessors and revolutionized the field of 
fluorescent imaging. 
 
GFP, from the jellyfish Aequorea Victoria, produces strong and stable fluorescence when 
expressed exogenously in prokaryotic or eukaryotic cells (Chalfie et al., 1994). Because GFP 
is a protein, its coding sequence can be incorporated directly into the genome of an 
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organism and its expression thereby becomes inheritable (Feng et al., 2000). Importantly, it 
can be fused to a protein of interest with minimal disruption to the system (Chalfie et al., 
1994). Unlike other staining methods, the GFP chromophore relies only on protein 
expression and does not require activation by cofactors or substrates (Chalfie et al., 1994). 
Since it is a relatively small protein (26.9kDa), it is able to diffuse throughout the entire cell 
without the need for peptide fusions that facilitate transport (Feng et al., 2000, Rodriguez et 
al., 1999). GFP is not toxic and does not perturb cellular activity, morphology or synaptic 
connectivity, even when expressed long-term in vivo in neurons (Feng et al., 2000). Finally, 
GFP cDNA has been mutated to produce spectral variants, called XFPs, that allow co-labeling 
of more than one cell population (Chalfie, 1995, Day and Davidson, 2009).  
 
Since the discovery of GFP, many fluorescent proteins (FPs) from several origins and 
spanning the entire spectral palette have been engineered to achieve proteins that are 
brighter and more photostable (Day and Davidson, 2009). Two example are DsRed from the 
sea anemone D. striata and mCherry, a third generation monomeric derivative of DsRed 
(Baird et al., 2000, Campbell et al., 2002, Shaner et al., 2004). The availability of FPs has also 
brought about new techniques, like optical highlighting, which enables the temporal study of 
proteins and cells (Dickson et al., 1997, Miyawaki, 2004). By exploiting the photophysical 
properties of certain fluorescent proteins, like photoactivation, photoconversion and 
photoswitching, some FPs can now be used to track temporal expression patterns, turnover 
rates and other time-dependent processes (Lippincott-Schwartz et al., 2003, Lukyanov et al., 
2005). The field of calcium imaging has also benefited from engineered FPs that can 
modulate their fluorescence in response to intracellular Ca2+ concentration (Zhao et al., 
2011b). In addition, voltage-sensitive fluorescent proteins facilitate the analysis of electrical 
activity at genetically defined neuronal populations (Akemann et al., 2010). 
 
The development of methods that utilize fluorescent proteins has been instrumental in the 
field of neurobiology as it allows dynamic cellular processes to be studied in a controlled and 
selective manner in vivo. Shortly after the discovery of GFP, fluorescent proteins became 
widely used to study cells and molecules in a vast range of species (Tsien, 1998), and to 
study neuronal processes in transgenic models (Knobel et al., 1999, Dynes and Ngai, 1998, 
Murray et al., 1998, van den Pol and Ghosh, 1998, Rodriguez et al., 1999).  As described in 
more detail below, the use of Cre-based fluorescent labeling has also become an essential 
tool (Feng et al., 2000). For example, the Brainbow technique, which uses the Cre/loxP 
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system, produces multicolor mosaicism by stochastic combinatorial expression of three or 
more XFPs (Livet et al., 2007). With up to 89 distinguishable colors, this method facilitates 
the visualization of cellular interactions in areas of high neuronal density (Havekes and Abel, 
2009). In addition to Brainbow, there are currently over 300 available lines of transgenic 
mice that use fluorescent proteins (www.jax.org, www.gensat.org). 
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1.2.2 Genetic Manipulation of Neurons 
 Site-specific recombination 1.2.2.1
 
Site-specific recombination (SSR) has greatly facilitated the large-scale study of mammalian 
gene function. Recombinases like Cre and Flp (Tyr recombinases) and φC31 (Ser 
recombinase) are commonly used in the field of mouse genetics because they allow for the 
accurate insertion, deletion or inversion of DNA (Branda and Dymecki, 2004, Turan and 
Bode, 2011). Recently, novel recombinases have also been characterized in Drosophila and 
mice (Nern et al., 2011).  When used in combination with other elements such as cell-type 
specific promoters and modified steroid receptor ligand binding domains, site-specific 
recombination has the power to render both spatial and temporal control of genetic 
manipulation. 
1.2.2.1.1 Cre & Flp recombinase 
Cre (short for “causes recombination”) is a recombinase protein derived from the 
bacteriophage P1 genome that recognizes target sites called loxP (locus of crossover in P1) 
(Abremski and Hoess, 1984). When two loxP sites are present, Cre catalyzes recombination 
between them in order to delete, invert or integrate DNA (Hamilton and Abremski, 1984). A 
loxP site consist of two 13 basepair (bp) palindromic sequences separated by an 8bp 
asymmetric spacer (Hoess et al., 1982). Similarly, Flp recombinase, from the 2µm plasmid of 
Saccharomyces cerevisiae , catalyzes recombination between FRT target sites (Cox, 1983). 
FRT target sites are similar in structure to loxP sites but differ in their precise nucleotide 
sequence (McLeod et al., 1986). 
 
In both systems, the asymmetry of the spacer sequence provides directionality to the site 
and thus recombination is only possible when the two target sites are properly aligned 
(Hoess et al., 1986). This means that the relative orientation of the two loxP or FRT sites 
determines the outcome of recombination (Fig 1.6). DNA that is flanked by two loxP sites 
(‘floxed”) or by two FRT sites (“flirted”) is deleted when the sites are oriented in the same 
direction (parallel) and inverted when the sites are in opposite directions (antiparallel). Two 
sequences, each containing its own target site, can also be integrated; for example, a circular 
donor sequence into genomic DNA (Golic and Lindquist, 1989) or interchromosomal 
crossover (Van Deursen et al., 1995, Zong et al., 2005).  
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DNA excisions are the most basic of the modifications catalyzed by recombinases because 
they are essentially irreversible. Since this technique is accurate and stable, it is widely used 
in the production of transgenic and knockout mice (Branda and Dymecki, 2004). 
Recombinase-mediated excisions can be used to either delete a gene by flanking it, or insert 
a gene by placing it downstream of a flanked STOP cassette. Insertions, however, result in a 
floxed or flirted DNA sequence that is susceptible to further deletion and/or inversion. 
Likewise, inversions can switch indiscriminately between conformations. Several methods 
attempt to rectify these problems, including the use of heat-shock promoters to control 
reaction time (Morris et al., 1991), as well as target site modification (Senecoff and Cox, 
1986).  
 
Figure 1.6 – DNA manipulations controlled by Cre and loxP directions or locations 
(a) If the two loxPs are in the same direction on one DNA molecule, the DNA between them will be 
deleted. (b) When one loxP is on a linear DNA while another is on a circular DNA, the circular DNA will 
integrate into the linear DNA at the target. Small circular DNA is easily lost in cells; hence, the reaction 
in (a) happens more easily than that in (b). (c) If two loxPs are opposite, the DNA fragment between 
them will be inverted. (d) The DNA molecules will exchange a segment if both loxPs lie on linear DNA 
molecules. The black triangles are loxP sites, and indicate the direction. The length of the arrows 
indicates the relative tendency of reactions. From Zhang et al. (2012) 
 
 Target site modifications fall into two categories, the first being spacer variants. RMCE 
(recombinase-mediated cassette exchange) and FLEx (flip excision) are two strategies that 
take advantage of the fact that loxP and FRT sites tolerate certain point mutations within 
their core (Hoess et al., 1986) and that only two identical sites can be recombined effectively 
(Senecoff et al., 1988). In general, two heterotypic sites containing different spacer 
sequences will not recombine efficiently (Senecoff et al., 1988). Spacer variants used in 
these two strategies have been developed for both Cre- and Flp-mediated recombination 
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(Lee and Saito, 1998, Langer et al., 2002, Schlake and Bode, 1994). In RMCE, a DNA sequence 
flanked by antiparallel heterotypic sites (e.g. “→DNA←”) can be inserted into a sequence 
containing the same combination of sites. The product is a newly replaced sequence flanked 
by heterotypic sites that cannot cross-react. RMCE is commonly used to replace selectable 
markers in embryonic stem (ES) cells used for gene targeting (Branda and Dymecki, 2004). In 
FLEx, a DNA sequence to be inverted is placed within two pairs of antiparallel homotypic 
sites (e.g. →→DNA←←). An inversion of either pair of homotypic sites leaves one site 
trapped for excision by the second pair of homotypic sites (e.g. “→AND←←←”). The 
product is an inverted sequence flanked by non-reacting heterotypic sites (→AND←).  
 
 
 
Figure 1.7 - Use of inverted repeat-variant target sites to achieve stable DNA Insertion or inversion 
 Stable DNA insertions (A) or inversions (B) may be achieved by exploiting lox or FRT sites that contain 
established substitutions in either the left or right inverted repeat, also referred to as the left element 
(LE) or right element (RE), respectively. While two wild-type (wt) target sites can recombine with each 
other repeatedly, an LE and RE mutant site will recombine efficiently only once, creating two different 
sites, a wild-type and a doubly (LE & RE) mutant inert site, that cannot recombine efficiently with each 
other. SM, selectable marker; GOI, gene-of-interest. From Branda and Dymecki (2004) 
 
In the second category of target site modifications, called inverted-repeat variants (Fig 1.7), 
a point mutation is made on one of the palindromic (inverted) sequences (Branda and 
Dymecki, 2004). A target site containing a nucleotide substitution on its left inverted repeat 
(LE mutant site) will recombine with a site that contains an analogous substitution on its 
right inverted repeat (RE mutant site). This strategy is often used to insert circular plasmid 
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DNA into chromosomal DNA, where one possesses an LE mutant site and the other an RE 
mutant site (Branda and Dymecki, 2004). The result is an inserted DNA sequence flanked by 
one wildtype target site and one double-mutant site (both RE and LE mutations). This 
strategy can also be used to invert a sequence flanked by one RE and one LE mutant site. 
The result is a stable inverted sequence flanked by one wildtype and one doubly mutant site.   
 
Advances in SSR technology have also focused on the recombinases themselves. Several 
modifications aim to enhance recombinase expression levels and enzymatic activity in 
mammalian cell culture and transgenic mouse models (Buchholz and Stewart, 2001, 
Voziyanov et al., 2003). A modified version of Flp called Flpe, for example, increases the 
protein’s thermostability and enhances its recombination efficiency four-fold (Buchholz et 
al., 1998). A modified version of Cre called iCre (improved Cre), is more compatible with 
eukaryotic systems and has a slightly elevated recombination efficiency (Shimshek et al., 
2002). Because unmodified Cre recombinase is substantially more efficient at 37oC than Flp, 
the Cre/loxP system has traditionally been favored in the field of mouse genetics. Improved 
versions of Flp, however, have recently shifted preference in favor of modified recombinases 
like Flpe and Flpo (Turan et al., 2011, Raymond and Soriano, 2007). 
1.2.2.1.2 ΦC31 recombinase 
In cultured ES cells, a more recent alternative to Cre and Flp is the Streptomyces phage-
derived φC31, which produces insertions that are inherently stable (Groth et al., 2000, 
Thyagarajan et al., 2001). ΦC31 catalyzes recombination between attP (39bp) and attB 
(34bp), which have similar but not identical inverted arm sequences, and produces two new 
sites termed attL and attR (Groth et al., 2000, Thorpe and Smith, 1998). ΦC31 by itself is 
unable to catalyze recombination between attR/attL, which means the reaction is 
unidirectional. Reversal of this recombination event has recently been found to be possible 
in human and mouse cells (Farruggio et al., 2012). The use of this recombinase in 
chromosomal engineering and gene therapy has recently gained popularity (Zhang et al., 
2012).  
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 Inducible genetic manipulation 1.2.2.2
 
The field of genetics has greatly benefited from the use of inducible techniques that provide 
temporal control of genetic manipulations. In transgenic models, these strategies make it 
possible to bypass any embryonic lethality, early developmental defects or secondary 
compensatory mechanisms due to modified gene function. Genetic modifications can 
therefore be analyzed in both the developing and adult brain. Temporal control can be 
achieved using transcriptional strategies, such as the tetracycline (tet), lac and GAL4/UAS 
systems, or by the use of ligand-induced recombination. Tetracycline and estrogen based 
ligand-inducible variants of Cre recombinase are most commonly used in transgenic mice 
(Saunders, 2011). Both of these are binary systems, wherein two genetically modified mice, 
a “driver” and a “reporter”, are mated in order to obtain double heterozygous mice that can 
undergo conditional genetic manipulation (Lewandoski, 2001). In these strategies, the driver 
line carries either tet-regulated transactivation factors or a drug-sensitive recombinase and 
the reporter line carries a gene of interest whose expression relies on activation by tet or Cre 
(Saunders, 2011).  
1.2.2.2.1 Ligand-induced recombinases 
In this method, the mutated ligand-binding domain (LBD) of a steroid receptor is fused to a 
recombinant protein so its catalytic activity becomes ligand-dependent (Logie and Stewart, 
1995, Metzger et al., 1995). The binding domains of these fusion proteins are engineered to 
be resistant to their natural ligands and sensitive to synthetic equivalents (Feil et al., 1996, 
Zhang et al., 1996, Kellendonk et al., 1996). This is particularly important in mammalian 
systems where endogenous steroids are present and could activate recombination. Estrogen 
receptor (ER) chimeras are insensitive to βestradiol and responsive to its synthetic 
equivalent 4-OH tamoxifen. The most popular ligand-induced recombinase, CreERT2, 
contains a triple mutation to the LBD and is ~10 fold as efficient as other CreER fusions (Feil 
et al., 1997, Indra et al., 1999, Feil et al., 2009). Over 300 Cre-based transgenic mouse lines 
have been developed, characterized and used successfully to study gene function 
(http://cre.jax.org, www.gensat.org/cre.jsp). A FlpeERT2 variant has also been developed but 
is not as commonly used as CerERs (Hunter et al., 2005). The progesterone receptor (PR) has 
also been used to design ligand-dependent recombinases, albeit with limited success in vivo 
(Wunderlich et al., 2001). Chimeras CrePR1 and Cre*PR are insensitive to endogenous 
progesterone but sensitive to the synthetic steroid RU 486 (Kellendonk et al., 1996, 
Wunderlich et al., 2001).  
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1.2.2.2.2 Tetracycline-inducible system for genetic manipulations 
A second method of temporal control uses tetracycline (tet) to regulate transcription (Fig 
1.8) (Gossen and Bujard, 1992). This method requires two components; a transactivator 
gene that binds tetracycline, and a fusion of the tetracycline operon (tetO) and a gene of 
interest (GOI) (St-Onge et al., 1996, Strathdee et al., 1999). In the tet-Off system, the 
transactivator tTA binds to tetO to initiate transcription in the absence of tetracycline 
(Gossen and Bujard, 1992). Constant administration of tetracycline, or its analog doxycycline 
(dox), must therefore be maintained to repress expression of the GOI. Gene transcription 
can be induced by discontinuing drug administration, although complete clearance of 
doxycycline in mice may take up to seven days (Kistner et al., 1996). In the tet-ON system, 
rtTA (reverse tTA) binds tetO to initiate transcription only in the presence of tetracycline 
(Gossen et al., 1995). This method relies on delivery of tetracycline or doxycycline in order to 
initiate GOI transcription. In adult transgenic mice, gene expression can be detected within 
an hour of drug administration (Hasan et al., 2001, Schonig et al., 2002).  
 
 
 
Figure 1.8 - Tetracycline-inducible system 
(a) Tet-Off system. tTA is active without Dox (or tetracycline), and the gene of interest is expressed. 
With Dox (or tetracycline) treatment, tTA is inactivated, and the gene is no longer expressed. (b) Tet-
On system. rtTA is inactive without Dox (or tetracycline), and the gene of interest is not expressed. 
With Dox (or tetracycline) treatment, rtTA is activated, and the gene is expressed. From (Zhang et al., 
2012) 
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 Neuronal cell-type specificity 1.2.2.3
 
Neuron-specific genetic manipulations can be produced in mice by assembling a DNA 
construct that contains neuron-specific promoter/enhancer elements. This DNA construct is 
then introduced into the host species by a conventional transgenic method like pronuclear 
microinjection. This is in contrast to gene targeting, where a transgenic construct is 
introduced by homologous recombination to a neuron-specific gene of interest (Rotolo et 
al., 2008). In theory, it could be possible to express a transgene in any desired cell-type by 
simply identifying a unique gene or enhancer in that cell population (Miyoshi and Fishell, 
2006).  In practice, however, robust and unique promoters are not abundant (Miyoshi and 
Fishell, 2006). Even so, some promoters have been used extensively, for example Thy1.2 
(Caroni, 1997, Feng et al., 2000), CamKIIα (Tsien et al., 1996) and Nestin (Zimmerman et al., 
1994, Tronche et al., 1999, Cheng et al., 2004). Additionally, several large-scale approaches 
set out to identify and characterize promising neuronal promoters (Gong et al., 2003, 
Madisen et al., 2010, Portales-Casamar et al., 2010).  
 
The Thy1 gene is expressed in pyramidal cells in both neuronal and non-neuronal tissue. 
Removal of one of its introns, however, eliminates expression in non-neuronal cell-types 
(Caroni, 1997). Using this modified Thy1.2 promoter, a transgene can be expressed 
throughout the central and peripheral nervous system without expression in non-neuronal 
tissue (Feng et al., 2000, Young et al., 2008, Heimer-McGinn and Young, 2011). Similarly, 
although the Nestin gene is expressed in several tissue types, one of its introns is neuron-
specific so, in combination with a minimal promoter sequence, it can be used to attain 
transgene expression almost exclusively in neural progenitor cells (Zimmerman et al., 1994, 
Burns et al., 2007). Finally, the CamKIIα (α-calcium-calmodulin-dependent kinase II) 
enhancer promotes activity in the forebrain region only (Mayford et al., 1995, Erdmann et 
al., 2007). 
 
Since transgene insertion is random, different lines produced from the same transgenic 
construct can display great variety of heritable expression patterns (Wilkie et al., 1986) 
Although position-effect variegation may lead to transcriptional silencing, the mosaicism it 
produces can also be beneficial if expression happens to be limited to a particular subset or 
area of interest. For instance, the SLICK lines (described in section 1.2.2.4.3) make use of the 
Thy1.2 promoter and display a wide range of mosaicism from less than 1% transgene 
expression in specific areas to over 95% neuronal expression in other lines (Young et al., 
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2008, Heimer-McGinn and Young, 2011). Transgenic lines using the CamKIIα promoter tend 
to have strong widespread expression in the cortex and hippocampus and more scattered 
expression in the rest of the forebrain (Tsien et al., 1996, Erdmann et al., 2007, Madisen et 
al., 2010).  
 
As illustrated by these examples, tissue-specific transgene expression can be combined with 
conditional gene manipulation strategies like SSR. Such binary systems use a “driver” 
transgenic line, in which recombinase expression (e.g. CreERT2 or Flpe) is controlled by a cell-
type specific promoter and a “reporter” line, in which gene deletion or transgene expression 
is achieved using recombinase recognition sites (e.g. loxP or FRT). The flexibility of binary 
systems allows for endless combinations that render precise spatial and temporal control in 
many different varieties of cell-types and subpopulations. Moreover, some of these lines 
utilize combinatorial control of gene expression or deletion by using more than one 
promoter/enhancer elements. Genetic manipulation in this case occurs only when the 
expression patterns of both promoters intersect (Zong et al., 2005, Farago et al., 2006, Kim 
et al., 2009). Some techniques that combine the use of cell-type specific genetic 
manipulation and cell labeling in sparse populations of cells are described in the following 
section.  
 
 Novel techniques that combine genetic manipulation and cell labeling  1.2.2.4
1.2.2.4.1 MARCM 
Developed by Luo and colleagues, MARCM (Mosaic Analysis with a Repressible Cell Marker) 
provides a way to introduce genetic manipulation in fluorescently labeled Drosophila 
melanogaster cells. As described by Lee and Luo (1999, 2001) this is achieved by placing a 
GFP marker under the control of a repressible promoter. The GAL4/UAS inducible system is 
used, where transcription of the ubiquitously-expressed promoter GAL4 is activated by UAS 
(upstream activation sequence)(Brand and Perrimon, 1993) and blocked by the antagonist 
GAL80 (O'Donnell et al., 1994). A single FRT site is placed on identical locations in 
homologous chromosome arms; one arm contains the GAL80 repressor distal to the FRT site 
and the other arm contains GAL4, GFP and a mutation of interest, all distal to the FRT site. 
Following Flp-mediated interchromosomal recombination during mitosis, only cells that are 
homozygous for the mutation will express GFP. MARCM was a significant improvement over 
earlier methods that relied on negative labeling (GFP on one arm and a mutation on the 
other)(Xu and Rubin, 1993). With MARCM, the neuronal morphology of a homozygous 
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mutant cell can be visualized and studied in vivo. This technique is still widely used in fruit 
flies (e.g. Kuert et al. (2012)) and has also been extended for use in mammalian systems 
(Zong et al., 2005), as described below.  
1.2.2.4.2 MADM Strategy 
Also developed by Luo and colleagues, MADM (Mosaic Analysis with Double Markers) is a 
method of generating mice with genetic manipulations in fluorescently labeled cells. As 
described in Zong et al. (2005) and Tasic et al. (2012), two reciprocally chimeric markers are 
knocked in at identical loci on homologous chromosomes in separate mice. The chimeras, 
referred to as GR and RG, each contain part of the GFP coding sequence and part of an RFP 
coding sequence (DsRed2 or tdTomato). The N-terminus of one fluorescent marker and the 
C-terminus of the other are split by a loxP-containing intron. A mutation of interest is placed 
distal to the GR knock-in site, creating a heterozygous mutation. The two chimeric mice are 
crossed to each other and then to a Cre-expressing driver line. The resulting triple transgenic 
mice can undergo Cre-mediated interchromosomal recombination in mitotic and post-
mitotic cells. Chromosomal crossover restores functional GFP and RFP expression cassettes. 
After mitosis, daughter cells are either (a) homozygous mutant expressing GFP, (b) 
homozygous wildtype expressing RFP, or (c) heterozygous expressing both GFP and RFP. In 
this way, the MADM strategy can introduce a genetic mutation, with fluorescent markers 
indicating cellular genotype. These mice can simultaneously be used to trigger genetic 
manipulation, analyze cellular lineage and visualize neuronal wiring patterns. 
 
MADM-generated mouse lines can be mated to any Cre-expressing line in order to induce 
recombinase-mediated interchromosomal exchange. Several Cre-expressing lines have been 
crossed to MADM lines and characterized, including β-actin-, Nestin- and Wnt1-expressing 
lines (Zong et al., 2005). As described in this publication, labeling efficiency depends on the 
driver line used. When crossed to conditional Cre-expressing lines like β-actinCreER, double 
heterozygous mice show tight control in the absence of tamoxifen induction. In all cases GFP 
is strongly expressed without the need for further immunostaining. RFP fluorescence is 
strong for dtTomato but not for DsRed2 (so a Myc tag is generally used to enhance labeling). 
As discussed in Zong et al. (2005), a single copy of the knocked-in fluorescent marker gene 
has proven sufficient to label all neuronal processes including dendritic spines and long-
distance axons. Since the strategy does not require a particular gene to be floxed/flirted, 
MADM can also provide markers for spontaneous or chemically induced mutations. 
Moreover, labeling of homozygous wildtype cells offers a built-in negative control. 
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Figure 1.9 – Schematic of the MADM Strategy 
G2 recombination followed by X segregation generates singly labeled cells that alter genotype if the 
original cell is heterozygous for a mutation of interest. G2 recombination followed by Z segregation 
generates either colorless or double-colored cells without altering genotype. From Zong et al. (2005) 
 
MADM provides a method for introducing genetic mutations that is compatible with any 
Cre-expressing driver line. The approach is limited, however, by the fact that it can only be 
applied to introduce mutations distal to the MADM cassette (from the centromere) on a 
given chromosome. Currently, MADM cassettes are available for Rosa26 on chromosome 6, 
Miya1 on chromosome 1, Miya10 on chromosome 10, and Hipp11 on chromosome 11 (Tasic 
et al., 2012). Although there are efforts underway to find and characterize efficient loci on 
other chromosomes, this restriction limits the number of genes that can be manipulated 
using MADM. Additionally, this method is quite laborious as it involves the generation of two 
mice by gene targeting (or at least one that harbors the desired modification if it is 
compatible with an available mutually chimeric line) and requires mating of three lines to 
obtain triple heterozygosity.  
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1.2.2.4.3 SLICK Mice 
Developed by Feng and colleagues, SLICK (Single-neuron Labeling with Inducible Cre-
mediated Knockout) is another recently developed technique that allows for inducible 
genetic manipulation in fluorescently labeled single cells. As described by Young et al. 
(2008), this is achieved by simultaneous expression of CreERT2 and YFP (yellow fluorescent 
protein), driven by two back-to-back copies of the Thy1.2 promoter (Fig 1.10). SLICK mice 
can be crossed to any loxP-based transgenic mouse to achieve efficient genetic 
manipulations in YFP-labeled cells. Due to position-effect variegation, expression of the 
SLICK transgene varies over 30 different lines (Fig 1.11) including SLICK-V, where genetic 
manipulation is spatially restricted to small subpopulations of projection neurons, and SLICK-
H, where expression is widespread in most populations of projection neurons in the brain. In 
both of these models, YFP fluorescence is bright and easily visualized in all cellular processes, 
including dendritic spines and long-distance axons. SLICK-V and SLICK-H, which have been 
characterized using the ROSA26 reporter line, display tight temporal control of induction in 
the absence of tamoxifen (Young et al., 2008, Heimer-McGinn and Young, 2011).   
 
The two components of the SLICK transgene, YFP fluorescent reporting and Cre/loxP 
compatibility, endow this method with several advantages. In SLICK-V, where expression is 
limited to less than 10% of cells in a given population, strong fluorescent labeling facilitates 
precise morphological analysis and examination of synaptic connectivity in individual mutant 
neurons. Because YFP fluorescence is expressed in the absence of Cre-mediated 
recombination, individual cells can be imaged before and after induction of a genetic 
manipulation, making it possible to analyze changes in neuronal properties. Dynamic 
processes like synaptic plasticity and spine morphology can also be visualized in vivo before 
and after gene activation or knockout. Another important feature of YFP expression before 
CreERT2 drug activation is that fluorescent cells in un-treated SLICK mice can be used as 
controls for mutant cells in treated mice.   
Figure 1.10 - Strategy for coexpression of YFP 
and Cre in SLICK transgenic mice. 
(a) Schematic representation of the DNA 
construct used to generate SLICK transgenic 
mice. Two copies of the Thy1 promoter drive 
expression of YFP and the inducible form of 
Cre recombinase, CreER
T2
. CreER
T2
 can be 
activated by the synthetic ligand tamoxifen, 
but not by endogenous estrogens. Tamoxifen 
administration can thus be used to control the 
timing of recombination. From Young et al. 
(2008) 
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As discussed in Young et al. (2008) and Heimer-McGinn and Young (2011) the CreERT2 
component renders SLICK lines compatible with any loxP-based genetically modified mouse 
model, which makes it widely applicable in the field of mouse genetics. Since YFP is not 
easily distinguished from GFP, however, GFP cannot be used as a reporter to characterize 
gene expression. This does not hinder SLICK recombination efficiency, which is >90% in many 
areas of the brain, but does diminish the convenience of GFP-expressing loxP mice. The 
inducible nature of this system permits genetic modifications to be analyzed in the stable 
adult brain without early developmental defects arising. Studies can also be performed in 
younger mice although recombination efficiency is reduced due to the developmental 
nature of the Thy1.2 promoter (Caroni, 1997). In SLICK-V, the sparse expression pattern 
enables the study of competitive processes in the long term and prevents the disruption of 
general function, thus reducing crossover between cell-autonomous effects and those 
caused by more widespread dysfunction (Young et al., 2008). As for SLICK-H, it is currently 
one of the most efficient Cre-expressing lines available for pan-neuronal genetic 
manipulation (Heimer-McGinn and Young, 2011).  
 
 
 
Figure 1.11– YFP labeling of distinct neuronal populations in SLICK transgenic lines 
From Young et al. (2008) 
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1.2.3 Altering neuronal activity 
 
The ability to modulate neuronal activity is essential to the study of neuronal circuits. 
Classical studies in the field of systems neuroscience used pharmacological agents like kainic 
acid or glutamate receptor antagonists to lesion, ablate or inhibit cell populations or brain 
regions (Wulff and Wisden, 2005). More recently, pharmacological agents like tetrodotoxin 
and bicuculline have been used to respectively inhibit or enhance global neuronal activity in 
cell cultures or brain slices (Khawaled et al., 1999, Narahashi, 2008). Although many 
important observations can be made using these methods, they do not provide cell-type 
specificity and are limited by compensatory mechanisms that complicate data analysis.  
 
The recent merging of genetics and pharmacology, as well as the application of light-
sensitive ion channels/pumps, provides a wealth of tools that offer precise spatial and 
temporal control. Select populations of cells can be activated or inhibited by either altering 
membrane potential or by regulating neurotransmitter release.  These instruments greatly 
facilitate the study of neuronal circuit dynamics in vivo. (Wulff and Wisden, 2005, Miyoshi 
and Fishell, 2006, Dymecki and Kim, 2007, Havekes and Abel, 2009, Rogan and Roth, 2011).  
 
 Alteration of ion gradients across the cell membrane 1.2.3.1
 
Neuronal activity can be modulated by altering ion gradients across the cell membrane. Ion 
channels and pumps can be altered genetically by overexpression or mutation, 
pharmacologically by ligand-induced activation or inhibition, and optically using light-
sensitive ion channels and pumps. Several approaches employ a combination of these 
methods. In this way, the modulated influx or efflux of certain ions can selectively alter 
neuronal excitability and therefore inhibit or activate Ca2+-dependent synaptic transmission 
(Wulff and Wisden, 2005, Havekes and Abel, 2009). In this thesis we aimed to inhibit 
neuronal activity by overexpression of the Kir2.1 inward rectifying potassium channel, which 
is discussed in the following section.  
1.2.3.1.1 Kir2.1 inward rectifying channel 
Inward rectifying potassium (Kir) channels are transmembrane proteins that create an 
inward K+ current and are critically involved in maintaining resting membrane potential 
following hyperpolarization (Hibino et al., 2010). Unlike conventional voltage-gated K+ 
channels, Kir channels are insensitive to membrane voltage and instead respond to the 
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electrochemical gradient for K+ (Hibino et al., 2010). At membrane potentials below 
potassium’s reversal potential of -86 mV (i.e. when the cell is hyperpolarized), K+ influx 
through Kir channels restores K+ equilibrium and returns the membrane to its resting 
potential (Alger and Nicoll, 1980, Nichols and Lopatin, 1997). This serves to counteract the 
hyperpolarizing effect of excessive outward K+ flux through voltage-gated channels following 
repolarization (Nichols and Lopatin, 1997). Inward rectification results from intracellular 
molecules like Mg2+ (Matsuda et al., 1987) and polyamines (Lopatin et al., 1994) that bind to 
Kir at several sites in order to block outward K+ flux (Lu et al., 1999). Kir channel function and 
localization are further modulated by a variety of factors including (a) extracellular K+ 
concentration, (b) intra- and extracellular pH, (c) phosphatidylinositol 4,5-bisphosphate 
(PtdIns-4,5-P2), (d) phosphorylation, (e) protein interactions, with PSD-95for example, and 
(f) internalization mediated by small GTPases. 
 
 
Figure 1.12 - Schematic representation of the structure of the Kir2.1 subunit 
The Kir2.1 channel is composed of four subunits, each containing two transmembrane domains (M1 
and M2) linked by a highly conserved pore region (P). The extracellular loops contains five negatively 
charged amino acid residues (D-Asp and E-Glu) that act as binding sites for Mg
2+
 or polyamides. These 
molecules block the outward flow of potassium and therefore enable inward rectification. From 
Hayashi and Matsuda (2007) 
 
Kir2.1, from the Kir2.X subfamily (Fig 1.12), is considered to be critically involved in 
regulating neuronal excitability and has been used as a tool to inhibit neuronal activity (Kubo 
et al., 1993, Hibino et al., 2010). It is expressed diffusely and weakly throughout the brain 
and is restricted to neuronal somata and dendrites (Pruss et al., 2005). This classical Kir 
channel (as opposed to G protein-gated, ATP-sensitive or K+ transport Kir channels) displays 
a strong inward rectifying conductance that can be further modulated by neurotransmitter 
activity (Hibino et al., 2010). Kir2.1 knockout mice display symptoms similar to Andersen’s 
syndrome (Zaritsky et al., 2000), which is caused by a mutation in the gene that encodes for 
Kir2.1 (Plaster et al., 2001).  
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For the study of activity-dependent competition in neuronal circuits, over-expression of the 
Kir2.1 channel has been widely used as a method to hyperpolarize individual neurons and 
therefore prevent them from firing action potentials (Burrone et al., 2002, Yu et al., 2004, 
Hua et al., 2005, Hartman et al., 2006). It was first overexpressed in mammalian cells by viral 
delivery in order to hyperpolarize cultured cervical ganglion cells (Johns et al., 1999, Holt et 
al., 1999). Transgenic delivery by microinjection has also been achieved in mice, where 
overexpression in a sparse population of olfactory neurons is regulated by tetracycline 
induction (Yu et al., 2004). Kir2.1 overexpression is a useful tool for the study of the activity-
dependent effects of prolonged neuronal silencing in sparse populations of cells.  
1.2.3.1.2 Other methods that alter ion gradients across the cell membrane 
Pharmacogenetic methods provide the ability to reversibly and selectively suppress neuronal 
activity. G-protein-gated inward rectifying K+ channels, for instance, can be used in 
combination with the allatostatin receptor, a D. melanogaster GPCR that is insensitive to 
mammalian peptide ligands (Lechner et al., 2002, Ehrengruber et al., 1997). When bound to 
its ligand, allatostatin receptors indirectly couple with GIRK channels to promote K+ efflux.  
Thus, administration of allatostatin peptide transiently induces membrane hyperpolarization 
and consequently inhibits action potentials (Lechner et al., 2002, Tan et al., 2006, Gosgnach 
et al., 2006). Glutamate-gated Cl- channels (GluCls), derived from C. elegans, can also be 
used in a similar fashion (Raymond and Sattelle, 2002). Administration of ivermectin , a GluCl 
agonist, promotes Cl- influx and subsequent neuronal silencing. This has been done 
successfully in mice that are transgenically engineered to express GluCl in select cell types 
(Slimko et al., 2002, Raymond and Sattelle, 2002, Lerchner et al., 2007). Similarly, the GABAA 
receptor is positively modulated by the drug zoldipem: drug administration facilitates 
GABAA-mediated transmission and thus inhibits excitatory activity (Rudolph and Mohler, 
2004). Wuff and colleagues generated zoldipem-insensitive mice by genetically mutating all 
GABAA receptors and then used Cre-mediated recombination to restore sensitivity in select 
populations of cells (Wulff et al., 2007).  
 
Reversible neuronal suppression can also be achieved using engineered GPCRs that are 
sensitive only to synthetic ligands (receptor activated solely by a synthetic ligand, RASSL) 
(Redfern et al., 1999, Scearce-Levie et al., 2001, Srinivasan et al., 2003). This method is 
advantageous because (a) there is an immense availability of natural GPCRs that can be 
targeted, (b) the relatively small size of GPCR cDNA constructs makes them easy to transfer, 
and because (c) they are commonly targeted for drug discovery, therefore many agonists 
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and antagonists have already been developed (Conklin et al., 2008). Several transgenic mice 
have been successfully developed that express RASSLs, including the modified κ-opiod 
receptor called Ro1 and the modified 5-HT4 serotonin receptor called Rs1 (Sweger et al., 
2007, Hsiao et al., 2011).  
 
The previously mentioned strategies allow the study of neuronal activity on the timescale of 
minutes to hours, or longer. Synaptic processes, however, occur on the scale of milliseconds, 
so these methods are insufficient for the study of fast-acting circuit dynamics. A decade ago, 
several labs began exploring the use of light stimulation to modulate neurons (Zemelman et 
al., 2002, Banghart et al., 2004, Volgraf et al., 2006, Chambers et al., 2006). In 2005 it was 
shown that channelrhodopsin-2 (ChR2), a light-gated cation channel from the algae C. 
reinhardtii (Nagel et al., 2003), can instantly prompt neuronal spiking by creating a cation 
influx in response to pulses of blue light (Boyden et al., 2005, Li et al., 2005, Deisseroth et al., 
2006). The field of optogenetics, as it is coined, has since grown rapidly and vastly. Many 
new opsins, with differing light and ion sensitivities, have been found or engineered 
(Bernstein and Boyden, 2011). Because they respond to different wavelengths of light, they 
can be used simultaneously to selectively activate and/or inhibit cells in vivo. For example, 
halorhodopsins, from archaea, inhibit neuronal activity by allowing an influx of Cl- in 
response to yellow/green light (Bamberg et al., 1993, Gradinaru et al., 2008), whereas light-
driven proton pumps derived from archaea, bacteria or fungi pump protons out of the cell to 
hyperpolarize it (Chow et al., 2010).  
 
Delivery of these microbial opsins to the neuronal cell membrane can be achieved by any 
gene-delivery method such as lentiviral transfer or transgenic delivery (Bernstein and 
Boyden, 2011). This has been done in a range of cell types, tissues, circuits and organisms 
(Zhao et al., 2011a, Goold and Nicoll, 2010, Portugues et al., 2013, Honjo et al., 2012, de 
Vries and Clandinin, 2013, Xu and Kim, 2011). Additionally, engineered step function opsins 
can be switched “on” or “off” in response to different wavelengths of light. These optical 
switches have an extended open-state conformation and can therefore operate on longer 
timescales (Berndt et al., 2009). Finally, chimeric light-activated GPCRs can be engineered by 
fusing the intracellular domain of a GPCR of interest to the transmembrane domain of 
rhodopsin (Airan et al., 2009). This approach facilitates the study of GPCR-mediated signaling 
pathways in behaving animals.  
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 Inhibition of neurotransmitter release  1.2.3.2
 
As described in the previous section, neurons can be inhibited by hyperpolarizing the cell in 
order to prevent action potentials and inhibit synaptic activity. Another way to inhibit 
neuronal activity is to impede synaptic vesicle function and therefore block 
neurotransmission. Manipulations that affect synaptic transmission include neurotoxin-
mediated cleavage or genetic manipulation of core SNARE proteins, and in Drosophila, 
temperature-sensitive paralysis induced by the shibire mutation (Schiavo et al., 2000, 
Karpova et al., 2005, Kitamoto, 2002). In this thesis we show that long-term inhibition of 
neurotransmission in a small population of cells by the tetanus toxin light chain can be used 
in the study of activity-dependent competition.   
 
 
Figure 1.13 – SNARE-mediated synaptic vesicle fusion to the plasma membrane 
From Purves et al. (2001)  
 
In neurotransmission, the SNARE complex mediates synaptic vesicle fusion to the 
presynaptic membrane (Fig 1.13). The complex, composed of syntaxin-1, SNAP-25 and 
VAMP2/synaptobrevin, assembles reversibly into a tight and highly stable bundle of four α-
helices (Fig 1.13) (Poirier et al., 1998). Syntaxin-1 and VAMP2 are transmembrane proteins 
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anchored to the synaptic membrane and synaptic vesicle, respectively and each contributes 
one α-helix to the SNARE complex (Bennett and Scheller, 1994, Sudhof, 1995). SNAP-25, 
which contributes two helices to the complex, is a cytosolic protein tethered to the plasma 
membrane by palmitoyl chains (Wilson et al., 1996). It is believed that the energy released 
during complex formation serves to overcome repulsive forces between the two membranes 
(Rizo and Sudhof, 1998, Li et al., 2007).  
 
The clostridial neurotoxins, tetanus toxin (TeNT) and seven serotypically distinct botulinum 
neurotoxins (BoNT, A through G), are endowed with metalloprotease activity and can 
catalyze the degradation of the core SNARE proteins mentioned above (Schiavo et al., 2000). 
Despite their sequence similarity, each toxin has a very particular target and peptide bond 
specificity (Schiavo et al., 2000). Syntaxin is cleaved by BoNT/C, VAMP2 is cleaved by TeNT, 
BoNT/B, D, F, and G, and SNAP-25 is cleaved by BoNT/A, C, and E (Fig 1.13) (Schiavo et al., 
2000, Ramakrishnan et al., 2012). It is well established that neurotoxin-mediated cleavage of 
SNARE proteins, particularly VAMP2, is responsible for blocking neurotransmission 
(Ramakrishnan et al., 2012). For this reason they are widely used for the purpose of 
neuronal silencing.  
1.2.3.2.1 Tetanus toxin light chain (TetoxLC) 
Tetanus neurotoxin (TeNT) is one of eight clostridial neurotoxins that act by directly 
interfering with neuroexocytosis. With a median lethal dose of 0.1 ng toxin/kg body weight, 
TeNT is one of the most toxic substances known. The protein is composed of three domains, 
(1) the NH2-terminal domain, called the light (L) chain, is a zinc-dependent endopeptidase, 
(2) the central domain (HN) is responsible for membrane translocation of the light chain, and 
(3) the COOH-terminal domain, is divided into two subdomains involved in protein-protein 
interactions at the synaptic membrane (Fig 1.14). The metalloprotease activity of the L-chain 
is responsible for cleaving the vesicle-associated membrane protein (VAMP)-
2/synaptobrevin, an essential component of the SNARE complex which mediates synaptic 
vesicle fusion to the synaptic membrane. Intoxicated synapses display severe inhibition of 
synaptic vesicle release, which blocks neurotransmission, with no effect on action potential 
propagation or on Ca2+ homeostasis.  
 
The TeNT light chain (TetoxLC), which is sufficient to inhibit neuroexocytosis (Bittner et al., 
1989), cleaves VAMP2 by proteolyzing the peptide bond between residues 76-Gln and 77-
Phe (Schiavo et al., 2000). An upstream remote cluster of amino acids initiates substrate 
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recognition and several additional residues close to the cleavage site are critical for catalytic 
activity (Sikorra et al., 2008). Several transgenic mice have been developed that conditionally 
express  TetoxLC, both reversibly and irreversibly (Yamamoto et al., 2003, Yu et al., 2004, 
Nakashiba et al., 2008, Kim et al., 2009, Kobayashi et al., 2008). When induced, TetoxLC-
mediated cleavage of VAMP2 blocks neurotransmission in select populations of cells of 
these transgenic models.  
 
 
 
Figure 1.14 – Schematic representation of the tetanus toxin protein domain structure. 
TeNT consist of 3 domains of similar size (50 kDa). NH2-terminal domain (left) is a zinc endopeptidase, 
and the active site zinc atom is coordinated by 2 histidine residues, a water molecule bound to a 
conserved glutamate residue and by the carboxylate group of another glutamate. HN, the central 
domain, is responsible for the membrane translocation of the L chain into the neuronal cytosol. The 
COOH-terminal HC domain (right) consists of two equally sized subdomains. The NH2-terminal 
subdomain has a structure similar to that of sugar binding proteins. The COOH-terminal subdomain 
folds similarly to proteins known to be involved in protein-protein binding functions such as the K1 
channel specific dendrotoxin. Such structure is consistent with the toxin binding to the presynaptic 
membrane via a double interaction, most likely with two different molecules of the nerve terminal. 
From Schiavo et al (2000) 
 
Some VAMP isoforms are insensitive to tetanus-mediated cleavage (VAMP4, 7 & 8), while 
others are sensitive to tetanus-mediated cleavage but absent from neurons 
(VAMP3/cellubrevin & VAMP5) (Proux-Gillardeaux et al., 2005). In the rat, VAMP1 is tetanus-
insensitive due to a variation at residue 76 (Schiavo et al., 2000), although this substitution 
does not occur in the mouse and human VAMP1 (Fig 1.15). To our knowledge this has not 
been experimentally tested but it is possible that VAMP1 in the mouse is also cleaved by 
TetoxLC. 
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Figure 1.15 - Sequence alignment for the TetoxLC cleavage site in mouse and rat VAMP1/2/3 
Sequence alignment of VAMP1/2/3 in mouse and rat shows the cleavage site for TetoxLC between 
Gln-76 and Phe-77 (box with solid lines). Rat VAMP1 is insensitive to TetoxLC-mediated cleavage 
because it has an amino acid substitution at position 76 (red box). The remote cluster where Tetox 
initiates substrate recognition is boxed with dotted lines and arrows indicate sites where mutagenesis 
results in a loss of cleavability. 
 
1.2.3.2.2 Other methods that inhibit neurotransmitter release 
Alternatively, molecules for inactivation of synaptic transmission (MIST) have been 
developed and characterized in cells and mice. In this technique, presynaptic proteins like 
VAMP2 and synaptophysin, a SNARE complex regulator, are crosslinked to small molecule 
“dimerizers” that interfere with protein function and consequently inhibit 
neurotransmission (Karpova et al., 2005). In Drosophila, a mutation in the shibire gene, a 
dynamin homolog, causes temperature-sensitive paralysis (van der Bliek and Meyerowitz, 
1991). Because shibire is involved in vesicle endocytosis (De Camilli et al., 1995), a 
heterozygous mutation of this gene restricts vesicle reuptake and consequently inhibits 
synaptic transmission (Kitamoto, 2001, Kasuya et al., 2009). All of the tools mentioned in this 
section have been helpful in the study of activity-dependent processes in the brain. 
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1.3 Concluding remarks 
 
 
It is fairly well established now that the processes of axonal and dendritic development and 
refinement occur in an activity-dependent manner and in response to competition between 
neurites and/or neurons. The precise mechanisms responsible for these alterations 
however, remain to be fully elucidated. Moreover, the field of neuroscience has evolved 
from studying the role of individual neurons, to trying to understand how cells within an 
entire circuit develop, interact and synchronize with each other. We are now interested, not 
only in synaptic plasticity, but also in the plasticity of whole circuits. 
 
 This higher-order plasticity, whereby the plasticity of individual synapses and cells is 
somehow synchronized throughout an entire network, is crucial to normal brain function. 
The development of the visual system, for example, relies on waves of spontaneous spiking 
activity that sweep across the retina, LGN and visual cortex in order to synchronize nearby 
cells to fire and group together (Huberman et al., 2008). Furthermore, Hebbian forms of 
synaptic plasticity like LTP and LTD are complimented by several forms of homeostatic 
plasticity, which ensure that the underlying circuits that drive behavior remain stable yet 
flexible (Turrigiano, 2012). The importance of higher-order plasticity is underscored by the 
fact that changes in normal activity patterns cause circuit-level alterations that can lead, for 
example, to intellectual disorders like Autism spectrum disorders and Fragile X syndrome 
(Goncalves et al., 2013).  
 
The tools mentioned in this Introduction make it now feasible to study individual neurons 
more closely and investigate how their activity relates to other cells within a circuit.  A 
common approach in studying activity-dependent competition is to alter the neuronal 
activity of a single cell or a sparse population of cells and observe the effect of an increased 
or decreased ability to compete in a wildtype environment. Previously, the effects of 
activity-dependent competition on dendritic and axonal arbors have been studied in the 
Xenopus and zebrafish visual systems as well as in mammalian hippocampal cell cultures and 
in the mouse olfactory system (Burrone et al., 2002, Ruthazer et al., 2003, Yu et al., 2004, 
Hua et al., 2005). The techniques used in these studies, however, are not broadly applicable 
to other structures in the mammalian brain. The hippocampus and cortex, for example, are 
of particular interest in the study of excitatory neurotransmission at dendritic spines.  
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In this thesis we aimed to develop two transgenic models that allow long-term inhibition of 
neuronal activity in a small subset of pyramidal cells; overexpression of the inward rectifying 
potassium channel Kir2.1 and expression of the tetanus toxin light chain (described in 
Chapter 3). We also apply the TetoxLC approach to study dendritic morphology in response 
to neuronal silencing in a small population of pyramidal CA1 cells (Chapter 5). The results 
from extreme manipulations such as these give insight into how normal circuit function may 
lead to disease and/or how these diseases might progress.  
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Chapter 2 Efficient inducible Pan-neuronal Cre-mediated 
recombination in SLICK-H transgenic mice 
 
2.1 Abstract 
 
Large-scale functional genomics in mice is becoming feasible through projects to develop 
conditional knockout alleles for every gene. Inducible neuron-speciﬁc gene knockout in such 
mice will permit the analysis of neuronal phenotypes while circumventing developmental 
defects or embryonic lethality. Here we describe a transgenic line, termed SLICK-H, that 
facilitates widespread inducible conditional genetic manipulation within most populations of 
projection neurons. In SLICK-H mice, the Thy1 promoter drives robust and relatively uniform 
expression of a drug-inducible form of Cre recombinase throughout the peripheral and 
central nervous system. This permits efﬁcient induction of Cre-mediated genetic 
manipulation upon tamoxifen administration in adult mice. Importantly, Cre activity in the 
absence of tamoxifen is minimal, permitting tight control of recombination. In the present 
study, we catalog in detail the transgene expression patterns and recombination efﬁciencies 
in SLICK-H mice. Our results highlight the utility of SLICK-H mice for functional genomics in 
the nervous system. 
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2.2 Results 
2.2.1 Background  
 
The utility of the Cre recombinase system is such that large scale projects are currently 
underway to generate Cre/LoxP-compatible conditional knockout alleles of almost every 
mouse gene (http://www.knockoutmouse.org/). In concert with these efforts, improved 
‘‘Cre driver’’ lines are being developed to facilitate gene knockout in any tissue or cell-type 
of interest. The temporal control afforded by the ligand-inducible CreERT2 recombinase is 
especially desirable, but the generation of such lines with optimal expression patterns and 
efﬁcient induction of Cre activity is not trivial. The expression patterns of an endogenous 
promoter can be hard to reproduce in a transgenic construct either because some promoter 
elements are missing or due to positional effects upon insertion of the transgene into the 
genome. Achieving appropriate expression levels of CreERT2 is also crucial. Weak promoters 
may yield inefﬁcient recombination, while strong promoters that drive very high levels of 
transgene expression will result in ‘‘leaky’’ recombination in the absence of tamoxifen 
administration. The efﬁcient application of CreERT2 technology in the central nervous system, 
though highly desirable, is particularly challenging due to the diversity of cell types and 
complex anatomy of the brain.  
 
Figure 2.1 - Strategy for conditional transgenic co-expression of SLICK and ROSA26 
(A) Schematic representation of the SLICK transgene. Two back-to-back copies of the Thy1 promoter 
drive expression of YFP and CreER
T2
. (B) Schematic representation of R26R reporter strain used to 
assess Cre-mediated recombination. A neomycin resistance gene and transcriptional stop sequence 
are removed upon Cre-mediated recombination to allow expression of the LacZ reporter gene coding 
for β-galactosidase. The black triangles represent loxP sites. From Heimer-McGinn and Young (2011) 
 
A recently developed a technique termed SLICK (single-neuron labeling with inducible Cre-
mediated knockout) allows for inducible genetic manipulation of ﬂuorescently labeled, 
single neurons in mice (Young et al., 2008). This is achieved by using two copies of the 
Thy1.2 promoter cassette to coexpress CreERT2 and yellow ﬂuorescent protein (YFP) within 
the same small subsets of neurons (Fig 2.1A). The Thy1.2 promoter has been widely used to 
drive robust transgene expression in projection neurons and was the ﬁrst promoter to yield 
bright labeling of neurons in mice through expression of ﬂuorescent proteins (Caroni, 1997, 
Feng et al., 2000, Oddo et al., 2003). The primary objective in developing the SLICK method 
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was to identify transgenic lines that exhibit sparse labeling due to position-effect 
variegation, thus enabling high resolution imaging of single neurons (Young and Feng, 2004). 
In the process, however, many lines with broader transgene expression were also generated. 
These are not suitable for single neuron imaging purposes, but are valuable tools for wide-
spread neuronal manipulation. In this chapter we describe one such line, called SLICK-H, 
which has expression properties that are optimal for efﬁcient, inducible neuron-specific 
genetic manipulation in adult mice.  
 
2.2.2 Transgene expression in adult SLICK-H mice 
 
 Transgene expression pattern shown by YFP fluorescence  2.2.2.1
We first set out to determine the patterns of SLICK transgene expression in the SLICK-H line. 
Examining YFP ﬂuorescence in adult SLICK-H mice, we observed that transgene expression is 
widespread and relatively uniform in many brain regions (Fig 2.2A,B). Areas with extensive 
YFP labeling in cell somas include the visual, parietal, somatosensory, motor, insular, 
piriform and entorhinal cortical areas, the major hippocampal ﬁelds except CA2, the 
amygdala, the inferior and superior colliculi, many thalamic and brainstem nuclei, the 
anterior olfactory nucleus, granule and Purkinje cells of the cerebellum, and mitral cells in 
the olfactory bulb. Notable regions with dim or no YFP ﬂuorescence in cell somas are the 
caudate-putamen, ventral striatum, hypothalamus, basal forebrain, and substantia nigra, 
although brightly labeled axons and nerve terminals are observed in some of these areas. 
SLICK-H also has strong YFP labeling in both sensory and motor neurons in the spinal cord, 
photoreceptors, and retinal ganglion cells in the retina and dorsal root ganglion (DRG) 
neurons (shown in Fig 2.7D). 
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Figure 2.2 - Transgene expression in SLICK-H transgenic line. 
Transgene expression as indicated by YFP labeling in a medial (A) and lateral (B) sagittal brain section from adult 
SLICK-H mice. Major anatomical brain regions are indicated. The CA1/subiculum (C), motor cortex (D), cerebellum (E), 
and thalamus (F) are shown at a magnification of 10X. FromHeimer-McGinn and Young (2011) 
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 Transgene expression is neuron-speciﬁc as shown by immunohistochemistry 2.2.2.2
 
In order to ensure that transgene expression is restricted to neurons, we performed 
immunostaining using an α-GFAP antibody (Fig 2.3A) that recognizes GFAP (glial fibrillary 
acidic protein) and is commonly used as an astrocytic marker (Methods, Table 7.1). We also 
stained for an α-Olig2 antibody (Fig 2.3B) that recognizes Olig2 (oligodendrocyte 
transcription factor 2) and is commonly used as a marker for oligodendrocytes (Methods, 
Table 7.1). We carefully examined all brain regions and determined that YFP ﬂuorescence or 
β-gal staining (described in section 2.2.3.1) does not colocalize with either glial cell-type in 
any brain region. We also carefully examined non-neuronal tissue for the presence of YFP 
fluorescence. Similarly, we observed no SLICK expression in these tissues (Fig 2.3C-F). SLICK--
H therefore appears to be expressed specifically in neuronal populations of only the central 
and peripheral nervous systems.  
 
 
Figure 2.3 - Neuron-specific transgene expression in SLICK-H mice. 
(A,B) YFP fluorescence (green) in brain sections from SLICK-H mice that were co-stained for the 
astrocyte marker GFAP (A; red) or the oligodendrocyte marker Olig2 (B; red). No YFP fluorescence is 
observed in either astrocytes (arrows)  or oligodendrocytes (arrowheads). (C-F) YFP fluorescence 
(green) imaged in various tissues from SLICK-H mice. No YFP fluorescence is observed in non-neural 
tissues. Fom Heimer-McGinn and Young (2011) 
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2.2.3 Induction of Cre-mediated recombination in SLICK-H;ROSA26 mice 
 Recombination pattern shown by X-gal staining 2.2.3.1
 
To examine the full extent and efﬁciency of recombination afforded by the SLICK-H Cre-
recombinase system, we crossed SLICK-H mice to the ROSA26 (R26R) Cre-reporter line that 
expresses β-galactosidase (β-gal) upon Cre activation (Soriano, 1999). β-gal cleaves the 
organic compound X-gal (5-bromo-4-chloro-indolyl-β-galactopyranoside) and results in an 
insoluble blue stain that is clearly visible under bright field microscopy (Kiernan, 2007). 
Double heterozygous mice for SLICK-H and R26R were treated with tamoxifen for ten days 
by oral gavage, rested for two weeks and then taken for analysis. Sections were stained for 
X-gal in order to detect the presence of β-gal and compared to age-matched untreated 
SLICK-H;R26R controls. We observed prevalent and efﬁcient induction of reporter gene 
expression in the brain, retina, spinal cord, and DRG of tamoxifen-treated mice (Fig 2.4A). 
The recombination pattern in SLICK-H;R26R reflects the transgene expression pattern 
displayed by YFP fluorescence. Moreover, recombination in the absence of tamoxifen 
induction is minimal and occurs in less than 1% of cells in most brain regions (Fig 2.4B, 
Table2.2). 
 Quantification of recombination efficiency measured by LacZ 2.2.3.2
immunostaining 
 
To quantify the recombination efﬁciency in tamoxifen-induced SLICK-H;R26R mice we 
performed immunostaining for the β-gal reporter using the rabbit polyclonal antibody α-
LacZ, a gift from Dr. Joshua Sanes at Harvard University (Methods, Table 7.2). We compared 
β-gal staining to the neuronal marker NeuN (Methods, Table 7.1) to calculate the percent of 
total neurons that expresses the reporter gene (Fig 2.5A-D, Table 2.1). We did not calculate 
β-gal abundance compared to SLICK transgene expression because YFP labeling is so 
ubiquitous that proper demarcation of cells is difficult to observe. We did, however, 
compare β-gal staining to YFP in some regions where α-NeuN was problematic (Fig 2.5E).  
Quantification was performed for the hippocampus (CA1, CA3, dentate gyrus and 
subiculum), the cortex (motor, visual, somatosensory and entorhinal), the cerebellum, 
amygdala, olfactory bulb, thalamus, superior and inferior colliculi, brainstem and spinal cord 
(Table 2.1). 
 
Recombination efﬁciencies of 90% or more of NeuN positive cells were achieved in many 
regions including the hippocampus, thalamus, brainstem, superior and inferior colliculi, and  
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Figure 2.4 - Induction of Cre-mediated recombination in the central and peripheral nervous system of SLICK-H mice 
Cre-mediated recombination in tamoxifen treated (a) or untreated control (b) SLICK-H/R26R mice was assessed by X-gal staining. 
Recombination with minimal leaky recombinase activity can be seen in both lateral and medial sagittal brain sections. Recombination is 
observed in most brain regions with some exceptions, such as the striatum. Likewise, efficient induction of Cre activity can be seen in the 
retina, spinal cord, and dorsal root ganglia (DRG) with just a small amount of leaky recombination in the DRG of control animals.
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various neocortical regions (Table 2.1). Since some β-gal- cells are probably NeuN+ 
interneurons, the actual efﬁciency in projection neurons probably approaches 100% in these 
areas. A few neuronal populations in SLICK-H mice, such as Purkinje cells of the cerebellum 
and mitral cells of the olfactory bulb show low recombination efﬁciency. Pyramidal cells of 
the visual cortex and motor and sensory neurons of the spinal cord also display lower levels 
of recombination compared to other areas. These cells exhibit bright YFP ﬂuorescence and 
presumably co-express high levels of CreERT2, so the reasons for inefﬁcient recombination 
are not apparent.  
 
 
 
 
Table 2.1 – Quantification of 
Recombination Efficiency in 
SLICK-H Mice 
 
Recombination efficiencies were 
calculated by quantification of the 
number of β-gal
+
 cells relative to 
either NeuN
+
 or YFP
+
 cells using 
immunostained images as shown 
in Figure 2.5. Data are derived 
from multiple brain sections from 
at least two tamoxifen-treated 
SLICK-H;R26R mice. n = number of 
cells counted.  
Table 2.2 – Quantification of 
leaky recombination  
in SLICK-H mice 
 
Leaky recombination per area was 
calculated by counting the 
number of β-gal
+
 cells in un-
treated SLICK-H;R26R mice. This 
number was compared to the 
total of NeuN
+
 cells in immuno-
stained sections. Data are derived 
from multiple brain sections from 
at least two untreated SLICK-
H;R26R mice. n = number of cells 
counted.  
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Figure 2.5 - Efficient tamoxifen-inducible recombination in many neuronal populations in SLICK-H 
mice. The efficiency of Cre-mediated recombination was assessed by immunofluorescent staining and 
confocal microscopy. Brain sections from tamoxifen-treated SLICK-H;R26R were costained for the 
neuronal marker NeuN (blue) and the Cre reporter β-galactosidase (β-gal; red). YFP fluorescence is 
shown in green. Colocalization of the punctate β-gal staining within NeuN or YFP-positive cell bodies 
was used to quantify recombination efficiencies. (A) Individual fluorescence channels are shown for 
the motor cortex for illustrative purposes. Most cells are YFP
+
, NeuN
+
, β-gal
+
 (solid arrow), though  
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there are some YFP
–
, NeuN
+
, β-gal
+
 cells in which recombination has occurred but YFP is absent or 
below the limit of detection (arrowhead). There are also a few NeuN
+
, β-gal
–
 cells that are YFP
–
 and 
may represent NeuN
+
 interneurons (open arrow). (B-D) Two-color merged images for NeuN and β-gal 
are shown for the indicated brain regions, with NeuN
+
, β-gal
+
 cells appearing pink, or blue with pink 
puncta. In most of these regions, 90% or more of NeuN
+
 neurons are β-gal
+
 positive. (E) In neuronal 
populations that are not stained by NeuN, recombination was assessed relative to YFP
+
 cells. In 
cerebellar Purkinje cells, mitral cells of the olfactory bulb and especially photoreceptor cells in the 
retina, recombination efficiency is poor and there is a significant proportion of YFP
+
, β-gal
–
 cells 
(arrows in E). Supplemental high-resolution images of the individual fluorescence channels and two-
color merges are provided for all neuronal populations in Figure 2.7.  
 
2.2.4 Comparison of SLICK-H and SLICK-A lines 
 
In order to emphasize the usefulness of the SLICK-H line as a tool for pan-neuronal Cre-
dependent manipulations, we compared it to another SLICK line called SLICK-A. The SLICK-H 
and SLICK-A lines both show strong YFP labeling in projection neurons across many brain 
regions as expected for the Thy1.2 promoter (Fig 2.6A,D). YFP ﬂuorescence is brighter in 
SLICK-A but is less uniform, with very bright labeling in some hippocampal regions and in 
cortical layer V. However, in other regions, such as the cerebellum, midbrain and brainstem, 
labeling is sparse and dim (Fig 2.6D). In comparison to SLICK-A, YFP ﬂuorescence in SLICK-H is 
moderately bright but there is a much more widespread and uniform pattern of transgene 
expression (Fig 2.6A). 
 
To examine the utility of these two lines for widespread neuron-speciﬁc induction of 
recombination, they were crossed to the R26R reporter line and assayed using X-gal staining 
for β-gal. Tamoxifen-treated SLICK-H;R26R and similarly treated SLICK-A;R262R mice were 
compared to their respective untreated controls. X-gal staining revealed that SLICK-A;R26R 
mice exhibit somewhat restricted reporter gene expression after induction compared to 
SLICK-H;R26R, with notably inefficient  recombination in hippocampal CA3 region and 
cortical layers 2 and 3 (Fig 2.6F). Moreover, they exhibit signiﬁcant recombination in the 
absence of tamoxifen induction, with leaky recombination being most prominent in areas 
that have bright YFP labeling such as hippocampal CA1 region and cortical layer V (Fig 2.6E). 
This suggests that YFP and CreERT2 expression levels are tightly coupled and that excessive 
levels of CreERT2 must be avoided to achieve tight control of recombinase activity. This is 
contrast to the SLICK-H line, which shows efﬁcient induction of reporter gene expression 
upon tamoxifen administration (Fig 2.6C) with minimal leaky Cre activity upon induction (Fig 
2.6B). SLICK-H thus appears to have an optimal level of CreERT2 expression.  
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Figure 2.6 – Comparison of transgene expression and induction of recombination in two SLICK transgenic lines. 
(A, D) YFP labeling in sagittal brain sections from SLICK-H and SLICK-A mice. Widespread fluorescence is seen in both lines with the hippocampus and 
neocortex being especially bright in SLICK-A. (B, C, E, F) Recombination assessed by X-gal staining of the hippocampus and neocortex from SLICK-H;R26R (B, 
C) and SLICK-A/R26R (E, F) mice. Efficient recombination upon tamoxifen treatment is seen in both lines (C, F), but significant recombination in untreated 
control animals is observed for the SLICK-A line (E). From Heimer-McGinn and Young (2011) 
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Figure 2.7 A – Efficient tamoxifen-inducible recombination in many neuronal populations 
in SLICK-H mice, Supplement to Figure 2.5. The efficiency of Cre-mediated recombination in 
the indicated brain regions was assessed by immunofluorescent staining and confocal 
microscopy. Individual channels for β-gal (red) and NeuN (blue) and two-color merges are 
shown for several cortical areas (motor, somatosensory, visual and entorhinal cortices). To 
demonstrate that β-gal staining is specific, β-gal negative cells are highlighted by yellow 
arrows.  
 
A 
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Figure 2.7 B – Efficient tamoxifen-inducible recombination in many neuronal populations 
in SLICK-H mice, Supplement to Figure 2.5. The efficiency of Cre-mediated recombination in 
the indicated brain regions was assessed by immunofluorescent staining and confocal 
microscopy. Individual channels for β-gal (red) and NeuN (blue) and two-color merges are 
shown for several hippocampal areas (dentate gyrus, CA3, CA1 and subiculum). To 
demonstrate that β-gal staining is specific, β-gal negative cells are highlighted by yellow 
arrows. 
 
  
B 
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Figure 2.7 C – Efficient tamoxifen-inducible recombination in many neuronal populations 
in SLICK-H mice, Supplement to Figure 2.5. The efficiency of Cre-mediated recombination in 
the indicated brain regions was assessed by immunofluorescent staining and confocal 
microscopy. Individual channels for β-gal (red) and NeuN (blue) and two-color merges are 
shown for the superior and inferior colliculi, thalamus and brain stem. To demonstrate that 
β-gal staining is specific, β-gal negative cells are highlighted by yellow arrows. 
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Figure 2.7 D – Efficient tamoxifen-inducible recombination in many neuronal populations 
in SLICK-H mice, Supplement to Figure 2.5. The efficiency of Cre-mediated recombination in 
the indicated brain regions was assessed by immunofluorescent staining and confocal 
microscopy. Individual channels for β-gal (red) and NeuN (blue) and two-color merges are 
shown for the cerebellum, olfactory bulb, retinal ganglion cells and photoreceptors. To 
demonstrate that β-gal staining is specific, β-gal negative cells are highlighted by yellow 
arrows. 
 
  
D 
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2.2.5 Characterization of two-week-old SLICK-H mice  
 
To further characterize the SLICK-H line, we examined transgene expression and 
recombination efficiencies in two-week-old mice. At embryonic and early developmental 
stages, transgene expression in SLICK-H is limited due to the late onset of Thy1 promoter 
activity (Caroni, 1997). Although not as widespread and intense as in adult mice (Fig 2.2), 
signiﬁcant YFP ﬂuorescence is observed in young mice (Fig 2.8).  
 
 
Figure 2.8 - Transgene expression in young SLICK-H transgenic line. Transgene expression as 
indicated by YFP labeling in a medial (A) and lateral (B) sagittal brain section from young SLICK-H mice. 
The CA1 (C), subiculum (D), motor cortex (E), and cerebellum (F) are shown at a magnification of 10X. 
 
To assess recombination pattern and efficiencies in young SLICK-H mice, 2-week-old SLICK-
H;R26R pups were treated with tamoxifen and then assayed by X-gal staining. Tight control 
of recombination in the absence of tamoxifen is observed in these younger mice (Fig 2.9). 
Recombination efficiencies were calculated by comparing β-gal staining to YFP labeling, 
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which in these younger mice provides a more clear definition of cell bodies (Fig 2.8, C-F). 
Recombination efficiencies in two-week-old mice that were administered tamoxifen for two 
days via intraperitoneal injection ranged from 50%-60% (Table 2.1). Mice of this age do not 
respond well to oral gavage, so tamoxifen delivery was performed either directly by 
intraperitoneal injection or indirectly by oral gavaging the nursing mother. Indirect delivery 
through nursing produced some activation of CreERT2 but to a much lesser extent than direct 
intraperitoneal delivery.  
  
 
Figure 2.9 - Induction of Cre-mediated recombination in the central and peripheral nervous system 
of young SLICK-H mice. Cre-mediated recombination in (A) tamoxifen treated or (B) untreated 
control SLICK-H/R26R mice was assessed by X-gal staining. Recombination with minimal leaky 
recombinase activity can be seen in both lateral and medial sagittal brain sections. Recombination is 
observed in most brain regions with some exceptions, such as the striatum. Likewise, efficient 
induction of Cre activity can be seen in the retina, spinal cord, and dorsal root ganglia (DRG) with just 
a small amount of leaky recombination in the DRG of control animals 
A B 
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2.3 Discussion 
2.3.1 SLICK-H as a technique for pan-neuronal conditional transgenic expression 
 
Our SLICK-A data demonstrate the challenges of generating transgenic lines that express 
CreERT2 and facilitate efﬁcient Cre-mediated gene knockout. Achieving optimal levels of 
transgene expression is crucial. Robust expression is required for efﬁcient recombination, 
but a strong promoter like Thy1.2 can produce excessive CreERT2 causing leaky recombinase 
activity as observed in the SLICK-A line. This is probably a consequence of overwhelming the 
cellular factors that sequester inactive CreERT2 in the cytoplasm. The SLICK-H line was 1 of 30 
SLICK transgenic lines generated and was selected for further characterization on the basis 
of widespread and uniform transgene expression. This expression pattern permits efﬁcient 
non-leaky recombination. The fusion of two copies of the estrogen receptor ligand binding 
domain to Cre-recombinase (ERT2-Cre-ERT2) has been reported to reduce leaky 
recombination associated with Cre-ERT2 in in vivo electroporation studies (Casanova et al., 
2002, Matsuda and Cepko, 2007). Although ERT2-Cre-ERT2 may be advantageous in this 
regard, our results indicate that Cre-ERT2 is adequate to achieve tight control of 
recombination, provided expression levels are not excessive. YFP labeling in SLICK-H is too 
dense for imaging of individual neurons. It does, however, highlight the cell populations and 
anatomic nuclei in which CreERT2-mediated recombination should be achievable. Since 
transgene expression is not excessively high, we do not anticipate any cytotoxic effects of 
either YFP or CreERT2 expression. The only drawback of strong YFP ﬂuorescence in SLICK-H is 
that it would mask GFP in loxP lines that use GFP either as a reporter or as a component of a 
fusion protein. The utility of SLICK-H in developmental studies is reduced due to the 
postnatal onset of Thy1-driven transgene expression and poor tolerance of repeated 
tamoxifen administration in these animals. 
 
2.3.2 Alternatives to the SLICK-H technique or pan-neuronal conditional 
expression 
 
 Methods using Thy1.2 variant of the Thy1 promoter 2.3.2.1
The Thy1.2 variant of the Thy1 promoter has been widely used as a neuron-speciﬁc 
promoter in transgenic mice including various disease models (Caroni, 1997, Feng et al., 
2000, Oddo et al., 2003). Several Thy1-Cre lines have been generated that exhibit neuronal 
Cre recombinase activity as expected (Campsall et al., 2002, Dewachter et al., 2002) 
(http://www.credrivermice.org/). However, at least two and perhaps all of these lines also 
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show recombination in non-neuronal tissues, most likely due to nonspeciﬁc promoter 
activity at early embryonic stages (Campsall et al., 2002) (http://cre.jax. org/Thy1/Thy1-
cre.html). By using CreERT2 we avoid this problem since the recombinase is not active in the 
absence of tamoxifen, even if it is expressed at embryonic stages. Transgenic mice in which 
Thy1 drives expression of an inducible Cre-progesterone receptor fusion protein have been 
generated (Kellendonk et al., 1999). However, the pattern of recombination in this line 
would not appear to be as widespread or uniform as in SLICK-H. To our knowledge, no other 
Thy1-CreERT2 lines have been generated.  
 Other promoters and techniques 2.3.2.2
A variety of other promoters have been used for neuron-speciﬁc expression of CreERT2, and 
several large-scale approaches have characterized neuronal promoters for this purpose 
(Gong et al., 2003, Madisen et al., 2010, Portales-Casamar et al., 2010) (2003; http:// 
www.credrivermice.org/). However, most of these lines have either a region-speciﬁc 
expression pattern or drive expression in neurons with a particular neurotransmitter 
phenotype and do not exhibit such widespread expression as SLICK-H. Pan-neuronal 
expression of CreERT2 has been achieved using a knock-in approach that targets the vesicle 
associate membrane protein 2 and neuroﬁlament light chain loci (Rotolo et al., 2008). 
However, the goal in this study was to achieve low recombination efﬁciency and sparse 
neuronal labeling. The CaMKIIα promoter has also been used to drive expression of Cre-
recombinase and other transgenes in projection neurons in a pattern that overlaps with 
Thy1 in the forebrain (Tsien et al., 1996). CaMKIIα-CreERT2 mice have also been generated; 
however, recombination in these mice is restricted to the forebrain and thus is not as broad 
as in SLICK-H (Erdmann et al., 2007, Madisen et al., 2010). The widespread expression and 
tight control of CreERT2 activity in SLICK-H thus offer signiﬁcant advantages over currently 
available inducible Cre recombinase lines, and make the SLICK-H line highly suitable for 
functional genomic analysis of behavioral and other neuronal phenotypes in adult mice. 
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Chapter 3 Generating Cre-compatible mouse lines that 
conditionally inhibit neuronal connectivity 
 
3.1 Results 
 
Our aim in the work described in this chapter was to develop efficient and simple-to-use 
transgenic methods that would allow neuronal activity-dependent processes to be studied in 
vivo throughout the mammalian brain. The SLICK-V line of mice is well suited for this 
purpose as it expresses CreERT2 and YFP in a small subset of pyramidal neurons throughout 
the central and peripheral nervous systems (Fig 3.1A). YFP fluorescence is strong in these 
mice and Cre-mediated recombination occurs efficiently with tight temporal control of 
induction. In combination with a Cre/loxP-compatible line that inhibits neuronal function, 
this model could be used to suppress neuronal activity in a small subset of cells and then 
observe how these cells behave in a competitive, wildtype environment.  
 
 
Figure 3.1 – Strategy for conditional transgenic co-expression of SLICK and either Kir2.1 potassium 
channel or tetanus toxin light chain, a schematic representation 
(A) In SLICK mice, two copies of the Thy1 promoter drive expression of both YFP and CreER
T2
 in 
projection neurons. (B) In the Kir2.1 construct, the Thy1 promoter drives conditional expression of a 
floxed STOP cassette, Kir2.1, an IRES sequence and a TauLacZ reporter gene. (C) Double transgenic 
mice (SLICK;Kir) treated with the drug tamoxifen will coexpress YFP, Kir2.1 and TauLacZ in projection 
neurons. (D) In the TetoxLC line, the Thy1 promoter drives conditional expression of a floxed STOP 
sequence, TetoxLC, and CFP (E) Double transgenic animals treated with the drug tamoxifen will 
coexpress YFP, TetoxLC and CFP in projection neurons. Black triangles represent loxP sites. 
 
The Kir2.1 transgenic construct (Fig 3.1B) includes a LacZ reporter that encodes for β-
galactosidase, which cleaves the organic compound X-gal (5-bromo-4-chloro-indolyl-β-
galactopyranoside) and results in an insoluble blue stain that is clearly visible using bright 
73 
 
field microscopy (Kiernan, 2007). Fusion to the protein tau localizes LacZ expression to 
axonal microtubules (Weingarten et al., 1975) and an upstream IRES sequence allows 
translation initiation of the TauLacZ reporter without requiring 5’ cap recognition (Pelletier 
and Sonenberg, 1988). The TetoxLC construct (Fig 3.1D) includes a cyan fluorescent protein 
(CFP) reporter that is spectrally distinct from the SLICK-derived YFP. Both constructs are 
driven by the Thy1 neuronal promoter and include a floxed transcriptional STOP cassette to 
prevent transgene expression in the absence of Cre-mediated recombination. 
Administration of the drug tamoxifen to double transgenic mice induces CreERT2-mediated 
recombination allowing the STOP cassette to be removed and the transgenic sequences to 
be expressed (Fig 3.1C,E). The inhibitory mechanisms of these two approaches are discussed 
below.  
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3.1.1 Cre recombinase-compatible transgenic mouse for the conditional 
expression of the Kir2.1 potassium channel in projection neurons 
 
 Construction of a transgene for conditional expression of Kir2.1 under 3.1.1.1
control of the Thy1 promoter 
 
We received a DNA plasmid from C. Ron Yu containing the Kir2.1 sequence followed by an 
internal ribosomal entry site (IRES) and a TauLacZ reporter gene (Yu et al., 2004). This Kir2.1-
IRES-tauLacZ sequence was then cloned into a customized pBlueScriptII SK+ plasmid that 
includes the neuronal promoter Thy1 and a transcriptional STOP cassette flanked by two 
loxP sites in the same orientation (Fig 3.2A). This aspect of the work was done prior to my 
joining the project.  Once I commenced my work I tested the construct by digesting it with 
the restriction enzyme HindIII, which produced DNA bands of the expected sizes (Fig 3.2B). 
We will henceforth refer to the Thy1-STOP-Kir2.1-IRES-tauLacZ transgene simply as Kir. 
 
 
 
 
Figure 3.2 – Production of Cre recombinase-compatible transgenic mice for the conditional 
expression of Kir2.1 inward-rectifying potassium channel 
(A) Schematic representation of the Kir2.1 DNA construct that we used to generate potential Kir 
transgenic mice. LoxP sites are shown as grey triangles and restriction enzymes used to linearize and 
verify the construct are shown in blue. The construct includes the pBlueScriptII-SK
+
 plasmid DNA and 
the Thy1 neuronal promoter sequence. (B) Restriction digest of the Kir construct by HindIII produces 
expected band sizes. Lanes 1 and 2 represent two clones of the same construct. (C) Genotyping PCR 
identified four founders produced by pronuclear microinjection of the Kir construct (red arrows). 
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 Generation and genotyping Kir transgenic mice 3.1.1.2
The Kir construct was linearized by digestion with the restriction enzyme NotI and purified 
from a 1% agarose gel. Pronuclear microinjection was then carried out in collaboration with 
Drs Tom Moore and Melanie Ball at University College Cork (Richa, 2000). The DNA construct 
was injected into the pronuclei of fertilized oocytes, which were then implanted into 
pseudo-pregnant CD1 female mice. Three rounds of injections produced litters of 15, 9, and 
8 pups respectively. Transgene presence was detected by PCR using two different primer 
combinations (Methods Table 7.2). Out of a total of 32 pups, 2 females and 2 males tested 
positive for both primer sets (Fig 3.2C). These founders are hereafter referred to as Kir-1A, 
Kir-7, Kir-1B and Kir-2.  
 Establishing Kir transgenic lines 3.1.1.3
All four founders were crossed to wildtype CD1 and C57 mice in order to establish the lines. 
Breeding patterns differed among founders. Founder Kir-1B, a male, was fertile but failed to 
produce any Kir-positive progeny. He was mated with various females over the course of 
nine months but produced only two litters with a total of 21 pups, none of which genotyped 
positive for Kir. Founder Kir-2, also a male, produced a total of 67 pups, out of which 5 pups 
(7%) were positive for the Kir transgene. From the entire Kir-2 line, 29 out of 137 (21%) pups 
were Kir-positive. Founder Kir-7, a female, produced two Kir-positive pups out of a total of 
18 born (11%). From the entire Kir-7 line, 15 out of 70 pups (21%) were positive for the Kir 
transgene. Founder Kir-1A, a female, was a poor breeder. She lost three litters before 
beginning to produce viable litters, four months after initial mating. She then produced 4 of 
18 (22%) Kir-positive pups. First and second generation Kir-1A mice were equally poor 
breeders, having many litter losses and long periods between litters compared to the Kir-7 
and Kir-2 lines. Once the Kir-1A line was established, 17 out of 82 pups were Kir-positive 
(21%). Distribution of males and females throughout the Kir-2, Kir-7, and Kir-1A lines was 
equal, as expected. In summary, from four Kir founders, two lines were easily established, 
one was not established at all and another was difficult to breed but was eventually 
established. 
 Characterization of potential transgene transcription in Kir lines 3.1.1.4
The Kir lines were first characterized at the RNA level to determine whether the transgene 
had inserted into a transcriptionally active locus of the genome. We tested this by in situ 
hybridization, using a probe designed to detect the STOP cassette. This gave us an indication 
of expression prior to crossing the Kir lines to Cre recombinase-expressing lines. The Kir-2 
line showed ample RNA expression in the brain, notably in the cortex and hippocampus (Fig 
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3.3). The caudate putamen, thalamus and hypothalamus did not exhibit any RNA expression 
in the Kir-2 line.  The Kir-7 line presented some expression in the brainstem and midbrain 
but not in the cortex and hippocampus. As a negative control we used wildtype mice that did 
not show any staining, as expected (Fig 3.3C). Kir-1A was not included in this study as the 
line was not yet well established.  
 
 
 
Figure 3.3 – RNA Expression of the Kir transgene 
In situ hybridization (ISH) was used to examine RNA expression of the STOP cassette (contained in the 
transgenic Kir sequence) throughout the brain, with particular interest in the cortex and 
hippocampus. (A) The Kir-2 line reveals moderate expression in both the cortex and hippocampus 
(mainly in the subiculum). (B) The Kir-7 line does not express Kir RNA in the cortex or hippocampus. 
(C) Wildtype mice acted as a negative control and do not exhibit any staining in either structure. 
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 Characterization of tauLacZ reporter gene expression in Kir lines 3.1.1.5
For characterization purposes, the Kir lines were crossed to the SLICK-H line, which, as 
described in the previous chapter, exhibits conditional pan-neuronal expression of Cre 
recombinase and YFP upon drug activation. SLICK-H;Kir double transgenic mice were 
administered the drug tamoxifen in order to activate Cre recombinase.  Cre should excise 
the STOP cassette and lead to the expression of Kir and tauLacZ (Fig 3.1). As a negative 
control, we used untreated transgenic mice. X-gal staining was not detected in any of our 
lines compared to untreated controls, revealing that our lines do not actually express the Kir 
transgene (Fig 3.4). SLICK-H;Kir-2 (n=3) and SLICK-H;Kir-7 (n=2) consistently lacked the LacZ 
reporter gene. SLICK-H;Kir-1A exhibited the LacZ reporter gene in only one of four animals 
tested so we concluded that it does not truly exhibit Kir expression either. Since consistent 
expression of the reporter gene could not be detected following recombination, we did not 
proceed with these lines and all three lines were terminated. 
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Figure 3.4 – LacZ reporter gene expression in the Kir lines 
SLICK-H;Kir double transgenic mice were tested for the presence of LacZ reporter using the X-Gal 
staining method. Drug-induced mice were compared to untreated transgenic controls. None of the 
potential Kir lines express the LacZ reporter gene. SLICK-H;ROSA26R mice served as positive controls 
and show ample LacZ expression in drug-induced mice but not in untreated controls. 
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3.1.2 Cre recombinase-compatible transgenic mouse for the conditional 
expression of the tetanus toxin light chain in projection neurons 
 
 Construction of a transgene for conditional expression of TetoxLC under 3.1.2.1
control of the Thy1 promoter 
 
We obtained the TetoxLC sequence in the pGEMT7-EZ vector as a gift from Dr. C. Ron Yu (Yu 
et al., 2004). Initially we attempted to ligate the TetoxLC sequence with an IRES-tau-LacZ 
sequence, as had been done for Kir. This, however, proved unsuccessful. Instead we fused 
TetoxLC to cyan fluorescent protein (CFP), which is spectrally distinct from the YFP that is 
expressed in the SLICK lines. The CFP sequence was obtained by PCR amplification using 
primers that contain restriction sites and then ligated to TetoxLC (for further details see 
Chapter 7, Section 7.1.2.2). The fusion of tetanus toxin light chain and CFP is known to 
express stably in neuronal cultures (Harms et al., 2005). 
 
 
 
Figure 3.5 –Production of Cre recombinase-compatible transgenic mice for the 
conditional expression of tetanus toxin light chain 
(A) Schematic representation of the tetanus toxin DNA construct that we used to generate potential 
TetoxLC transgenic mice. LoxP sites are shown as grey triangles and restriction enzymes used to 
linearize and verify the construct are shown in blue. The construct includes the pBlueScriptII-SK
+
 
plasmid DNA and the Thy1 neuronal promoter sequence. (B) Restriction digests of the TetoxLC 
construct with EcoRI/NotI/MluI (lane 1), EcoRI/NotI/XhoI (lane 2), and EcoRI/Not (lane 3) produced 
bands of the expected sizes. (C) A western blot of transfected cell lysate probed with a rabbit-anti-GFP 
antibody shows a strong band for TetoxLC with no degradation product. Lanes 1 and 2 represent 
lysates from two different transformations. (D) Genotyping PCR identified one founder produced by 
pronuclear microinjection of the TetoxLC construct (red arrow). TetoxLC-CFP construct DNA was used 
as a positive control, shown in the last lane. 
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It is worth noting that tetanus-related cloning was problematic. When XL1Blue E.coli cells 
were transformed and plated onto selective antibiotic agar plates, normal-sized colonies 
were consistently obtained from cells transformed with either an empty vector or a TetoxLC-
containing vector. Small colonies, which we originally mistook for background, were only 
present in TetoxLC-transformed plates and not in control plates. After performing colony 
PCR on a variety of colonies from several plates we concluded that these smaller colonies 
did in fact contain the TetoxLC insert, whereas the conventional colonies did not. We also 
observed that E. coli cells harboring a tetanus plasmid grew very slowly. 
 
As with the Kir construct, we cloned TetoxLC-CFP into a modified pBlueScriptII SK+ vector 
that contains the neuronal promoter Thy1 and a STOP cassette flanked by loxP sites with 
parallel orientation (Fig 3.5A, for more detail refer to Chapter 7, Section 7.1.2.2). Once we 
successfully cloned our TetoxLC construct, we carried out several restriction digestions using 
different combinations of restriction enzymes to ensure the accuracy of our final construct. 
Expected bands were produced upon digestion with EcoRI, NotI and MluI (Fig 3.5B, lane 1), 
with EcoRI, NotI and XhoI (Fig 3.5B, lane 2), and withEcoRI and NotI (Fig 3.5B, lane 3). The 
finalized TetoxLC construct was then linearized with the restriction enzymes NotI and EcoRI, 
which removed the pBlueScript portion of the vector. This linearized DNA construct was 
then purified from a 1% agarose gel in preparation for pronuclear injection.  
 
To check the expression and stability of the TetoxLC-CFP fusion protein we cloned the 
TetoxLC-CFP sequence into pCMV, a eukaryotic expression vector and transfected this into 
COS7 cells. We then performed a western blot on the cell lysates from these cultures. Blots 
probed with a rabbit-anti-GFP antibody (Methods Table 7.1) resulted in a single band with 
no degradation product, signifying that TetoxLC-CFP was successfully expressed in cells (Fig  
3.5C). Cell cultures were also inspected under a fluorescent microscope where we confirmed 
that CFP staining was visible in transfected cells. Judging by morphology and rate of cell 
growth, we detected no obvious toxicity. 
 Pronuclear injections of the TetoxLC construct 3.1.2.2
Two rounds of pronuclear injections were performed at UCC in collaboration with Dr. Tom 
Moore's laboratory. Only one litter of 3 pups was produced. Tail samples were genotyped 
using two primer sets that recognized TetoxLC but no Tetox-positives were detected. After 
several lost litters, and/or small litter sizes, we decided to send the TetoxLC-CFP construct to 
the Transgenic Production Facility at the University of Cardiff in Wales, England, for 
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microinjection. Two rounds of injections there yielded 6 litters. Out of a total of 53 mice, 
several sporadically showed positive for the TetoxLC genotyping PCR but only one was 
consistent after several repetitions (Fig 3.5D). Tail samples were often received in a 
degraded state from the Cardiff transgenic facility as judged by failure to produce PCR 
products using primers that identify wildtype genes such as choline acetyltransferase. It is 
therefore possible that we overlooked other founders. Moreover, by the time we identified 
the only TetoxLC-CFP founder, she was 9-12 months old and did not produce any litters upon 
mating. 
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3.2 Discussion 
 
Our objective was to create a mouse model for Cre recombinase-dependent over-expression 
of Kir and another for Cre recombinase-dependent expression of tetanus toxin light chain. 
We successfully created DNA constructs for both of these models and performed pronuclear 
injections. Kir injections produced four transgenic founders but one did not breed, and the 
other three did not express the LacZ reporter gene. Of these three, two expressed the 
transgene at the RNA level. Microinjections of the TetoxLC-CFP construct produced one 
founder from whom we were not able to establish a colony.  
 
3.2.1 Transgenic delivery and germline transmission of the Kir construct 
 
Genome integration typically occurs in only 10-30% of mice produced by microinjection 
(Wilkie et al., 1986). Our injections for Kir DNA yielded 4 founders out of 32 pups (12.5%), 
which is low but still within the established range. Our founders Kir-1B, Kir-2, Kir-7 and Kir-
1A in turn yielded a germline transmission of 0%, 7%, 11% and 22% respectively. These 
numbers suggest a high level of mosaicism in germline cells of these founders, which is 
common in transgenic founders (Wilkie et al., 1986, Palmiter and Brinster, 1986). This is 
probably a consequence of injecting the transgenic DNA after more than one round of 
mitosis or of delayed DNA integration. Pronuclear injections were not regularly practiced by 
Dr. Tom Moore’s lab at the time, so it is likely that the timing of delivery was not optimal, 
resulting in a high level of mosaicism. In the case of Kir-1B (0%) and Kir-2 (7%), which were 
males, it is also possible that the heterozygous transgenic sperm was less efficient at 
fertilizing ova than non-transgenic sperm (Ellison et al., 2000). The high level of mosaicism 
made the Kir lines more difficult than usual to establish but it did not affect the final 
outcome regarding protein expression.  
 
3.2.2 RNA expression and reporter gene characterization of the Kir lines 
 
Two of our lines, Kir-2 and Kir-7, showed transgenic RNA expression when probed for the 
STOP cassette by in situ hybridization. We know therefore, that in these lines the transgene 
was inserted into a transcriptionally active locus and that transcription was possible. Further 
characterization by X-gal staining, however, revealed no expression of the reporter gene 
LacZ. This could indicate either (1) transgene silencing, (2) absence of recombination or (3) 
that the IRES strategy was ineffective or insufficient. 
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Since insertion site and copy number are random following pronuclear microinjection, it is 
possible that our transgene was silenced due to position effect variegation (Graubert et al., 
1998, Feng et al., 2000). Insertion of the construct into heterochromatin regions, for 
example, can cause site-dependent silencing, while in other regions, endogenous enhancers 
could alter transgene expression levels (Gama Sosa et al., 2010). It is likely that our lines Kir-
2 and Kir-7 suffered from these position-site-dependent effects. We assume that 
recombination in SLICK-H;Kir mice did occur, based on known efficiency levels of 
recombination in SLICK-H;ROSA26 mice upon tamoxifen administration (Heimer-McGinn and 
Young, 2011). However, it is possible that recombination is less efficient for the Kir 
transgene if Cre cannot easily access the locus where it was randomly inserted. If 
recombination did not occur, then the floxed STOP cassette would not be excised and Kir 
would not have been transcribed. Finally, it is possible that recombination occurred and that 
the Kir sequence was translated, but that the IRES sequence did not properly initiate the 
translation of tau-LacZ. Although the IRES sequence has previously been shown to function 
in projection neurons (Dahlhaus et al., 2008), other studies have found that sequences 
following IRES are not always well expressed in these cells (Young et al., 2008). We are 
ultimately interested in applying this model to single-cell studies, so a malfunctioning 
reporter gene would pose a great inconvenience in distinguishing between endogenous and 
transgenic Kir at the single-cell level. Since convenience was one of the major benefits of this 
model, we did not think that any further characterizations were worthwhile.  
 
3.2.3 Transgenic delivery of the TetoxLC construct 
 
Pronuclear injections of the TetoxLC construct that were carried out at UCC yielded very few 
mice. Considering a typical genome integration rate of 10%-30% (Wilkie et al., 1986), it is not 
surprising that we did not obtain any founders from these injections. The low birth rate 
could be due to either toxicity of the construct, which we will discuss, or to technical 
problems. It is important to note that pronuclear microinjections in Dr. Moore’s lab were not 
performed on a regular basis at the time. The injections that were carried out at the 
University of Cardiff did yield larger litter sizes but produced only one founder out of 53 
(2%). This can again be an effect of either toxicity or technical problems. It is also important 
to point out that we had various difficulties with the Transgenic Production Facility at Cardiff 
University. More than once we received tail samples for genotyping that appeared to be 
degraded due to extended time in transit at room temperature.  The only founder for 
TetoxLC was discovered past her optimal breeding age and did not produce any litters upon 
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being mated. Moreover, it is possible that more founders were in fact produced but 
overlooked due to the quality of the samples received. 
 
It is possible that TetoxLC toxicity may have contributed to reduced litter sizes at UCC and 
reduced frequency of founders at the commercial facility, although we consider this to be 
unlikely. Our construct contains only the light chain domain of the toxin, which is the 
proteolytic domain responsible for cleaving the vSNARE protein VAMP2 (Schiavo et al., 
2000). Without the heavy chain domain, which is responsible for membrane trafficking, 
tetanus should be unable to cross membranes and therefore attack the host at other 
locations (Schiavo et al., 2000). Moreover, the transcriptional STOP cassette upstream of the 
tetanus sequence should only be removed if these mice are crossed to a Cre recombinase-
expressing line and, in the case of conditional Cre lines like SLICK, after administration of the 
drug tamoxifen. Also, the fact that cell cultures transfected with TetoxLC were stable 
provides some indication that this construct should not be toxic to its host. Alternatively, 
toxicity could arise from impurities in the actual DNA sample. Although possible, this does 
not seem likely since each injection was performed using a newly-made lot of purified DNA 
and yet the same difficulties arose for each injection. Judging by the relative success of Kir 
transgene delivery, we do not think we were experiencing a systemic problem of impure 
DNA.  
 
As far as we understand, we were not able to produce enough TetoxLC-CFP founders either 
because (a) the DNA construct was toxic (due to DNA impurity or inherent toxicity of the 
gene), (b) because the DNA construct was not delivered effectively or (c) because we were 
not able to identify founders due to poor quality of tissue samples. In either case, 
considering we had already received and begun to characterize a tetanus-expressing line 
from Dr. Susan Dymecki's laboratory at Harvard University (discussed in the next chapter), 
we decided not to pursue the TetoxLC-CFP mouse model. 
 
3.2.4 Alternative delivery methods 
 
Although production of transgenic mice by pronuclear injection is beneficial because it is less 
expensive, time consuming and less technically challenging than other alternatives, it does 
have some shortcomings (Gama Sosa et al., 2010). Since copy number and insertion site of 
the DNA are random in this type of procedure, our transgene might have been silenced due 
to site-dependent effects or due to excessive copy number (Gama Sosa et al., 2010). In the 
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future we might consider either (a) modifying our construct so as to increase our likelihood 
of success or (b) attempting an alternative strategy of DNA delivery.  
 
As far as the actual construct is concerned, we might consider adding insulator sequences 
that can protect the DNA from the effects of neighboring sequences (Bushey et al., 2008). 
Introducing an intron either up or downstream from the gene of interest may also result in 
more stable mRNA and more efficient translocation of RNA from the nucleus (Haruyama et 
al., 2009). We do not believe that the size of our fragment has negatively impacted our 
efficiency rate. These modifications would require careful planning and design but would 
ultimately be a reasonable approach. 
 
We might also attempt to design a bacterial artificial construct (BAC) because they contain 
many of the regulatory elements required for expression and regulation of the gene of 
interest, some of which may also serve as insulator sequences (Montoliu et al., 1993). Also, a 
more widespread expression pattern that is independent of the Thy1 promoter may increase 
the likelihood of high transgene expression levels. BAC’s, however, are more difficult to 
design, produce and deliver (because it is much larger) and may contain genes that affect 
phenotype in a manner independent of the gene of interest (Gama Sosa et al., 2010).   
 
Other delivery methods we might consider are intracytoplasmic sperm injection, which is 
also random but produces a higher frequency of founders than pronuclear injection (Kaneko 
et al., 2005), or gene targeting by homologous recombination. Gene targeting would be a 
more controlled way of delivering DNA; we could prevent silencing of our gene and also 
disruption of normal endogenous gene function (Joyner, 2000, Notarianni and Evans, 2006). 
We would also have more consistent expression levels from generation to generation 
(Joyner, 2000). Gene targeting, however, is more laborious and expensive and requires a 
much longer timeframe. It is interesting to note that the tetanus-expressing mice we 
received from Dr. Dymecki’s lab are knock-ins rather than transgenics. Although we do not 
know why they chose gene targeting over pronuclear injection, it is possible that this 
approach works best for this particular protein. 
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Chapter 4 Characterization of inducible TetoxLC expression in 
RC::Ptox mice 
 
4.1 Results 
 
4.1.1 General Strategy 
 
While attempting to generate Cre recombinase-compatible mouse models for Kir2.1 and 
TetoxLC, we learned that Dr Susan Dymecki’s laboratory (Harvard University, USA) recently 
created a line with Cre-compatible TetoxLC expression, albeit using a different approach of 
gene reporting (Kim et al., 2009). As an alternative strategy we requested access to 
Dymecki’s RC::Ptox line (distinct from RC::PFtox described in Kim et al 2009). The RC::Ptox 
mice we received express a transgene (Fig 4.1A) that is knocked-in to the ROSA26 locus 
(Zambrowicz et al., 1997) and contains a CAG promoter (Niwa et al., 1991), a floxed STOP 
cassette and GFPtox, which is a fusion of enhanced green fluorescent protein (EGFP) and 
tetanus toxin light chain (Yamamoto et al., 2003).  
 
 
Figure 4.1 – Strategy to conditionally coexpress SLICK and GFPtox in pyramidal neurons 
(A) The RC::Ptox construct contains a STOP cassette flanked by loxP sites (triangles), followed by 
GFPtox, a fusion protein between eGFP (enhanced green fluorescent protein) and the tetanus toxin 
light chain. The transgene is targeted to the ROSA26 locus and also contains a CAG promoter. (B) The 
SLICK transgene contains two copies of the Thy1 neuronal promoter that drive simultaneous 
expression of YFP (yellow fluorescent protein) and the Cre recombinase CreER
T2
. The drug tamoxifen 
activates Cre-mediated recombination in double transgenic mice (SLICK;Ptox). (C) Drug-induced 
SLICK;Ptox mice coexpress YFP and GFPtox in pyramidal neurons. Since YFP and GFP are spectrally 
very similar, GFP is not a useful reporter as it will not distinguish between cells that are SLICK
+
/Ptox
-
 
and cells that are SLICK
+
/Ptox
+
. 
 
Although RC::Ptox transgene expression has been previously characterized (unpublished 
data from Dr. Dymecki’s lab), we wanted to ensure compatibility with our SLICK lines as well 
as efficient levels of recombination upon administration of the drug tamoxifen. For this 
purpose we crossed the RC::Ptox and SLICK lines. As described in Chapter 2, the SLICK 
transgene (Fig 4.1B) contains the Cre recombinase CreERT2 as well as yellow fluorescent 
protein (YFP), both under the control of the Thy1 promoter. Upon drug activation, cells in 
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double transgenic SLICK-H;Ptox mice will express both YFP and GFP (Fig 4.1C). YFP and GFP, 
however, are spectrally very similar (unlike YFP and CFP). Moreover, since YFP is expressed 
strongly in SLICK mice (refer to Chapter 2), whereas GFPtox produces weak expression 
(unpublished data; Dymecki), cells that express GFPtox will be difficult to distinguish from 
cells that only contain the SLICK transgene but no recombined GFPtox. Since our future 
studies with SLICK-V;Ptox require single-cell detection of tetanus expression, we were eager 
to either (a) detect a high recombination efficiency and GFPtox expression and/or (b) 
establish a reliable method for direct tetanus detection. 
 
4.1.2 Does recombination occur in tamoxifen-treated SLICK-H;Ptox mice? 
 
For the purpose of characterization, the Cre-compatible RC::Ptox transgenic mouse line 
received from Susan Dymecki’s laboratory was crossed to our SLICK-H line that exhibits 
conditional widespread neuronal expression of CreERT2 and YFP (Fig 4.1B). SLICK-H;Ptox 
double transgenic mice were treated with tamoxifen in order to activate CreERT2 and induce 
expression of GFPtox. Untreated SLICK-H;Ptox mice served as controls.  
 Characterization of recombination by polymerase chain reaction 4.1.2.1
We tested several PCR primer combinations intended to ensure that recombination occurs 
only upon tamoxifen-induced CreERT2 activation. The first primer set is designed to produce 
a band of 372 bp in the presence of drug-induced recombination and a 3040 bp band in the 
absence of treatment (Fig 4.2A, in blue). As shown in figure 4.2B, top panel, tamoxifen-
induced SLICK-H;Ptox mice display a strong band at the expected size signifying that 
recombination has occurred (lanes 1-3), whereas un-induced SLICK-H;Ptox samples do not 
(lanes 4-6). In two of three un-induced samples, the 3040 bp band representing the un-
recombined transgene is weakly visible. Another primer set detects only the un-recombined 
transgene and produces a band of 381 bp (Fig 4.2A, in pink). As seen in figure 4.2B, middle 
panel, all three un-induced SLICK-H;Ptox samples (lanes 4-6) produced strong bands at the 
appropriate size. Two of the three tamoxifen-induced SLICK-H;Ptox samples also show bands 
signifying the presence of un-recombined transgene (lanes 1,3). Finally, a wildtype PCR 
primer pair detecting the presence of choline acetyltransferase (ChAT) assured us that all 
samples of the purified DNA were of good quality (Fig 4.2B, bottom panel). 
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Figure 4.2 – Characterization of Cre-mediated recombination in SLICK;Ptox mice 
by PCR and by Southern blot 
(A) Schematic representation of two PCR primer sets used to identify Cre-mediated excision of the 
STOP cassette in the RC::Ptox construct. The GPFtox1 (blue) primer combination recognizes both 
recombined and non-recombined DNA, whereas the GPFtox2 (pink) primer combination identifies 
only un-recombined DNA. Because GPFtox2 amplifies a smaller DNA sample than GPFtox1 in the 
presence of the STOP cassette, it is more useful in consistently recognizing the widespread presence 
of the RC::Ptox construct (SLICK
-
/Ptox
+
 cells will contain un-recombined DNA). (B) PCR amplification. 
Lanes 1-3 contain samples extracted from tamoxifen-treated SLICK-H;Ptox mice, lanes 4-6 contain 
control samples extracted from un-treated SLICK-H;Ptox mice. Amplification was performed using 
GPFtox1 (top panel, blue), GPFtox2 (middle panel, pink) and a combination of wildtype ChAT primers 
that verify the quality of the samples (bottom panel, green). A blue arrow in the top panel points out 
a weak band identifying un-recombined DNA. (C) Schematic representation of the probes used to 
identify Cre-mediated recombination of the RC::Ptox construct by Southern blot. Vertical red lines 
represent the sites where DNA samples were digested using restriction enzymes. Horizontal purple 
and orange lines represent the probes that recognize the un-recombined and the recombined DNA, 
respectively. (D) Southern blot. Lanes 1-4 contain samples extracted from tamoxifen-treated SLICK-
H;Ptox mice, lanes 5-6 from untreated SLICK-H;Ptox control mice, and lane 7 from untreated wildtype 
mice. A purple arrow points to a band that represents the un-recombined construct and an orange 
arrow points to a band that represents the recombined construct.  
 
 Characterization of recombination by Southern blot analysis 4.1.2.2
Once we knew that Cre-recombinase is properly activated in the presence of tamoxifen, we 
attempted to quantify the levels of recombination by Southern blot (SB) analysis. Our 
approach was to compare the amount of recombination in SLICK-H;Ptox versus SLICK-
H;ROSA26 mice, whose recombination efficiency is known to be high (see Chapter 2). We 
administered three doses of tamoxifen to SLICK-H;Ptox mice and purified DNA from brain 
tissue. As negative controls for recombination, we used untreated SLICK-H;Ptox mice as well 
as a wildtype mouse. Purified DNA from these mice was digested using EcoRV and EcoRI and 
then tested with a probe that we designed to recognize the full TetoxLC sequence (Fig 4.2C). 
Recombination should be marked by a band at 1957bp (Fig 4.2C, in orange), the un-
recombined transgene should produce a band at 2827bp (Fig 4.2C, in purple), and the 
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wildtype control lacking the transgene should exhibit no bands. To test recombination of 
SLICK-H;ROSA26, we treated age-matched SLICK-H;ROSA26mice with three doses of 
tamoxifen and compared them to untreated ROSA26 mice, and to a wildtype mouse. We 
designed a probe that recognizes the LacZ sequence and digested the purified DNA using 
EcoRV. 
 
As expected, the tamoxifen-induced SLICK-H;Ptox and the untreated controls exhibit the 
2827bp band signifying the un-recombined transgene, whereas the wildtype control does 
not. The band at 1957bp is faintly observed in the tamoxifen-induced samples but is not 
strong enough to draw any conclusions. Furthermore, the band may also be faintly observed 
in the untreated control samples, although not in the wildtype control. Detection of LacZ by 
Southern blot produced bands for both the recombined and un-recombined transgene but 
these bands were present in both the tamoxifen-induced and the untreated samples. No 
bands were produced in the wildtype control.  
 
To summarize, our Tetox probe is not sensitive enough to confidently detect the recombined 
transgene in SLICK-H;Ptox at the administered dose of tamoxifen. Both the Tetox and the 
LacZ probe seem to pick up a band in untreated controls that should signify the presence of 
recombined transgene. Considering this unspecific band, we did not use these data to 
quantify recombination in SLICK-H;Ptox relative to SLICK-H;ROSA26 tissue.   
 
4.1.3 Do tamoxifen-treated SLICK;Ptox mice express RC::Ptox mRNA? 
 Characterization of transgene mRNA expression by ISH in SLICK-H;Ptox mice 4.1.3.1
In order to characterize the mRNA expression of GFPtox we designed a single-stranded RNA 
probe for in situ hybridization (ISH) that detects the full tetanus toxin light chain sequence 
(1398 bp).  We also carried out staining with a probe for proteolipid protein (PLP) as a 
positive control to assess tissue sample quality; all tissue included in our analysis displayed 
widespread PLP staining in oligodendrocytes, as expected. SLICK-H;Ptox mice were treated 
with three doses of tamoxifen and compared to age-matched untreated SLICK-H;Ptox or 
untreated Ptox mice (Fig 4.3). ISH labeling can be observed in the cortex (Fig 4.3a,f), 
hippocampus (Fig 4.3b,d,e), cerebellum (Fig 4.3c), brainstem (Fig 4.3g), and thalamus (Fig 
4.3h). In the hippocampus, staining is most abundant in the subiculum (Fig 4.3e), followed by 
the CA1 (Fig 4.3d). Occasional staining is observed in the dentate gyrus and CA3 and no 
staining is seen in the CA2 area. Taking into account the fact that recombination the 
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Figure 4.3 – Widespread mRNA expression of TetoxLC in SLICK-H;Ptox double transgenic mice 
In situ hybridization (ISH) was used to examine RNA expression levels of the RC::Ptox construct in Ptox 
mice crossed with the SLICK-H line of mice, which expresses CreER
T2
 in almost all pyramidal neurons. 
Tamoxifen-treated SLICK-H;Ptox double transgenic mice (a-h) were compared to untreated double 
transgenic controls (a’-h’). The cortex and hippocampus are shown at a magnification of 4X (a-b, a’-
b’). The cerebellum and CA1 are shown at 10X (c-d, c’-d’). Individual cells that express TetoxLC mRNA 
in the subiculum (e), cortex (f), brainstem (g) and thalamus (h) are magnified at 20X, along with their  
corresponding controls (e’-h’).  
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efficiency for SLICK-H;R26R in the cerebellum was found to be low compared to other areas 
(Chapter 2), cerebellar staining in SLICK-H;Ptox is relatively abundant. In general however, 
ISH staining for tetanus shows labeling throughout the brain in a pattern similar to SLICK-
H;R26R albeit less abundantly (Chapter 2). 
 
Multiple optimizations, including higher hybridization temperature, shorter wash steps, use 
of proteinase K, and use of polyvinyl alcohol (PVA) did not increase the degree of labeling in 
our treated samples compared to background levels in the untreated controls.  To obtain 
better tissue penetration, we also designed three smaller probes to be used simultaneously, 
each of which should detect roughly one third of the full tetanus sequence. These probes, 
however, produced excessive background even in the untreated control. We also compared 
staining in mice treated with either three or six doses of tamoxifen and saw no significant 
increase in staining. In general, we were able to detect of GFPtox mRNA expression in SLICK-
H;Ptox mice although not with the abundance that we expected based on our SLICK-
H;ROSA26 characterization in Chapter 2.  
 Characterization of transgene mRNA expression by ISH in SLICK-V;Ptox mice 4.1.3.2
 
Once we established the optimal conditions for testing GFPtox mRNA expression through 
ISH, we decided to look at expression in SLICK-V;Ptox mice as well. SLICK-V exhibits 
extremely sparse labeling in the hippocampus and cortex (Young et al., 2008) where we are 
interested in studying activity-dependent processes in single cells.  
 
 
Figure 4.4 – Sparse mRNA expression of TetoxLC in SLICK-V;Ptox double transgenic mice 
In situ hybridization (ISH) was used to examine RNA expression levels of the RC::Ptox construct in Ptox 
mice crossed with SLICK-V, which expresses CreER
T2 
in a sparse number of pyramidal neurons. (A) The 
hippocampus of a tamoxifen-treated SLICK-V;Ptox mouse is shown at a magnification of 4X. (B) 
Stained cells in the CA1 and subiculum of tamoxifen-treated SLICK-V;Ptox mice are magnified to 20X 
and compared to untreated SLICK-V;Ptox controls. In both panels, red arrows point to individual cells 
that express the RC::Ptox mRNA. 
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SLICK-V;Ptox mice treated with ten doses of tamoxifen were compared to age-matched 
untreated SLICK-V;Ptox mice. ISH staining using the same full-length tetanus probe described 
above revealed several single cells that show GFPtox expression. Hippocampal staining (Fig 
4.4A) is most common in the subiculum (Fig 4.4B), followed by the CA1 (Fig 4.4B) and least 
common in the dentate gyrus (Fig 4.4A). We did not detect any labeled cells in the CA3 or 
cortex. Labeled cells were also observed in the brainstem and midbrain but not in the 
thalamus, cerebellum or amygdala. 
 
4.1.4 Do tamoxifen-treated SLICK-H;Ptox mice express the GFPtox protein? 
 Characterization of TetoxLC antibodies by western blot analysis 4.1.4.1
 
 
Figure 4.5 – Western blot characterization of TetoxLC antibodies using transfected cell lysates 
(A) A western blot using Rb-α-Tetox (1:2000) as the primary antibody. A clear band at 75kDa 
represents the TetoxLC-CFP fusion protein. (B) A western blot using MoAb51-α-Tetox (1:100) as the 
primary antibody. The 1
st
 lane contains control cell lysate derived from CFP-transfected cells, the 2
nd
 
and 3
rd
 lanes contain lysate from TetoxLC-CFP transfected cells and the 4
th
 lane contains control lysate 
from untransfected cells. A red arrow identifies the 75kDa band that represents TetoxLC-CFP. (C) A 
western blot using MoAb62-α-Tetox (1:100) as the primary antibody. Cell lysates are the same as in 
the previous blot.  
 
We characterized three antibodies that recognize the 50kDa light chain of tetanus toxin 
(TetoxLC), one polyclonal unpurified serum raised in rabbit (Rb) and two purified monoclonal 
antibodies received as gifts from Dr. Vladimir Petrusic (Chapter 7, Table 7.1). In order to do 
this we transfected COS-7 cells with a TetoxLC-CFP fusion protein (as described in Fig 3.5C) 
and probed total cell lysates by western blot  (WB) analysis. As negative controls in some 
trials we used un-transfected cells and cells transfected with only CFP. Rb-α-Tetox, which we 
tested at 1:100, 1:500, 1:2000 and 1:5000, recognizes the protein robustly at all but 1:5000 
(Fig 4.5A) and does not pick up any other background bands. MoAb51-α-Tetox recognizes 
Tetox-CFP at 1:100 (Fig 4.5B) and more weakly at 1:500. It also picks up several other 
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background bands. MoAb62-α-Tetox does not recognize the fusion protein at 1:100 (Fig 
4.5C). As expected, the CFP-transfected lysates and the un-transfected lysates did not exhibit 
the 75kDa band that represents TetoxLC-CFP. We therefore have one polyclonal unpurified 
serum that recognizes TetoxLC robustly with no background and one purified monoclonal 
(MoAb51) that recognizes the protein less intensely and with some background. 
 Characterization of GFPtox protein expression by western blot analysis 4.1.4.2
 
 
 
Figure 4.6 – Western blot analysis of TetoxLC protein in 
brain samples extracted from tamoxifen-treated SLICK-H;Ptox mice 
(A) A western blot using Rb-α-Tetox as the primary antibody. The 1
st
 lane contains TetoxLC-CFP 
transfected cell lysate as a positive control. The 75kDa band represents the TetoxLC-CFP construct. 
The 2
nd
 lane contains a marker, the 3
rd
 lane contains brain homogenate from untreated SLICK-H;Ptox 
mice and the 4
th
 lane from SLICK-H;Ptox mice treated with 3 doses of tamoxifen. (B) A western blot 
using Rb-α-GFP as the primary antibody. Sample setup is identical to the previous blot. The strong 
lower band in the 3
rd
 and 4
th
 lanes represents YFP (27 kDa) from the SLICK transgene. (C) A western 
blot using MoAb51-α-Tetox (1:100) as the primary antibody. The lanes labeled “control” and 
“tamoxifen” refer respectively to brain homogenate from untreated SLICK-H;Ptox mice and from 
SLICK-H;Ptox mice treated with 8 doses of tamoxifen. 
 
We then attempted to use these antibodies to detect GFPtox expression in tamoxifen-
treated SLICK-H;Ptox mice. We homogenized whole-brain samples of tamoxifen-treated (3 
doses) versus untreated SLICK-H;Ptox mice and used these lysates to probe by western blot 
analysis. As primary antibodies we used either Rb-α-Tetox, MoAb51-α-Tetox or a rabbit 
polyclonal GFP antibody (since Ptox mice contain the GFPtox fusion construct) (Methods, 
Table 7.1). As a positive control we included the TetoxLC-CFP-transfected lysate used in 
Figure 4.5. Rb-α-Tetox recognized TetoxLC-CFP in the transfected lysate but did not pick up 
any GFPtox in the tamoxifen-treated SLICK-H;Ptox (Fig 4.6A). Rb-α-GFP was equally 
ineffective at recognizing any GFPtox protein (Fig 4.6B) although it did detect the transfected 
positive control as well as the YFP derived from the SLICK-H transgene (Fig 4.1B). Similarly, 
MoAb51-α-Tetox did not recognize any expressed GFPtox (Fig 4.6C) although it did recognize 
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the positive control. In summary, neither of the three antibodies we used for western blot 
was able to successfully recognize GFPtox protein in cell lysates from SLICK-H;Ptox mice 
treated with three doses of tamoxifen. 
 Characterization of GFPtox protein expression by immunoprecipitation 4.1.4.3
 
We next performed an immunoprecipitation (IP) assay in order to concentrate GFPtox 
protein levels and increase our chances of detecting low levels of the tetanus toxin. We first 
tested the Tetox antibodies for their ability to precipitate the desired protein (Fig 4.7A). We 
used COS7 cell lysates transfected with TetoxLC-CFP and precipitated the protein by 
incubation with either Rb-α-Tetox, MoAb51-α-Tetox or MoAb62-α-Tetox. We then 
performed three western blots of the immunoprecipitated samples, and each blot was 
probed using one of the three Tetox antibodies.  
 
 
Figure 4.7 – Western blot of TetoxLC immunoprecipitation in cell lysates 
and in brain samples derived from tamoxifen-treated SLICK-H;Ptox mice 
(A) A western blot probed with Rb-α-Tetox. Blot shows the immunoprecipitation of TetoxLC protein 
from cell lysates transfected with TetoxLC-CFP. The 1
st
 lane contains crude lysate used as a positive 
control. The 2
nd
 and last lanes contain mock precipitations using the polyclonal and monoclonal 
antibodies, respectively. The 3
rd
, 4
th
 and 5
th
 lanes, labeled “IP”, show immuno-precipitation by 
incubation with Rb-α-Tetox, MoAb51-α-Tetox or MoAb62-α-Tetox respectively. The strongest and 
clearest staining is obtained by incubation with MoAb51-α-Tetox (in red). (B) A western blot probed 
with Rb-α-GFP. Blot shows the immunoprecipitation of GFPtox protein by incubation with MoAb51-α-
Tetox in brain homogenates derived from treated and untreated SLICK-H;Ptox mice. The first two 
lanes contain un-precipitated brain homogenate samples. The 1
st
 lane is derived from the combined 
brain homogenates of three untreated SLICK-H;Ptox control mice. The 2
nd
 lane is derived from the 
combined brain homogenates of three SLICK-H;Ptox mice treated with 8 doses of tamoxifen. The last 
two lanes contain control and tamoxifen-treated brain homogenates incubated with MoAb51-α-
Tetox. A yellow arrow points to the 75kDa band that represents the GFPtox transgenic protein. 
 
Immunoprecipitation with MoAb51 presented the strongest and clearest staining (Fig 4.7A) 
compared to Rb -α-Tetox (Fig 4.7A, lane 3) and MoAb62 (Fig 4.7A, lane 5). This was true 
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when the samples were probed by western with any of the three antibodies (only Rb-α-
Tetox used as a primary antibody is shown) but as expected, Rb-α-Tetox proved to be the 
most effective as a primary antibody for western blotting (Fig 4.7A). The monoclonal 
antibodies displayed a great deal of background when used as primary antibodies for the 
western blot. As expected, the transfected lysate displayed the TetoxLC-CFP band, whereas 
the two mock precipitations did not. In conclusion, after testing several combinations of 
antibodies with which to precipitate and probe, we concluded that precipitation by MoAb51 
α-Tetox, followed by western analysis using Rb-α-Tetox as a primary antibody provides the 
clearest data.  
 
Once we established the optimal combination of antibodies to precipitate and probe Tetox, 
we treated three SLICK-H;Ptox mice with eight doses of tamoxifen and pooled their whole-
brain lysates. These were compared to three whole-brain lysates for untreated SLICK-H;Ptox 
mice.  We used MoAb51-α-Tetox to immunoprecipitate the samples, and then performed a 
western blot analysis using either Rb-α-Tetox or Rb-α-GFP as the primary antibody (Fig 4.7B). 
Rb-α-Tetox did not pick up any protein expression, whereas Rb-α-GFP successfully detected 
the precipitated GFPtox protein in tamoxifen-treated SLICK-H;Ptox mice compared to 
untreated controls. Neither antibody was sensitive enough to detect protein expression in 
the crude lysates consisting of three brain homogenates pooled (for either control or 
tamoxifen-treated). Although GFPtox protein concentration appears to be quite low even in 
SLICK-H;Ptox mice treated with a higher dose of tamoxifen (8 doses), we were able to detect 
it after pooling three whole-brain samples and then concentrating the protein by 
immunoprecipitation.  
 
Judging by the low levels of GFPtox detected by immunoprecipitation, we suspected that the 
antibodies would not be sensitive enough to detect the protein by immunofluorescence. We 
did, however, test them by immunocytochemistry (ICC) in transfected cells and by 
immunohistochemistry (IHC) in SLICK-H;Ptox and SLICK-V;Ptox mice treated with tamoxifen. 
In both assays, staining proved to be non-specific, showing equal levels of background in 
transfected versus un-transfected cells, and in treated versus untreated tissue. 
Optimizations such as pre-absorption of antibody using wildtype brain extract or purification 
of the polyclonal antibody by proteinG did not increase the sensitivity of the antibodies. 
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4.1.5 Behavioral observations of SLICK-H;Ptox mice treated with elevated doses 
of tamoxifen 
 
When treating SLICK-H;Ptox mice, we generally administered a reduced dosage of tamoxifen 
because we reasoned that if recombination efficiency was a high as in SLICK-H;ROSA26 
(Chapter 2), a full ten-day course of tamoxifen administration might be lethal. In SLICK-
H;R26R this “reduced dose” produces detectable levels of recombination. After performing 
several assays that showed that GFPtox expression in SLICK-H;Ptox mice was low compared 
to SLICK-H;R26R, we decided to increase the tamoxifen dosage. Mice were closely examined 
daily upon tamoxifen administration to ensure that the animals did not show any signs of 
distress. Using age-matched pairs of treated versus untreated SLICK-H;Ptox mice, we 
observed that 8-9 doses of tamoxifen produces an ataxic phenotype in treated mice only. 
Additional wildtype mice treated in tandem served as controls to rule out any effect that the 
tamoxifen delivery itself might inflict. Ten tamoxifen-treated mice displayed the ataxic 
phenotype compared to ten untreated controls and compared to treated wildtype controls. 
 
 
Figure 4.8 – Still frames from video footage of tamoxifen-treated SLICK-H;Ptox mice showing a 
slightly ataxic phenotype. SLICK-H;Ptox mice treated with 8-9 doses of tamoxifen display reduced 
coordination resulting in repeated falls or slips. These still images show two affected mice attempting 
to recover after a fall. Full videos include comparison with control mice. These are available in digital 
format upon request. 
 
SLICK-H;Ptox mice treated with 8-9 doses of tamoxifen display reduced coordination, 
repeated loss of balance resulting in falls or slips and lateral deviations when attempting to 
walk. They display mild tremors when standing still and their backs appear slightly arched in 
comparison to controls. Their movements are slower in general than those of the control 
mice and they seem less inclined to explore their environment. We are not currently 
equipped to quantify these behavioral observations but they are apparent upon casual 
observation and were observed consistently in treated animals versus controls (n=10). These 
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observations indicate that at least in SLICK-H;Ptox mice, 8-9 doses of tamoxifen results in 
enough TetoxLC expression to produce an observable behavioral phenotype. 
 
4.1.6 Do tamoxifen-treated SLICK-H;Ptox mice exhibit reduced expression levels 
of VAMP2? 
 
Having observed a phenotype in SLICK-H;Ptox mice treated with eight doses of tamoxifen, 
we decided to look at expression of the vesicle-associated membrane protein 2 (VAMP2) in 
these mice. VAMP2, also known as synaptobrevin-2, resides in the synaptic vesicle 
membrane and assembles to form part of the SNARE complex responsible for vesicle fusion 
to the presynaptic membrane (Sutton et al., 1998). Tetanus toxin light chain acts by cleaving 
this protein between residues 76-77, which prevents synaptic vesicle exocytosis and 
therefore inhibits neurotransmitter release (Schiavo et al., 1992, 2000). If GFPtox is 
functional in tamoxifen-treated SLICK-H;Ptox mice, we should see a reduction in the amount 
of full-length VAMP2 protein compared to untreated controls.  
 Characterization of VAMP2 expression by western blot analysis 4.1.6.1
In order to characterize VAMP2 expression in SLICK;Ptox mice, we obtained two 
commercially available antibodies that recognize synaptobrevin-2 (Methods, Table 7.1). 
Monoclonal mouse α-VAMP2 recognizes residues 2-17 from the rat VAMP2 sequence and 
has no cross-reactivity with the other two isoforms, VAMP1 or VAMP3. Although the epitope 
for this antibody is present in the tetanus-cleaved form of VAMP2, the supplier Synaptic 
Systems states that the cleaved VAMP2 is not recognized. Moreover, this antibody is widely 
used for verifying VAMP2 cleavage (Yu et al., 2004, Kim et al., 2009). Polyclonal rabbit α-
VAMP1/2/3 is raised against residues 1-81 of VAMP3, also known as cellubrevin, and 
recognizes all three isoforms VAMP1, 2 and 3. The antibody also weakly recognizes the 
cleaved product of VAMP2.  
 
We compared SLICK-H;Ptox mice treated with eight doses of tamoxifen to age-matched 
untreated SLICK-H;Ptox controls by western blot analysis using both antibodies α-VAMP2 
and α-VAMP1/2/3.  We also used α-GAPDH as a loading control (Methods, Table 7.1). 
Considering that ataxic behavior in these mice could implicate cerebellar dysfunction 
(Schmahmann, 2004), we analyzed cerebellum tissue lysates separately from forebrain 
tissue lysates. As shown in Figure 4.6A, α-VAMP2 (in green) detects the protein strongly 
(only 15ug of total protein was loaded) and is very specific (no other bands displayed even 
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when 60ug of total protein was loaded). α-VAMP1/2/3 (Fig 4.6B) robustly and specifically 
recognizes VAMP1 (top band), VAMP2 (middle band) and VAMP3 (bottom band) but does 
not seem to pick up the cleavage product of VAMP2 in our samples. Both antibodies seemed 
suitable for comparing levels of VAMP2 expression.  
 
 
 
In order to quantify VAMP2 expression levels, we repeated the assay using five age-matched 
pairs of tamoxifen-treated versus untreated SLICK-H;Ptox mice. Each pair was analyzed over 
several blots, using both antibodies, for both forebrain and cerebellar lysates. We observed 
average reductions in protein expression in treated versus untreated controls but none of 
the relationships were significant (p>0.05) (Fig 4.6C). Moreover, different blots using the 
exact same samples showed different relationships; sometimes averages showed a 
reduction in VAMP2 in treated samples, sometimes an increase and sometimes no 
difference at all.  Loading controls usually showed equal levels of protein loading; blots that 
did not fulfill this requirement were excluded from calculations. In general, we did not 
detect any significant reduction in VAMP2 expression levels in tamoxifen-treated SLICK-
H;Ptox mice versus untreated controls. The same was true in forebrain tissue and cerebellar 
tissue probed with either α-VAMP2 or α-VAMP1/2/3. 
Fig 4.9 – Western blot analysis of VAMP2 
expression levels in SLICK-H;Ptox mice 
 
(A) A western blot comparing forebrain 
homogenates from tamoxifen-treated SLICK-
H;Ptox mice (1
st
 and 2
nd
 lanes) and untreated 
SLICK-H;Ptox mice (3
rd
 and 4
th
 lanes). Anti-
VAMP2 is shown in green and α-GAPDH is 
shown in red. (B) A western blot comparing 
forebrain homogenates from tamoxifen-
treated SLICK-H;Ptox mice (2
nd
 and 3
rd
 lanes) 
and untreated SLICK-H;Ptox mice (4
th
 and 5
th
 
lanes). Anti-VAMP1/2/3 is shown in green. (C) 
Graph of normalized K-counts comparing five 
age-matched pairs of tamoxifen-treated SLICK-
H;Ptox versus untreated SLICK-H;Ptox mice. 
Forebrain and cerebellum samples were 
repeatedly probed using either α-VAMP2 or α-
VAMP1/2/3. Mean normalized k-counts for 
each pair were averaged and graphed as 
shown. Error bars represent standard error.  
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 Characterization of VAMP2 expression by immunohistochemistry 4.1.6.2
Along with performing western blot analysis, we also used α-VAMP2 to stain SLICK;Ptox 
brain tissue. Immunohistochemistry (IHC) was performed on vibratome sections of 
tamoxifen-treated versus untreated SLICK-H;Ptox mice. We did not observe a global 
reduction in VAMP2 fluorescence, as we would have expected from the behavioral 
observations in these mice. Moreover, the staining was indistinct and did not resemble the 
clear punctate staining previously observed in rats (Johnson et al., 2005). The staining also 
did not colocalize well with SLICK-labeled cells. We wondered whether the punctate staining 
might be more clearly visible in SLICK-V;Ptox where Cre-mediated recombination is more 
sparse. We compared treated versus untreated SLICK-V;Ptox staining, and looked for 
staining in areas like the entorhinal cortex, where projection neurons synapse onto cortical 
cells (Andersen, 2007) and in the cerebellum where SLICK+ mossy fibers synapse onto 
granule cells (Shepherd, 2004). We observed some VAMP2 staining in the cerebellum but 
could not detect any obvious reduction in treated versus untreated animals. It is worth 
noting that staining is so sparse in SLICK-V that this approach might not be the most efficient 
in finding individual terminals. In summary, we were not able to detect a reduction in 
VAMP2 in tamoxifen-treated double transgenics compared to untreated controls. 
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4.2 Discussion 
 
SLICK mice were crossed to RC::Ptox mice and administered the drug tamoxifen in order to 
induce coexpression of (a) YFP and CreERT2 and (b) the fusion protein GFPtox that consists of 
GFP and the tetanus toxin light chain (TetoxLC). Since the bright YFP labeling in the SLICK 
system precludes the detection of GFP fluorescence as an indication of GFPtox expression, 
we instead characterized the mice using several other methods (Table 4.1). We first 
confirmed by PCR that Cre-mediated recombination occurs in tamoxifen-treated but not 
untreated SLICK-V;Ptox mice. Next, induction of GFPtox mRNA expression was observed by 
in situ hybridization in several brain regions including the CA1 region of the hippocampus. 
The sparse GFPtox expression observed was in line with the sparse labeling of neurons in the 
SLICK-V line. Furthermore, although the available antibodies directed against TetoxLC do not 
work well for immunohistochemistry, induction of GFPtox protein could be observed by 
western blotting following immunoprecipitation from brain lysates of tamoxifen-treated 
SLICK-H;Ptox mice. We could not detect a reduction in VAMP2 expression in tamoxifen-
treated mice versus untreated controls. Importantly, however, we observed that SLICK-
H;Ptox mice treated with 8-9 doses of tamoxifen show a behavioral phenotype. Taken 
together, these observations validate SLICK;Ptox as a model in which inducible expression of 
GFPtox can be achieved in CA1 pyramidal cells of the hippocampus, as well as other brain 
regions.   
 
Table 4.1 – Characterization summary for SLICK;Ptox mice 
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The levels of GFPtox expression in tamoxifen-induced cells of SLICK-V;RC::Ptox mice appear 
to be quite low, although this should not be a hindrance considering that tetanus toxin is a 
potent synaptic inhibitor that is lethal even at very low doses (Schiavo et al., 2000). In 
Aplysia, for example, 4-10 molecules of tetanus toxin are sufficient to inhibit 50% of 
neurotransmission within 20 minutes (Schiavo et al., 2000). Accordingly, although we cannot 
directly detect GFPtox expression within individual cells, expression levels are nonetheless 
sufficient to elicit behavioral affects in SLICK-H;Ptox mice. In RC::PFtox mice, which are 
similar to the RC::Ptox mice used in this study, GFPtox cannot be directly detected by GFP 
fluorescence but is nonetheless sufficient to cleave a significant fraction of VAMP2 and elicit 
behavioral and electrophysiological effects (Kim et al., 2009). The inability to detect GFPtox 
in individual cell does, however, poses an inconvenience as we are unable to distinguish 
between SLICK+/Ptox– and SLICK+/Ptox+ neurons.  
 
4.2.1 Recombination in SLICK-H;Ptox 
 
We carried out polymerase chain reaction (PCR) and Southern blot to assess whether or not 
recombination is possible in tamoxifen-induced SLICK-H;Ptox mice. PCR results clearly 
indicate that recombination does take place in treated versus untreated mice (n=4), as 
shown by two primers sets that detect the presence of the recombined transgene in drug-
induced mice and one primer set that detects the presence of the un-recombined transgene 
in all un-induced mice. One tamoxifen-induced mouse did not test positive for the un-
recombined transgene. This could be an indication that recombination was higher in this 
mouse than in the others and that non-recombined DNA was below detection level. 
 
Southern blot was performed with the intention to quantify the relative levels of 
recombination in SLICK-H;Ptox mice compared to SLICK-H;R26R mice. Results are 
inconclusive for two reasons: (1) the sensitivity of our assay was very weak and (2) a band 
that should represent the recombined transgene was observed very faintly in untreated 
controls. The sensitivity issue could arise from the probe and perhaps designing another 
could increase detection of the recombined transgene. Alternatively, lack of sensitivity could 
have resulted from poor sample quality. The recombination band observed in untreated 
controls could be a sign of (a) contamination in our samples, (b) background produced by 
our probe, or (c) leaky recombination in untreated controls. Judging by the fact that the 
wild-type sample did not show any trace of this band, it seems more likely that our 
untreated samples were either contaminated or that the band indicates leaky recombination 
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in these mice, although this is not expected based on the data in Chapter 2 showing tight 
control of recombination in the SLICK-H line. 
  
4.2.2 GFPtox mRNA expression in SLICK-H;Ptox and SLICK-V;Ptox 
 
We used in situ hybridization (ISH) to evaluate mRNA expression of the GFPtox transgene. 
SLICK-H;Ptox mice, which exhibit widespread SLICK expression, showed clear widespread 
staining in treated versus untreated controls. The pattern of mRNA expression we detected 
is similar that of SLICK-H crossed to the reporter line ROSA26, although staining is not as 
abundant. The pattern and abundance of mRNA staining is even more similar to the 
immunostaining of GFPtox protein observed by Dr. Jun Chul Kim in RC::Ptox mice crossed to 
the CamKIIα -Cre line (Fig 4.10, unpublished data provided by Dr. Jun Chol Kim)  
 
 
 
Figure 4.10 – GFPtox detection in tamoxifen-treated CaMKIIα;Ptox mice 
Unpublished data provided by Dr. Jun Chol Kim, Harvard University 
Since GFP fluorescence was not readily detectable in these mice, 3,3'-diaminobenzidine (DAB)-
staining was instead used to detect GFPtox expression. Expression levels in the hippocampus and 
cortex of tamoxifen-treated double transgenic mice are shown. 
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In SLICK-V;Ptox, which has sparse SLICK expression, we observed a very small number of cells 
labeled in the hippocampus, brainstem and midbrain, but not in the cortex, thalamus, 
cerebellum or amygdala. Although the number of GFPtox+ cells that we found in these 
treated double-transgenic mice is far fewer that the number of YFP cells labeled in SLICK-V 
mice, we suspect that we are only detecting cells with the most robust GFPtox expression.  
 
We do not know why SLICK-H;Ptox and SLICK-V;Ptox show reduced expression of GFPtox 
compared to the amount of cells that express the SLICK transgene itself. Since GFPtox is 
targeted to the ROSA locus, we should expect recombination to occur with the same 
frequency as in SLICK;R26R. Technical problems, although possible, do not seem likely in 
light of the many optimizations that we attempted, including new probe designs and higher 
tamoxifen doses. It seems more likely that the ISH is not sensitive enough to detect neurons 
with very low levels of tetanus which, as mentioned already, would be sufficient to inhibit 
neurotransmitter release in these cells. We suspect that we have only detected cells with 
very robust expression of GFPtox and these are only a small proportion of the total number 
of cells that actually express the protein.   
 
4.2.3 GFPtox protein expression in SLICK-H;Ptox 
 
We examined GFPtox protein expression by western blot, by immunoprecipitation followed 
by western blot, and by immunohistochemistry (IHC). We used three antibodies raised 
against the light chain of tetanus toxin, as well as an antibody against GFP. Western blotting 
was not sensitive enough to detect any expression, whereas IHC showed excessive 
unspecific labeling. We were able to detect GFPtox expression only by pooling together 
three whole-brain lysates of treated SLICK-H;Ptox mice (administered with an elevated 
dosage of tamoxifen) and then immunoprecipitating them to concentrate the protein. These 
data indicate that toxin levels in tamoxifen-induced SLICK;Ptox mice are quite low. 
Considering the previously described efficiency of tetanus toxin at low levels, however, this 
should not hinder the efficiency of the model (Schiavo et al., 2000). Moreover, since very 
low levels of GFPtox in a cell would be difficult to detect, there are probably many cells 
expressing GFPtox at levels below the detection threshold of our assays, particularly 
immunohistochemistry.  
 
Further studies to concentrate tetanus-expressing cells could include isolation of YFP-labeled 
cells in SLICK-V;Ptox by fluorescence activated cell sorting (FACS) or laser capture 
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microdissection. These isolated cells could then be used for quantitative assays like real-time 
polymerase chain reaction (qPCR), to determine what proportion of SLICK+ cells express 
GFPtox. Since we currently cannot detect GFPtox directly in individual cells, this information 
would at least allow us to determine what percentage of cells express TetoxLC.  
 
4.2.4 Behavioral observations in SLICK-H;Ptox 
 
We observed a behavioral phenotype in SLICK-H;Ptox mice administered with 8-9 doses of 
tamoxifen (n=10). The defects in motor coordination are similar, although less pronounced, 
than those observed by Kim et al in RC::PFtox mice crossed to the Math1-Cre line (Matei et 
al., 2005). The reduced prominence of motor coordination defects in our double transgenics 
is likely due to the fact that SLICK-H exhibits low recombination rates in the cerebellum 
(refer to Chapter 2) whereas Math1-Cre has robust recombination efficiency in this area 
(Matei et al., 2005). Since expression of TetoxLC in the cerebellum, which exhibits low 
recombination rates in SLICK-H mice, is sufficient to produce a phenotype, we assume that 
TetoxLC expression is even higher in other areas of the brain like the cortex and 
hippocampus. In any case, the observed phenotype suggests that despite our difficulty 
detecting the GFPtox protein, TetoxLC expression is sufficient to inhibit neurotransmission in 
a significant proportion of cells. 
 
4.2.5 VAMP2 expression in SLICK-H;Ptox 
 
Having detected minute levels of GFPtox protein, as well as a behavioral phenotype in SLICK-
H;Ptox mice, we examined VAMP2 protein expression using western blot and 
immunohistochemistry. Reduced expression of VAMP2 in tamoxifen-induced mice would 
indicate successful GFPtox expression and translocation from the cell body to the 
presynaptic terminal and subsequent proteolysis of the SNARE complex.  
 
Using two different antibodies for the western blot, we were not able to detect any 
consistent VAMP2 reduction in tamoxifen-treated SLICK-H;Ptox (n=5). One of these 
antibodies, α-VAMP2, is widely used for confirming tetanus-mediated cleavage of the 
protein, and should therefore be adequate for our study (Yu et al., 2004, Kim et al., 2009). 
Considering that our samples resulted in inconsistent relative expression levels across 
several blots, we suspect that we are faced with a systematic technical problem rather than 
a true indication of uniform expression in treated versus untreated mice.  
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We were likewise not able to detect a loss of VAMP2 fluorescence through 
immunohistochemistry (n=3). In the case of IHC, however, α-VAMP2 has not been 
characterized or used as widely in mouse tissue. Although staining in rat tissue produces 
clear punctate staining of VAMP2 in pre-synaptic terminals (Johnson et al., 2005), staining in 
our mouse tissue appears more diffuse. This would render the approach inadequate for 
looking at specific terminals in SLICK-V;Ptox mice. As for SLICK-H;Ptox mice, however, it 
should have been possible to detect a global loss of VAMP2 in treated transgenics. This 
reduction should be similar in proportion to the amount of GFPtox labeling observed with in 
situ hybridization.  
 
We are not sure why we were not able to detect a decrease in VAMP2 levels in tamoxifen-
induced SLICK-H;Ptox mice. We suspect that technical complications are a likely factor 
influencing our results for both assays. Also, although the SLICK lines have been shown to 
display tight control of recombination in the absence of tamoxifen administration, it is 
possible that SLICK;Ptox do experience leaky recombination. This could result in irregular 
data considering our small sample sizes. Southern blot data showing “recombination” in 
untreated controls could support this suggestion. Finally, it is possible that a small amount of 
cleaved VAMP2 is exerting a dominant negative effect on uncleaved VAMP2. Considering (a) 
the successful reduction of VAMP2 in RC::PFtox mice when crossed to several other Cre-
expressing lines (Kim et al., 2009), (b) the efficiency of recombination in the SLICK lines, and 
(c) our detection of GFPtox expression and behavioral observations, it seems unlikely that 
VAMP2 expression is genuinely not reduced in treated SLICK-H;Ptox mice. 
 
4.2.6 Further studies 
 
Our data present reassuring evidence that the GFPtox protein is expressed in SLICK;Ptox 
mice, although we have not yet been able to confirm an effect on VAMP2 expression levels.  
We attempted to clarify our results by using FM stryryl dyes to study exocytosis but found 
the technique problematic and were not able to obtain clear staining of vesicles. We were 
able to visualize the dye in cell cultures treated with AM-65 but not in wild-type tissue. 
We are now collaborating with Dr. Mark Rea of the Physiology Department at UCC to carry 
out electrophysiological studies in SLICK-V;Ptox mice. His laboratory will, among other 
studies mentioned in Chapter 5, measure synaptic input to muscle fibers innervated by 
SLICK+ axons (labeled brightly with YFP) in treated versus untreated SLICK-V;Ptox mice. He 
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will also compare these measurements to wildtype terminals in SLICK-V single transgenic 
mice to determine whether there is in fact leaky recombination in untreated double 
transgenics. Muscle fibers in treated SLICK-V;Ptox mice should suffer reduced synaptic input 
compared to cells in untreated and wild-type controls. If successful, these studies will 
determine conclusively whether GFPtox expression in SLICK;Ptox mice leads to effective 
inhibition of neurotransmission. 
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Chapter 5 Analysis of dendritic spines in single-neurons 
inhibited with tetanus toxin  
 
5.1 Results 
 
We conditionally suppressed neurotransmission in a small subset of neurons and 
investigated the effect that this has on synaptic inputs to individual cells. Burrone and 
colleagues had shown that cultured hippocampal neurons whose activity has been 
suppressed by Kir2.1 overexpression exhibit a competition-dependent reduction in dendritic 
spine density and mEPSC frequency (Burrone et al., 2002). Based on these and other results, 
we examined dendritic spine density and morphology in a small subset of CA1 hippocampal 
neurons.  
 
5.1.1 Experimental Design  
 
In order to suppress neuronal activity in a small subset of cell, we crossed the CreERT2-
expressing SLICK-V line to the RC::Ptox line, which conditionally expresses TetoxLC 
(characterized in Chapter 4). Double transgenic mice treated with tamoxifen should exhibit 
YFP labeling in small subsets of pyramidal neurons that simultaneously express the tetanus 
toxin light chain and therefore display reduced ability to release neurotransmitter signals. 
Since the Thy1 promoter used in SLICK is developmentally expressed and generally produces 
optimal expression after 6 weeks postnatal, this study is of the adult mouse brain, ages 4-7 
months.   
 
Male SLICK-V;Ptox mice aged 6-10 weeks were administered ten doses of tamoxifen and 
then rested for two months or more. We used two control groups for this study; the first is 
untreated SLICK-V;Ptox mice used to compare induced versus un-induced transgenic cells, 
and the second is tamoxifen-treated Ptox–/SLICK-V+ mice that will control for any effects 
caused by drug delivery. Tamoxifen is a modulator of estrogen receptors and has been 
shown to alter dendritic spine density in CA1 pyramidal neurons of male rats (Gonzalez-
Burgos et al., 2012). Both controls are sex and age matched in most cases (Table 5.1B). For 
clarity, the three treatment groups, (1) tamoxifen-treated SLICK-V;Ptox, (2) untreated SLICK-
V;Ptox, and (3) tamoxifen-treated SLICK-V, are color coded and referred to in this chapter as 
VP-tmx (in red), VP-ctrl (in blue) and V-tmx (in green) respectively. We performed eight 
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trials, each of which includes one mouse from each treatment group. Imaging, data analysis 
and quantification were performed under blinded conditions. 
5.1.2 Strategy for cell and dendritic segment selection  
 
Since we do not know the rate of recombination in treated SLICK-V;Ptox, nor the extent of 
leaky recombination (if any) in untreated SLICK-V;Ptox controls, we decided to analyze 
multiple cells per animal. CA1 hippocampal neurons were chosen based on overall 
brightness of the cell body and preference was given to cells whose dendritic branches ran 
parallel to the surface of the section (filaments will then lie in the x/y plane of the z-stack 
and therefore exhibit better resolution). Where possible, we avoided cells that were very 
close to the subiculum or to the CA2. 
 
 
 
Figure 5.1 – Strategy for selecting dendritic branch segments of CA1 pyramidal cells 
(A) Using the cell body as the center, we drew two circles with radii of 50 and 100 µm using the Zen 
Imaging Software (Zeiss, UK). For each cell we chose two primary branch segments that fell between 
the two circles (shown as “Area 1” and “Area 2” with arrow). We did not select bifurcated branches 
(open arrow). Once selected, a 3.5X optical zoom was applied for imaging (shaded box, to scale). (B) 
Example of a dendritic segment z-stack of ~8 µm in thickness.  
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Within each cell, we only analyzed primary branches of the main apical dendrite; higher 
order branches were avoided for consistency (Fig 5.1A). These were always approximately 
50-100 µm from the pyramidal cell layer. Two to three different branch segments per cell 
were imaged at 63X with an additional 3.5X optical zoom (Fig 5.1B). In total, we documented 
approximately 70-120 µm of dendrite length per cell, averaging out to about 450 µm per 
animal (Table 5.1). These images were then analyzed using the Filament Tracer module in 
Bitpane Imaris software. We focused on spine number and spine length. Including all three 
treatments groups, we counted a total of 21,391 spines over a total dendritic length of 
11,188 µm. 
 
5.1.3 Dendritic spine density and length in tamoxifen-treated SLICK-V;Ptox 
 
Since we do not know whether recombination is high in VP-tmx or whether VP-ctrl 
experiences any leaky recombination, a nested statistical approach most appropriately fits 
our experimental design because it takes into account variation between cells of a single 
animal. In order to obtain mean spine densities using a nested design, we grouped all of the 
cells for each treatment group and directly calculated an average (as opposed to averaging 
cells within each mouse and then averaging the mice within a treatment group).  Using the 
nested approach we obtained mean spine densities for VP-tmx, VP-ctrl and V-tmx of 1.696 
(n=39 cells), 1.990 (n=40 cells), and 2.088 (n=42 cells), respectively (in spines/µm) (Table 
5.1). Mean spine lengths for VP-tmx, VP-ctrl and V-tmx were 0.800 µm (n=39 cells), 0.756 
µm (n=40 cells), and 0.807 µm (n=42 cells), respectively (Table 5.1).  Further information for 
each trial, including age and mean spine density and length for each mouse, is provided in 
Table 5.1.  
 
For spine density, general significance between the three treatment groups was obtained 
using a mixed-model nested ANOVA (p<0.05). This was followed by three post-hoc tests that 
revealed that the observed reduction in spine density in VP-tmx mice is significant compared 
to both controls (p<0.05) (Table 5.2). A nested analysis of our data produces a more 
conservative p-value than a one-way ANOVA or individual Student T-tests (see section 5.2.2 
for further discussion). Differences in spine length were not significant according to both a 
mixed model nested ANOVA and a one-way ANOVA. 
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Table 5.1 – Additional information for each treatment group and animal analyzed 
 
 
 
 
Overall, VP-tmx mice show a 15% and 19% decrease in spine density compared to VP-ctrl 
and V-tmx, respectively (Fig 5.2A), whereas spine length appears to be unaffected (Fig 5.2B). 
VP-tmx compared to V-tmx is more significant than VP-tmx compared to VP-ctrl. A closer 
look at individual measurements also revealed that VP-ctrl mice exhibit greater variation 
than VP-tmx or V-tmx at the level of cells (Fig 5.3B) and of animals (Fig 5.3A). This is 
demonstrated by a larger 95% confidence interval for both nested (Fig 5.3B) and non-nested 
(Fig 5.3A) datasets, as well as by uneven variance components calculated by the mixed-
model nested ANOVA.  
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Figure 5.2 –Mean spine density and mean spine length 
(A) Graph of mean spine densities. Error bars represent Gabriel’s confidence intervals, a statistical 
test that indicates significance (p<0.05) when intervals do not overlap. An asterisk shows the 
treatment group that is significantly reduced. (B) Graph of mean spine length. Error bars represent 
95% confidence intervals. (C) Representative dendritic segments for the three treatment groups. The 
left panel shows confocal projections and the right panel shows the 3D representations used for 
quantification. Spine densities of the segments shown are 1.6919, 1.990, and 2.0973 spines/µm, 
respectively for VP-tmx, VP-ctrl and V-tmx. 
 
 
 
Figure 5.3 – Mean spine densities for animals and for cells; organized by trial number 
(A) Scatter plot of mean spine densities obtained by averaging cell means for each animal. Shaded 
area represents 95% confidence interval (CI) and dotted line represents one standard deviation. Red 
dots, blue diamonds and green triangles indicate VP-tmx, VP-ctrl and V-tmx mice respectively. This 
un-nested approach is misleading as it does not acknowledge the possibility of differential expression 
of TetoxLC in each cell (B) Scatter plot of mean spine densities for each cell analyzed. Clustered dots, 
diamonds or triangles indicate the cells analyzed for each animal within each corresponding 
treatment group. 
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Thus, as demonstrated by a nested ANOVA and three post-hoc tests of mean comparisons, 
our results clearly show a reduction in spine density in tamoxifen-treated SLICK-V;Ptox 
compared to untreated SLICK-V;Ptox (15%) and compared to treated SLICK-V (19%). 
Representative dendritic segments for each treatment group show that this reduction is 
visually apparent (Fig 5.2 C-E and C’-E’). Our results also show that average spine length is 
not affected in tamoxifen-treated SLICK-V;Ptox compared to controls. 
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5.2 Discussion 
 
Using a technique that conditionally inhibits neurotransmission in a small subset of YFP-
labeled CA1 pyramidal neurons we found that apical spine density is decreased by 15%-19% 
in cells that express the tetanus toxin light chain. This reduction is apparent in adult VP-tmx 
mice, double transgenics that have been treated with the drug tamoxifen in order to induce 
recombination of the GFPtox transgene. The reduction is statistically significant (p<0.05, 
n=8) when compared to VP-ctrl mice (un-induced double transgenics), as well as to V-tmx 
mice (tamoxifen-treated Ptox–/SLICK-V+). Significance is obtained using both a nested 
approach (mixed-model nested ANOVA and three post-hoc tests) and a non-nested 
approach (one way ANOVA or two tailed t-tests). Spine length does not appear to be altered 
in tamoxifen-treated SLICK-V;Ptox mice compared to either control. The observed reduction 
in apical spine density of single tetanus-expressing cells is further discussed in Chapter 6, 
General Discussion. 
 
5.2.1 Spine length stability in tamoxifen-induced SLICK-V;Ptox mice 
 
Spine length in the apical dendrites of CA1 pyramidal neurons does not appear to be altered 
in response to neuronal silencing. We investigated this property because it is one possible 
way in which a cell could compensate for a reduction in the total number of spines at its 
disposal. Since longer/thinner spines can undergo LTP more readily (Matsuzaki et al., 2004), 
this homeostatic change would allow the remaining synapses to become more plastic. 
Further studies should include an investigation of spine shape; since spine morphology is 
closely related to synaptic function (Lee et al., 2012), knowing whether a certain type of 
spine shape is preferentially eliminated or maintained could provide insight into the 
mechanisms for spine density reduction. In terms of molecular parameters, synaptic scaling 
of AMPARs (Gainey et al., 2009) or NMDARs (Rao and Craig, 1997) in remaining spines 
should also be investigated as they could point to homeostatic compensatory mechanisms 
(Turrigiano, 2011).  
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5.2.2 Statistical Analysis 
 
 Mixed-model nested ANOVA 5.2.2.1
 
Because we do not know the recombination rate for VP-tmx, or the extent of leaky 
recombination in VP-ctrl, variation in our data could occur on three levels: across treatment 
groups, across animals within a group, or across cells within an animal. A nested ANOVA, 
which takes into consideration such variation, is therefore the most appropriate statistical 
test for our design. This test gives a p-value indicating significance between treatment 
groups and also provides a variance component indicating which level produces the most 
variation (MacDonald, 2009, Picquelle and Mier, 2011). “Mixed-model” indicates that the 
difference between treatment groups is inherently interesting as opposed to a design where 
first-level groups represent samples within a population (MacDonald, 2009). A nested 
analysis of our data produces a more conservative p-value than a single ANOVA or individual 
Student T-tests, reassuring us that significance is genuine. Values were adjusted for uneven 
sample sizes (n=39, 40, and 42 cells for VP-tmx, VP-ctrl and V-tmx respectively). 
 Post-Hoc tests comparing group means 5.2.2.2
 
Following a significant result from the nested ANOVA, we performed three post-hoc tests to 
determine which groups are significantly different from each other. Using Dunnett’s T-test, 
Tukey’s standardized range and Gabriel’s comparison intervals, we compared the means of 
VP-tmx versus VP-ctrl and of VP-tmx versus V-tmx. All three algorithms are similar to a 
Student’s T-test, except that they are more conservative because they adjust for the fact 
that increasing the number of comparisons also increases the probability of falsely rejecting 
the null hypothesis (Sokal and Rohlf, 1995, Zar, 1999, MacDonald, 2009).  
 
Dunnett’s T-test, which is designed to compare one reference group against all others, is the 
test most appropriate for our experimental setup (Ludbrook, 1998). A typical example of this 
design is a single placebo being compared to several new drugs. In our case, a single 
experimental condition is being compared to two controls in a two-tailed fashion. Tukey’s T-
test is similar except that it allows for multiple comparisons to be made without the need for 
a particular reference group (Ludbrook, 1998). When sample sizes are unequal, this test is 
especially conservative (Ludbrook, 1998). Gabriel’s comparison intervals is similar to Tukey’s 
test except that significance is displayed by comparison limits (similar to a confidence 
interval) (Gabriel, 1978). When the intervals for two group means do not overlap, the 
relationship is considered significant (Gabriel, 1978). We used this method because it is 
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practical for presenting significance in graphical form (Fig 5.2A). In summary, Dunnett’s T-
test is the most relevant to our experimental design, whereas Tukey’s T-test is the most 
conservative. Both of these, along with a third test that plots significance on a graph, show 
that the spine density reduction in VP-tmx is significant compared to both controls.  
 Unequal distribution of variance could indicate leaky expression in 5.2.2.3
SLICK;Ptox mice  
 
The nested ANOVA comparing the three treatment groups revealed that variation at the 
level of cells and animals is greater than at the level of treatment groups. Individual nested 
ANOVAS (comparing VP-tmx to each control separately), revealed that this unequal 
distribution of variance occurs when VP-tmx is compared to VP-ctrl but not when it is 
compared to V-tmx. This suggests that a greater variation occurs among cells of untreated 
SLICK-V;Ptox mice. This is consistent with the fact that this group, when averaged using 
either a nested or non-nested approach, has a higher standard deviation and confidence 
interval than the other two. This variation is evident at the level of animals (Fig 5.3A) and at 
the level of cells (Fig 5.3B).  
 
Variation among the cells from the same animal could be due to some percentage of leaky 
recombination in untreated SLICK-V;Ptox mice. Although this is not fully substantiated by our 
data in Chapter 4 (we did not, for instance observe leaky recombination in the in situ assays; 
Figs 4.3 & 4.4), it could partially account for the results of the Southern blot, where a band 
for recombined DNA appears weakly in un-treated controls (Fig 4.2). Our difficulty detecting 
a reduction in VAMP2 expression through western blotting (Fig 4.9) could also have been 
partially confounded by leaky expression in VP-ctrl considering our small sample size. Finally, 
the fact that variation does not seem to be significant among cells of tamoxifen-treated 
SLICK-V;Ptox suggests that these mice exhibit a high rate of recombination.  
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Chapter 6 General Discussion 
 
 
In this thesis we have characterized in detail two transgenic mouse lines that facilitate the 
study of neuronal circuits by allowing conditional genetic manipulations to be triggered in 
fluorescently labeled pyramidal neurons throughout the central and peripheral nervous 
system. SLICK-H (Chapter 2 & Section 6.1.1) can be crossed to any Cre-loxP driven mouse line 
to induce widespread conditional neuron-specific genetic manipulation. SLICK-V::Ptox 
(Chapters 4 - 5 & Sections 6.1.2 - 6.2) conditionally inhibits neurotransmission in a small 
subset (<1%) of YFP-labeled pyramidal cells due to the inducible expression of TetoxLC (the 
tetanus toxin light chain). In Chapter 3 we also describe the attempt to create two additional 
Cre-driven mouse lines that would allow conditional expression of either the potassium 
channel Kir2.1 or of TetoxLC. Finally, in Chapter 5 we use SLICK-V::Ptox mice to show that 
single neurons whose neurotransmission is disrupted by TetoxLC experience a 15% - 19% 
decrease in apical spine density compared to wildtype neurons (Section 6.2). 
 
The tools presented in this thesis directly address the outstanding biological questions in the 
field of neuroscience today. SLICK-V::Ptox in particular, which allows single cells to be 
conditionally inhibited in an otherwise wildtype environment, greatly facilitates the study of 
activity-dependent competition. Extreme manipulations of this sort are instrumental in 
deciphering the mechanisms by which the normal brain synchronizes activity within and 
among circuits and how a disruption in this activity can lead to disease. 
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6.1 Novel mouse models for the study of neuronal circuits 
 
 
6.1.1 SLICK-H mice for pan-neuronal Cre-mediated inducible recombination  
 
We have cataloged in detail the transgene expression patterns and recombination 
efﬁciencies in SLICK-H mice, a transgenic line that facilitates widespread inducible 
conditional genetic manipulation within most populations of projection neurons. Using two 
back-to back copies of the Thy1.2 promoter cassette, SLICK-H mice co-express robust and 
relatively uniform levels of CreERT2 (a drug-inducible form of Cre recombinase) and YFP 
throughout the peripheral and central nervous system. This allows for efﬁcient induction of 
Cre-mediated genetic manipulation upon tamoxifen administration in fluorescently labeled 
neuronal populations in adult mice. Importantly, Cre activity in the absence of tamoxifen is 
minimal, permitting tight control of recombination.  
 
Compared to other available neuron-specific “Cre driver” lines, SLICK-H displays a more 
widespread transgene distribution, superior control of recombination in the absence of 
tamoxifen, higher recombination efficiency upon drug administration and higher tissue and 
cell-type specificity. SLICK-H mice thus offer signiﬁcant advantages over currently available 
inducible Cre recombinase lines (discussed in Section 2.3.2), and make the SLICK-H line 
highly suitable for functional genomic analysis of behavioral and other neuronal phenotypes 
in adult mice. SLICK-H transgenic mice are available from The Jackson Laboratory. 
 
6.1.2 SLICK-V/Ptox mice for single-cell silencing 
 
We crossed the SLICK-V line, which expresses robust levels of CreERT2 and YFP in very sparse 
populations of projection neurons (<1%) throughout the nervous system, to the RC::Ptox 
line, which conditionally expresses TetoxLC (Young et al., 2008, Kim et al., 2009). Double 
transgenic mice thus contain single fluorescent projection neurons in which pre-synaptic 
neurotransmitter release (and possibly post-synaptic dendritic exocytosis) is inhibited. 
Detailed characterization of this model confirmed that Cre-mediated recombination takes 
place, and that TetoxLC mRNA and protein are expressed. Importantly, we observed an 
ataxic behavioral phenotype similar to that seen when RC::PFtox mice are crossed to other 
Cre-expressing lines. Although we were not able to detect a reduction in VAMP2, whose 
TetoxLC-mediated cleavage causes inhibition of neurotransmitter release, we suspect that 
this is either due to inaccurate detection of VAMP2 levels, or to a dominant negative effect 
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caused by a small amount of cleaved VAMP2 (discussed in Section 4.2.5). In any case, all 
other lines of evidence suggest that this model is fully functional.    
 
This model is a useful tool for studying cellular processes that are shaped by activity-
dependent competition. As an initial application, for example, we used these mice to 
observe in vivo whether dendritic spine density is reduced in single-suppressed cells, as is 
observed in cultured hippocampal cells (Burrone et al., 2002), discussed below. This model 
could also be widely applicable, for example, to the study of guidance molecules that govern 
axonal and dendritic growth and refinement.  
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6.2 Spine density reduction in tamoxifen-expressing projection 
neurons 
 
 
Our results in Chapter 5 show that when tetanus toxin is expressed in a small subset (<1%) of 
CA1 neurons in the adult mouse hippocampus, these cells have difficulty maintaining 
excitatory post-synaptic connections. This is evidenced by a 15%-19% spine density 
reduction on apical dendrites. Since the tetanus toxin light chain cleaves v-SNARE proteins, it 
inhibits neurotransmitter release pre-synaptically and possibly inhibits activity-dependent 
dendritic exocytosis. This raises the question as to which of these is responsible for the 
observed loss of synaptic connectivity. Both possibilities are discussed in the next two 
sections.  
 
6.2.1 Reduced spine density as a result of inhibiting dendritic exocytosis 
 
The most straightforward explanation for the observed reduction in dendritic spine density 
is that TetoxLC cleaves a v-SNARE protein present in dendrites and thereby inhibits Ca2+-
dependent dendritic exocytosis. While not as extensively studied as presynaptic vesicle 
fusion, the ability of clostridial neurotoxins to block regulated dendritic exocytosis implicates 
SNARE proteins in some forms of synaptic plasticity. SNAP-25 and syntaxin-4, for example, 
are known to be involved in calcium-dependent dendritic exocytosis (Lau et al., 2010, 
Kennedy et al., 2010). Regulated dendritic exocytosis is essential for the secretion of 
retrograde signaling molecules, dendritic neurotransmitter release and the delivery of 
neurotransmitter receptors to synapses during synaptic plasticity (Kennedy and Ehlers, 
2011). 
 
The evidence for VAMP2 involvement in dendritic exocytosis is promising but not entirely 
clear. VAMP2 is localized in the somatodendritic compartment of spiny dopaminergic 
neurons of the substantia nigra (Witkovsky et al., 2009) and botulinum toxin B, which 
cleaves VAMP2, reduces somatodendritic dopamine release in cultured dopaminergic 
neurons (Fortin et al., 2006). Dopamine release, however, is not inhibited in vivo by tetanus 
neurotoxin in the substantia nigra or the striatum (Bergquist et al., 2002). Importantly, 
TetoxLC has been shown to inhibit calcium-dependent dendritic exocytosis in cultured 
hippocampal neurons (Maletic-Savatic and Malinow, 1998) and to block LTP-associated 
membrane insertion of AMPA-type glutamate receptors (Lu et al., 2001). A study conducted 
in cultured hippocampal neurons found that VAMP2 is trafficked to both the axon and 
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dendrites but is endocytosed from the dendritic membrane and subsequently transported 
back to the axon (Sampo et al., 2003). This roundabout delivery to the axon may allow 
VAMP2 to be transiently active in the dendrite (Kennedy and Ehlers, 2011). 
 
If VAMP2 is indeed present and active in dendrites, TetoxLC could inhibit Ca2+-dependent 
dendritic exocytosis that is required for LTP (Lledo et al., 1998). Over time, the blockade of 
LTP-associated exocytosis of AMPA-type glutamate receptors to the synaptic membrane 
(and possibly other synaptic components) could lead to structural changes and ultimately 
the loss of dendritic spines. For example, perturbation of LTP induction through genetic 
deletion of NMDA-type glutamate receptor subunits decreases spine density (Brigman et al., 
2010). Our observations would suggest that blocking exocytosis – a much later step in the 
LTP pathway – is sufficient to lead to spine loss in vivo.  This would agree with findings that 
exocytosis of AMPA receptors is required for the maintenance of LTP-associated spine 
growth in hippocampal slice preparations (Kopec et al., 2007, Yang et al., 2008).     
 
6.2.2 Reduced spine density as a result of inhibiting neurotransmitter release 
 
Although less direct, it is also possible that presynaptic inhibition alone is somehow 
responsible for shaping postsynaptic connectivity within the same cell. Do the axons and 
dendrites of an individual cell act in response to each other? Is there a mechanism, either 
permissive or instructive, by which presynaptic partners avoid postsynaptic partners whose 
axons cannot efficiently relay information? Thinking in terms of a whole circuit, synapsing 
onto a “silent” cell seems like a waste of resources and it does not seem far-fetched that 
neurons are equipped with ways to prevent this. In a three-cell chain, as shown in Figure 6.1, 
one could hypothesize that a postsynaptic retrograde messenger from cell C affects the 
ability of dendrites from cell B to form or maintain synapses with cell A. For example, (1) a 
retrograde messenger such as a neurotrophin is secreted by the postsynaptic membrane of 
cell C and (2) travels retrogradely via the axon to the nucleus of cell B where it (3) regulates 
gene transcription for postsynaptic proteins required in synapse formation or maintenance. 
If presynaptic activity is inhibited in cell B, and retrograde messengers from cell C are not 
received, transcription of essential postsynaptic proteins in cell B could be downregulated. 
This would reduce the ability of dendritic spines on cell B to maintain synapses or to form 
new ones. Such hypothetical molecular circuits could help to ensure optimal wiring of the 
brain.  
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Figure 6.1 – Schematic diagram of three interconnected cells 
 
 
6.2.3 Relevance to dendritic activity-dependent competition 
 
In terms of activity-dependent competition, our results relate to previous work in two ways. 
Firstly, they complement studies showing that long-term inhibition of synaptic release in 
small subsets of cells produces activity-dependent reductions in synaptic inputs, as well as 
axonal misguidance and reduced axonal arborization (Burrone et al., 2002, Buffelli et al., 
2003, Yu et al., 2004, Hua et al., 2005, Yasuda et al., 2011). This is in contrast to global 
inhibition of synaptic release, where cells do not experience such alterations. A study by 
Burrone et al (2002) showed that small subsets of cultured hippocampal neurons whose 
activity is inhibited by Kir2.1 overexpression display reduced spine density and reduced 
frequency of miniature excitatory post-synaptic currents (mEPSCs). By showing that synaptic 
input reduction does not occur in cells treated globally with tetrodotoxin (TTX), they also 
demonstrate that these alterations in synaptic connectivity arise from a relative inhibition of 
activity, rather than from non-specific effects on cell viability or function. Our results expand 
on this study by showing that the same effect is evident in vivo, where mammalian neuronal 
circuits are kept intact. Our work should be expanded to investigate whether the same 
effect is seen when CA1 neurons are suppressed globally. 
 
Our results differ substantially, however, when developmental time-points are taken into 
consideration. While Burrone and colleagues find a substantial reduction in dendritic spine 
density (35%) and mEPSC frequency (50%) when hippocampal cultures are transfected with 
Kir2.1 before synapse formation, they find no such effects when transfection is performed 
after synapse maturation. In fact, they find that neurons in mature cultures experience a 
homeostatic increase in spine density (12%) and mEPSC frequency (46%) when silenced by 
Kir2.1 overexpression (Burrone et al., 2002). By contrast, our results provide evidence that 
competitive synaptic input reduction may also occur in the adult brain, albeit less 
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dramatically than in the developing brain. This difference could arise from the use of 
TetoxLC versus Kir2.1 and/or from the behavior of cultured hippocampal cells compared to 
cells in an intact circuit. The use of Kir2.1 versus TetoxLC, for example, has been shown to 
differentially affect axonal arborization during topographic map formation and maintenance 
in the mouse olfactory system (Yu et al., 2004).  
 
Finally, a study performed in the rat somatosensory barrel cortex found that suppressing 
somatodendritic spiking in a small subset of cells by  siRNA knockdown of Na+ channels 
results in a 16% increase in dendritic spine density (Komai et al., 2006). This increase, 
observed in young developing synapses, is attributed by the authors to the cell’s inability to 
prune immature and synaptically silent filopodia. The sharp contrast between the results of 
this study and ours could be due to the fact that Na+ channel knockdown was shown to 
affect only somatodendritic and not axosomatic spiking (Komai et al., 2006), whereas 
TetoxLC expression in our study affects axonal and potentially dendritic exocytosis. Another 
consideration is the fact that their study was performed at a much earlier developmental 
timepoint than our own, although this is also in contrast to the hippocampal culture studies 
that found reduced spine density in neurons transfected with Kir2.1 before synapse 
formation (Burrone et al., 2002). The effects of single-cell inhibition on dendritic spine 
morphology/density have not been extensively studied, so a variety of factors, such as brain 
region specificity, temporal specificity throughout development or pre- versus postsynaptic 
inhibition, could be at play.  
 
6.2.4 Pathological relevance of spine density reduction 
 
The magnitude of the reduction in spine density that we observed (15%-19%) can be 
considered biologically relevant when compared to human case studies of neuropsychiatric 
diseases. Synaptic anomalies are prominent, for example, in diseases like schizophrenia (SZ) 
and Alzheimer’s disease (AD) (Glantz and Lewis, 2000, Garey et al., 1998, Selkoe, 2002, 
Penzes et al., 2011). In postmortem brains of schizophrenia patients, for example, cortical 
neurons exhibit spine density reductions that range from 23% to 66%. Furthermore, even 
minor synaptic loss may have a drastic effect on the onset and/or progression of disease. In 
AD for example, spine loss has been shown to occur very early (Arendt, 2009) and to show 
stronger correlation to cognitive decline than do neurofibrillary tangles, amyloid beta 
oligomers or neuronal death itself (DeKosky and Scheff, 1990, Terry et al., 1991). Since 
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synaptic connectivity plays such an important role in the brain – as evidenced by the diverse 
clinical manifestations of spine pathologies – we assume that a 15%-19% loss of dendritic 
spine density observed in the adult mouse hippocampus is biologically relevant to the study 
of neuropsychiatric disease. 
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Chapter 7 Materials and Methods 
 
7.1 Molecular Biology, Biochemistry and Immunostaining 
Techniques 
 
7.1.1 General Cloning Procedures 
 DNA digestion and purification 7.1.1.1
 
DNA sequences (0.5 µg) intended for general restriction analysis or for ligation into a cut 
vector were digested in 1X NEB buffer, 1X BSA, and 0.5 µl of each required enzyme in a 20 µl 
reaction volume. Reaction was incubated at 37oC for 2 hours. DNA vectors (1 µg) to be 
opened were digested in 1X NEB buffer, 1X BSA, and 0.7 µl of each required enzyme in a 50 
µl reaction volume. This reaction was incubated at 37oC for 4 hours. Plasmids linearized in 
preparation for microinjection (8-10 µg) were digested in 10X NEB buffer, 10X BSA, and 2 µl 
of each required enzyme in a 100 µl reaction volume. Digested DNA was run on an agarose 
gel and purified from the gel using Quiagen II Gel Extraction Kit standard protocol.  
 Ligation and transformation 7.1.1.2
 
3 µl of DNA were ligated into 1 µl of cut vector using 0.3 µl of T4 DNA Ligase and 10X T4 
ligation buffer in a 20 µl reaction volume. Reactions were incubated at room temperature 
(RT) for 2 hours. Half of the ligation reaction (10 µl) was incubated with 50-100 µl of 
competent cells (XL1Blue or DH5α) on ice for 20 minutes, transformed by heat shock (at 
42oC) for 1 minute, and then incubated at 37oC in SOB medium. Transformed cells were 
pelleted in a tabletop centrifuge at 3,000 rpm for 3 minutes, resuspended in 100 µl SOB, 
plated onto selective LB agar medium and incubated overnight at 37oC. Kanamycin and 
ampicillin agar plates were made by adding 50 μg/ml of antibiotic into the agar before 
setting. 
 Plasmid Preparation 7.1.1.3
 
In some instances, colony PCR was used to select transfected colonies that express the 
desired construct. This was done using one primer from the vector and one from the insert, 
using a small amount of bacterial colony as the template. A single colony was picked and 
grown overnight in 5 ml of selective LB liquid medium in a 37oC shaker. Plasmid purifications 
were performed using QIAprep Miniprep or QIAGEN Plasmid Midi standard protocols. 
Antibiotics used for selective LB media were ampicillin and kanamycin, both at 50 μg/ml. 
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 Competent cell preparation 7.1.1.4
 
DH5α E. coli cells, which are stored at -80°C in a glycerol stock, were streaked on an LB-agar 
plate containing no antibiotics and allowed to grow overnight at 37°C. A single colony was 
picked and grown overnight at 37°C in 5 ml of liquid LB medium. 1 ml of the overnight-grown 
DH5α culture was inoculated into 50 ml of SOB medium and grown at room temperature in 
a shaker until cell density reading gave an O.D. 600 value in the range of 0.4 - 0.6 . The 
bacterial culture was kept on ice for 10 minutes and then centrifuged at 3,000 rpm for 6 
minutes at 4°C. The bacterial pellet was then processed using a Z-Competent E. coli 
Transformation Kit & Buffer Set (Zymo Research, Irvine, CA, USA) as per manufacturer’s 
instructions. 50, 100, and 200 μl aliquots of Z-competent cells were snap-frozen in liquid 
nitrogen and stored at -80°C for further use in transformations.   
 
7.1.2 Cloning strategies for transgenic constructs 
 
 Kir2.1-IRES-tauLacZ DNA construct 7.1.2.1
 
The pBlueScriptII SK+ vector (pBS II-SK+) was previously modified to contain the Thy1 
promoter and a floxed transcriptional STOP cassette (Caroni, 1997), and is hereafter referred 
to as pBThy1.  The Kir2.1-IRES-tauLacZ sequence was received as a gift from Dr. C. Ron Yun 
and then ligated into pBThy1. In preparation for pronuclear injection, 6-8 µg of plasmid DNA 
was linearized using 2 µl of NotI in a 100 µl reaction volume. The reactions was incubated at 
37oC for 6 hours and then heat-inactivated at 65oC for 20 minutes. The linearized product 
was run on a 1% agarose gel under sterile conditions and purified from the gel using Roche 
High Pure PCR Product Purification Kit standard protocol. Purified product was quantified by 
comparing it HyperLadderI on a 1% agarose gel. 
 TetoxLC-CFP DNA construct 7.1.2.2
 
We obtained the tetanus toxin light chain sequence (TetoxLC) from Dr. C. Ron Yu in the 
pGEMT7-EZ vector (Yu et al., 2004). For the CFP sequence, we designed a 3’ primer 
containing an HA tag, as well as the restriction sites MluI and XbaI. The CFP sequence was 
amplified (Methods Table 7.2), digested with EcoRI and XbaI and ligated into the pBSII-SK+ 
multiple cloning site (MCS). The TetoxLC sequence was digested with XhoI and XmaI and 
ligated directly upstream of CFP-HA in the pBSII-SK+ MCS. The TetoxLC-CFP-HA sequence was 
then digested with XhoI and MluI and ligated into the pBThy1 vector described above 
(Section 7.1.2.1). In all transformation reactions involving TetoxLC, colony PCR was 
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performed (Methods Table 7.2) to assess expression in the E. coli cells. In preparation for 
pronuclear injection, 6-8 µg of plasmid DNA were linearized using 2 µl of NotI and 2 µl of 
EcoRI in a 100 µl reaction volume. The reactions was incubated at 37oC for 6 hours and then 
heat-inactivated at 65oC for 20 minutes. The digested product, containing Thy1-TetoxLC-CFP 
was run on a 1% agarose gel under sterile conditions and purified from the gel using Roche 
High Pure PCR Product Purification Kit, standard protocol. Purified product was quantified by 
comparing it to HyperLadder I on a 1% agarose gel. 
 
7.1.3 Polymerase Chain Reaction (PCR)   
 
Mice genotypes were determined by PCR using the primer combinations described in 
Methods Table 7.2. Genomic DNA was obtained by digesting 5mm of mouse tail overnight 
at55oC in 100µl tail digestion buffer (50 mM Tris-HCl pH8.0, 1 mM CaCl2, 1% Tween-20) plus 
10µl proteinaseK (10 mg/ml) (Roche, Indianapolis, IN).Digested tails were boiled for 10 
minutes to inactivate proteinase K. PCR reactions mixture included 10X Taq buffer, 0.25 µM 
of each primer, 0.25 mM of each dNTP, 0.25 µl of TAQ, and 2 µl of genomic DNA in a 25 µl 
reaction volume. Conditions were: 960C – 3min, 40 cycles of [96oC – 40 sec, 60oC – 40 sec, 
68oC – 1.5min], 68oC – 10min, hold at 4oC. Similar conditions were used to asses 
recombination in SLICK;Ptox mice (annealing temperature of 62oC) and to amplify probes for 
Southern blotting (annealing temperature of 56oC) (Methods Table 7.2). 
 Colony PCR 7.1.3.1
 
Colony polymerase chain reaction (PCR) was performed in some cases to select for colonies 
containing plasmids with the desired insert. Reaction mixture per colony included 10X buffer 
with 15 mM MgCl2, 0.25 µM of each primer, 0.25 mM of each dNTP and .025 µl of TAQ 
polymerase (homemade) in a 20 µl reaction volume. Conditions were: 940C – 3min, 35 cycles 
of [94oC – 30 sec, 60oC – 40 sec, 70oC – 1min], 70oC – 7min, hold at 4oC. For primer 
information see Methods Table 7.2.  
 
7.1.4 Insitu hybridization (ISH) 
 Designing antisense probes for TetoxLC 7.1.4.1
 
In preparation for probe production, 7 µg of DNA sequence was linearized using 3 µl of 
restriction enzyme in a 100 µl reaction volume. Linearized DNA was digested with proteinase 
K at 55oC for 30 minutes, extracted with phenol/chloroform, re-purified with sodium acetate 
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and resuspended in 30 µl of diethylpyrocarbonate (DEPC)-treated water. Digoxygenin (DIG)-
labeled probes were produced by in vitro transcription using 1 µg of template DNA, and 2 µl 
of either T3 or T7 RNA polymerase (DIG RNA Labeling Kit, Roche) and then purified with 
sodium acetate. RNA probes were stored at -80oC. Immediately before using, probes were 
diluted in hybridization solution (Section 7.1.4.3) and denatured at 80oC for 5-10 min.   
 
Specifically, the full-length TetoxLC antisense probe used in Chapter 4 (Fig4.3, Fig4.4) was 
linearized with BamHI from the pGEMT7-EZ vector (obtained from C. Ron Yu) and 
transcribed with T7 RNA polymerase. To generate three smaller TetoxLC probes (432bp, 
515bp and 496bp), we designed primers to amplify different sections of the full sequence. 
Forward primers included an XhoI restriction site and reverse primers included an EcoRI site. 
These tetox “bits” were amplified by PCR, purified by gel extraction, digested with XhoI and 
EcoRI, and ligated into the pBSII-SK+ multiple cloning site. Antisense probes were linearized 
with XhoI and transcribed with T3 RNA polymerase. 
 ISH procedure 7.1.4.2
 
Tissue sections were prepared as described in Section 7.3.4.3, post- fixed for 10 minutes in 
4% PFA/PBS, washed 3 times in DEPC-PBS, acetylated for 10 min at room temperature in 
acetylation solution and washed again in DECP-PBS. Processed slides were pre-hybridized in 
hybridization solution for 1-3 hours at room temperate and then hybridized with a DIG-
labeled probe overnight at 68oC in a sealed chamber humidified with 50% formamide/2XSSC. 
Slides were washed in 0.2XSSC for 3 hours with 4 changes of solution and then washed twice 
for 5 min in TBS. For color development with NBT/BCIP slides were blocked for 1 hour in 
blocking solution and incubated overnight at 4oC in alkaline-phosphatase-conjugated sheep 
anti-DIG antibody, Fab fragments (Roche) at 1:2000 in blocking solution. Slides were then 
washed four times 10 minutes with TBST and once with detection buffer, and then 
incubated with NBT/BCIP solution overnight at 37oC in a dark humidified chamber. Stained 
sections were imaged under bright field using a Leica DMI 3000 microscope. 
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 Solutions for ISH 7.1.4.3
 
Acetylation solution  Detection buffer 
     49 ml 
666 µl 
87.5 µl 
125 µl 
H2O 
triethanolamine (Sigma 90278) 
concentrated HCl 
acetic anhydride (Sigma A6404) 
 0.1 M 
0.1 M 
50 mM 
0.24 mg/ml   
Tris-HCl (pH9.5) 
NaCl 
MgCl2 
levamisole 
in dH2O 
add 0.05% Tween 20 
     
Hybridization solution  NBT/BCIP solution 
     50%  
5X 
5X   
250 µg/ml 
500 µg/ml 
50 µg/ml 
Formamide (Sigma F9037) 
SSC 
Denhart's solution (Sigma D2532) 
yeast tRNA (Roche 10109495001) 
salmon sperm DNA (Sigma D7656) 
heparin (Sigma H9399) 
in DEPC-dH2O 
 0.35 mg/ml 
0.175 mg/ml 
NBT (Sigma N 6639) 
BCIP (Sigma B8503) 
in detection buffer with 
Tween 
   
 Blocking solution 
    10% 
0.2% 
normal sheep serum 
Blocking Solution (Roche 
1096176) 
in TBS 
7.1.5 Southern blotting 
 
Digoxigenin (DIG)-labeled probes were amplified using the DIG High Prime DNA Labeling and 
Detection Starter Kit II (RocheDiagnostics, West Sussex, UK) following standard protocol. PCR 
conditions are described in Section 7.1.3 and primers are outlined in Methods Table 7.2. 
Probe concentration was measured using a standard dot blot method with reagents from 
the same kit. Following quantification, the remainder of the synthesized probe was purified 
using the High Pure PCR Product Purification Kit (Roche Diagnostics, West Sussex, UK). 
 
Genomic DNA was isolated from brain tissue as described in Section 7.3.4.2. Purified DNA 
(20 µg) was digested overnight at 37oC in total reaction volume of 500 µl. Samples to be 
tested with the TetoxLC probe were digested with 10 µl of EcoRV-HF and 10 µl of EcoRI-HF, 
and samples to be tested with the ROSA26 probe were digested with 10 µl of EcoRV-HF. 
Digested DNA was precipitated with isopropanol (500 µl DNA, 100 µl NaCl, 400 µl 
isopropanol, 1 µl glycogen) at room temperature for 30 minutes, centrifuged for 30 minutes, 
washed with 75% ethanol and resuspended in double distilled water.  
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DNA was loaded onto a 0.9% agarose gel and separated by electrophoresis at 60V for 2 
hours; 0.1 M TAE buffer was replaced once after 1 hour. Southern blot was performed 
according to standard protocol as detailed in several sources, including Sambrook and 
Russell (2006). A general outline of the protocol is: (1) gel is denatured and neutralized, (2) 
DNA is transferred onto an uncharged nylon membrane by capillary transfer, (3) membrane 
is UV-crosslinked, (4) immobilized DNA is hybridized using the DIG-labeled probes described 
above, (5)membrane is incubated with horseradish peroxidase-conjugated anti-DIG 
antibody, (6) probe is detected using ECL substrate (Thermo Scientific Pierce, Rockford, IL, 
USA), and (7) chemiluminescent signal is developed onto X-ray film (Thermo Scientific 
Pierce) using an Agfa CP 1000 film developer. 
 
7.1.6 Western blotting 
 
Protein concentration from cell or tissue lysates was measured using a BCA assay kit 
(Thermo Scientific Pierce) and a microplate reader (Tecan Group Ltd., Männedorf, 
Switzerland).  In preparation for immunoblotting, protein samples were combined with 2X 
SDS gel loading buffer, boiled for 10 minutes and centrifuged briefly. Samples were then 
loaded onto SDS-polyacrylamide gels of varying percentages and resolved at 100V in running 
buffer (1X TRIS/glycine/SDS). Proteins were transferred by electroblotting to an Immobilon 
membrane (Millipore, Carrigtwohill, Ireland) at 100V in cold transfer buffer (25 mM TRIS, 
192 mM glycine, 10% methanol). PonceauS staining was applied to verify protein content 
and then washed off using distilled water. Protein-containing membranes were washed 
briefly (2-3 min) in TBST (TBS plus 0.1% Tween-20) and then blocked for 1 hour at room 
temperature in 4% non-fat dried milk diluted in TBST. Primary antibody incubation was 
performed overnight at 4oC in a humidified chamber. The membrane was then washed three 
times for 5 minutes at room temperature in TBST on a rocker. Secondary antibody 
incubation was performed at room temperature in a dark container while rocking. The 
membrane was then washed three times in TBST and once in TBS. Both primary and 
secondary antibodies were diluted in blocking solution (4% milk/TBST). Proteins tagged with 
peroxidase secondary antibodies were detected using ECL substrate (Thermo Scientific 
Pierce) and developed onto X-ray film using a table top film processor (Agfa CP 1000). 
Proteins tagged with fluorescent secondary antibodies were detected using the Odyssey 
Infrared Imaging System (LI-COR Biosciences, Cambridge, UK). Signal intensities were 
analyzed quantitatively using the Odyssey V3.0 software. 
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7.1.7 Immunoprecipitation (IP) 
 
Tissue lysates were prepared as described in Section 7.3.4.1 and then pre-cleared for 1 hour 
at 4°C using 25 μl of Protein G Sepharose beads (Thermo Fisher Scientific, Dublin, Ireland). 
Pre-cleared lysates were immunoprecipitated for 2 – 4 hours at 4°C by incubation with 8 μl 
of MoAB51 antibody (Methods Table 7.1). Pre-clearing and immunoprecipitation were 
performed under constant mixing using a nutator mixer. The protein beads (~25 μl) were 
then washed with 1X PBS, blocked with 1% BSA for 30 minutes at 4°C (with mixing), washed 
again, and then spun down. Wash buffer (50 ml of cell lysis buffer) was added to the blocked 
beads in a 1:1 ratio. Part of this mixture (25 μl) was added to each of the pre-cleared protein 
lysates and incubated with constant mixing for 1 – 4 hours at 4°C. Following 
immunoprecipitation, the samples were centrifuged at 1,000g for 2 minutes at 4°C, 
interspersed with washing the agarose beads with wash buffer every 5 minutes. The wash 
and spin down steps were repeated at least 5 times so as to ensure removal of any non-
specific protein interactions occurring with the beads. Following the final wash and spin 
down step, most of the wash buffer was removed except the last 25 μl (containing the 
beads) and 25 μl 2X gel loading buffer was added 50 μl of 2X gel loading buffer was added to 
protein lysates kept aside as input protein samples. All samples were boiled for 5 minutes, 
spun down briefly and resolved by SDS-polyacrylamide electrophoresis. Western blotting of 
both lysate and immunoprecipitates was performed using an anti-GFP antibody (Method 
Table 7.1) coupled with enhanced chemiluminescence detection. 
7.1.8 Immunohistochemistry (IHC) 
 
Tissue was dissected, sectioned, and post-fixed as described in Section 7.3.4.4. Floating 
sections were blocked for 4 hours at room temperature (RT) in a 24-well plate. They were 
then incubated overnight at 4oC in primary antibody dilution, washed 3 times for 20 minutes 
in PBS, incubated for 4 hours at RT in secondary antibody dilution (in the dark) and washed 
again. Stained sections were mounted with Fluoromount (Sigma), sealed with nail varnish 
and stored at -20oC. Primary and secondary antibodies were incubated in separate wells to 
prevent carryover. Cryosections were encircled with a PAP pen, blocked for 1 hour, 
incubated in primary antibody dilution for 4 hours, washed 4 times for 5 minutes in 1X PBS, 
incubated in secondary antibody for 1 hour, washed again, and mounted with Fluoromount, 
all at RT.  
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Blocking solution for both types of sections contained 5% normal goat serum (NGS), 3% 
bovine serum albumin (BSA) and 0.2% triton X-100 in PBS (blocking solution for LacZ staining 
had 1% triton X-100). Primary and secondary antibodies, outlined in Methods Table 7.1 were 
diluted in blocking solution without triton X-100. 
 Sections used for dendritic spine analysis 7.1.8.1
 
The brain was extracted, separated into hemispheres, post-fixed in 4% PFA/PBS for 2 hours 
and then transferred to 1X PBS for 1-2 hours. Vibratome sections (50-66 µm) were cut and 
stained on the same day as the tissue was harvested. Sections were blocked at RT for 2-3 
hours in a 24-well plate (5% NGS, 3% BSA and 0.2% Triton-X in PBS), incubated in Att-488-
GFP Booster (Chromotek, Somewhere. Germany) overnight at 4oC (1:200 in blocking solution 
without triton), washed 4 times for 40 minutes in 1X PBS and mounted with Fluoromount. 
Slides were sealed with nail varnish and stored overnight at 4oC to avoid freeze-thawing and 
preserve morphology. Confocal images were taken over the next two days.  
 
7.1.9 X-Gal Staining 
 
X-gal staining for β-galactosidase was performed by incubating sections in X-gal staining 
solution (2 Mm Xgal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM 
MgCl2) at room temperature for 16 hours. Sections were then washed in 1X PBS, mounted 
using Fluoromount and viewed under bright field using a Leica DMI 3000 microscope. Thick 
X-gal-stained vibratome sections show some nonspecific brown staining that is apparent in 
Chapter 2 (Fig 2.4, Fig2.6, and Fig2.8) and Chapter 3 (Fig3.3, Fig3.4). 
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7.2 Tissue Culture Techniques 
 
COS-7 cells were cultured in Dulbecco’s Modified Eagle Media (Sigma-Aldrich, catalog # 
D6429), 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 1% L-glutamine. Cells 
were maintained routinely at 37°C at 100% humidity and 5% CO2 saturation. 
7.2.1 Calcium phosphatase transfection and cell extract preparation 
 
COS-7 cell cultures were transfected when subconfluent (2.5 x 106 cells for a 10 cm dish) 
using the calcium phosphate precipitation method described by Schenborn and Goiffon 
(2000). For each transfection, 4 μg of DNA was the set upper limit of DNA transfected per 10 
cm dish or per well of a 6-well dish to prevent cytotoxicity. Media was changed 12 hours 
post-transfection and cells were allowed to grow for another 24 hours before being 
harvested.  
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7.3 Animal Procedures 
 
All animal experiments at University College Cork were approved by the University Ethics 
Committee and conducted under a license from the Irish Department of Health and 
Children. Mice were housed at the Biological Services Unit of University College Cork, Cork. 
7.3.1 Transgenic mice generation at UCC 
 
Injections of gel-purified DNA into fertilized oocytes were carried out by Dr. Melanie Ball 
using standard techniques (Richa, 2000). Embryos were introduced into pseudo-pregnant 
CD1 females. Transgenic founders were backcrossed to C57 mice for initial analysis of mRNA 
expression patterns and then to SLICK-H mice (Jackson Labs stock #012708) for analysis of 
reporter gene expression.  
7.3.2 Tamoxifen Administration 
 
Tamoxifen (Sigma, Arklow, Ireland; catalog numberT5648) was dissolved in corn oil (Dunnes 
Stores, Cork, Ireland) at a concentration of 20 mg/ml by rocking overnight at room 
temperature. This was stored at room temperature for immediate use. Adult mice (2 to 3 
months-old) were administered 0.25 mg of tamoxifen per gram of body weight by oral 
gavage. Mice were dosed once daily for one, three, or five consecutive days and rested for at 
least 10 days before analyzing. Untreated control mice were housed in separate cages to 
avoid carryover of tamoxifen. 
7.3.3 Animal sacrifice 
 
Mice were anesthetized by isofluorane inhalation and perfused through the left ventricle of 
the heart using a peristaltic pump. Ice-cold 0.1 M PBS (pH =7.4) was used to flush out blood 
from all vessels and tissues. Animals whose tissue was intended for immunohistochemistry 
or X-Gal staining were further perfused with 4% paraformaldehyde dissolved in PBS. For in 
situ hybridization, mice were perfused manually using a syringe with 10ml of DEPC-treated 
PBS. 
7.3.4 Tissue processing 
 
 Tissue homogenization for western blot an immunoprecipitation 7.3.4.1
 
Whole brains were harvested and then either processed immediately or stored at -20oC for 
several days to weeks. A glass homogenizer placed in ice was used to grind tissue in 500 µl of 
ice-cold solution (20mM Tris pH7.5, 100mM NaCl, 1% NP40, 0.1% deoxycholate, 1mM EDTA, 
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protease inhibitors). Tissue lysate was left on ice for 30 minutes and then spun down (13,000 
rpm) at 4oC for 20 minutes. Supernatant was collected, measured for total protein 
concentration using a BCA assay kit, and stored at -20oC for future use. For 
immunoprecipitation, 3 brains per treatment group were homogenized together in a 9X 
volume of lysis buffer. 
 DNA extraction used for Southern blot and PCR  7.3.4.2
 
For PCR, the hippocampus or brainstem were dissected on ice and immediately processed. 
Tissue was lysed on ice using a glass homogenizer with 500 µl of lysis buffer (100 mM Tris-
HCl pH 8.5, 5 mM EDTA pH 8.0, 0.2% SDS, 200 mM NaCl), rested on ice for 20 minutes, spun 
down for 15 minutes at 4oC in a tabletop centrifuge (13,000 rpm), and the supernatant 
collected. DNA was extracted using phenol/chloroform/isoamyl alcohol (25:24:1), then 100% 
ethanol, washed with 75% ethanol, airdried for 20 minutes and resuspended in 100 µl of TE 
buffer at 65oC. Exceptional care was taken not to sheer the DNA; gentle rocking was used 
instead of vortexing, P1000 tips were cut to allow a wider opening and pipetting was done 
gently in all instances. 
 
For Southern blot, whole brains were extracted, halved into hemispheres and stored at -
20oC for several weeks until required for further processing (being careful to maintain the 
shape of the hemispheres). When needed, a medial sagittal slice weighing approximately 60 
g was cut from the frozen tissue, then diced finely with a blade and aliquoted into two 
different tubes. Isolation of genomic DNA was performed using the QIAamp DNA Mini Kit 
according to manufacturer’s protocol. Great care was again taken not to sheer the DNA; 
gentle rocking was used instead of vortexing (except during tissue lysis), P1000 tips were cut 
to allow a wider opening and pipetting was done gently in all instances.  
 Tissue sectioned for in situ hybridization 7.3.4.3
 
Brain tissue was removed, embedded in cryomatrix resin and snap-frozen in liquid nitrogen-
cooled isopentane or in dry ice-cooled ethanol. Tissue blocks were immediately sectioned 
(20 µm) using a Leica CM 1850 cryostat, placed onto sterile SuperFrost Plus slides (VWR 
International, Dublin, Ireland), air dried for 10 minutes, placed at 65oC for 10 minutes, and 
then air dried again for 10 minutes. Slides were processed immediately as described in 
Section 7.1.4. 
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 Tissue sectioned for immunohistochemistry and X-Gal stain 7.3.4.4
 
Tissue was extracted, post-fixed in 4% PFA/PBS (30 min for X-Gal stain, overnight for IHC), 
and then transferred to PBS for either 1 hour or overnight. Brains were sectioned (50-100 
µm thick) using a Lancer Vibratome Sectioning System Series 1000 (Technical Products 
International Inc., Saint Louis, MO, USA). Spinal cord, dorsal root ganglia (DRG) and retina 
were embedded in cryomatrix, snap-frozen in liquid nitrogen-cooled isopentane, and 
sectioned (20 µm) using a Leica CM 1850 cryostat. Some DRG and retina were mounted 
whole onto slides. 
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7.4 Microscopy 
7.4.1 Fluorescent imaging  
 
The following filters from the Leica DMI 3000 fluorescent microscope were used: 
 
(1) A  excitation filter BP 340-380 suppression filter LP 425 
(2) CFP excitation filter BP 436/20  suppression filter BP 480/40  
(3) GFP excitation filter BP 470/40 suppression filter BP 525/50 
(4) YFP excitation filter BP 500/20 suppression filter BP 535/30 
(5) Y3 excitation filter BP 545/30 suppression filter BP 610/75 
7.4.2 Confocal imaging  
 
The Zeiss LSM 510 confocal microscope, which belongs to Mary McCaffrey in the 
Department of Biochemistry, University College Cork, Ireland, has the following four lasers:  
 
(1) 405 diode, 25-30mW 
(2) argon 458, 477, 488, 514 
(3) HeNe 543 
(4) HeNe 633 
 
Confocal images shown in Chapter 2 were obtained using 40X or 63X objectives (Fig7.1A). 
YFP was excited using the 488 nm laser line and fluorescence emission collected between 
505 and 550 nm. Cy3 was excited at 543 nm and fluorescence collected between 555 and 
627 nm. DAPI was excited using the 405 nm laser and fluorescence collected between 420 
and 480. Dylight 649 was excited using the 633 nm laser line. Confocal images presented in 
Chapter 5 were taken using a 63X objective. YFP/GFP Booster was excited using the 488 nm 
laser line and fluorescence emission collected between 505 and 530 nm (Fig7.1B).  
 
Figure 7.1 – Confocal settings for images presented in Chapter 2 (A) and Chapter 5 (B) 
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7.5 Data Analysis 
 
In Chapter 2, confocal images of β-galactosidase, NeuN, DAPI and YFP were merged using 
Adobe Photoshop software, and ImageJ Cell Counter was used to count cells manually. Cells 
were scored as β-gal positive only when one or more large puncta or numerous small puncta 
were present within a cell body. Very weak staining for NeuN and YFP was excluded from 
the total number of cells. 
 
In Chapter 4, western blot signal intensities were determined with the Odyssey V3.0 
software (LI-COR Biosciences, Cambridge, UK) using GAPDH as loading control. The sum of K-
counts for each pair of tamoxifen-treated versus untreated control samples was normalized 
to 100. When the same sample pair was analyzed on more than one blot, the normalized K-
counts were averaged. Five forebrain sample pairs were probed for VAMP2, four forebrain 
sample pairs were probed for VAMP1/2/3, four cerebellum sample pairs were probed for 
VAMP2 and two cerebellum sample pairs were probed for VAMP1/2/3. Differences between 
tamoxifen-treated and untreated control sample pairs were statistically evaluated using 
Student’s t-test. These results were graphed with an error bar representing standard error 
(Fig4.9C). 
 
In Chapter 5, confocal images were analyzed under continued blinded conditions using the 
Filament Tracer module in BitpLane Imaris software (Bitplane AG, Zurich, Switzerland). Initial 
identification of dendritic spine was performed automatically but this was inspected and 
corrected manually.  Spine density and spine length parameters were obtained from the 
Imaris software. In order to account for possible variation between cells in the treatment 
groups, we analyzed our data using a mixed-model nested ANOVA test.  This test returned a 
p-value of 0.04714, indicating that one or more relationships between experimental groups 
are statistically significant with a confidence level of 0.05.  In order to determine which 
relationship(s) are statistically significant, we ran three post-hoc tests comparing the means 
of either tamoxifen-treated versus untreated SLICK-V;Ptox or tamoxifen-treated SLICK-V;Ptox 
versus tamoxifen-treated SLICK-V mice. These tests were: Dunnett’s T-test, Tukey’s 
Standardized Student Range, and Gabriel’s Comparison Intervals.  All three tests revealed 
that the observed reduction in spine density in tamoxifen-treated SLICK-V;Ptox mice is 
significant compared to both controls (p<0.05).   
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7.6 Materials 
7.6.1 Materials and reagents 
 
All reagents used in these studies were purchased from Sigma-Aldrich (Arklow, Ireland) 
unless otherwise stated. Restriction enzymes, T4 DNA ligase, and pre-stained molecular 
weight protein markers were purchased from New England Biolabs (Hitchin, UK). 
Bicinchoninic acid (BCA) protein assay kit was obtained from Thermo Scientific Pierce 
(Rockford, IL, USA) through Medical Supply Company (Dublin, Ireland). Immobilon Transfer 
PVDF (polyvinylidene difluoride) membranes, western blotting filter papers, and bacterial 
plating beads were obtained from Merck Millipore Ltd. (Cork, Ireland). DNA ladder - 
HyperLadder 1kb was obtained from Bioline Reagents Ltd. (London, UK). Taq polymerase 
used routinely for PCR amplifications was prepared in-house following a protocol obtained 
from Charles Spillane, NUI Galway, Ireland. Primers and oligonucleotides designed by us for 
this study were purchased from Integrated DNA Technologies, Inc. (Leuven, Belgium).  
7.6.2 Antibodies 
 
Table 7.1 - List of antibodies used in this thesis; with dilutions and sources  
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7.6.3 Primers 
 
Table 7.2 – List of primers and oligonucleotides used in this thesis; with sequence and 
location information 
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